<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="r">
		<monograph id="1" status="active">
			<mono_name>RABEprazole (Rx)</mono_name>
			<info>
				<pronunciation>(rah-bep′rah-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x212">Aciphex</tradename>
					<tradename id="tnidelem4x211">Aciphex Sprinkle</tradename>
					<tradename id="tnidelem4x210">
						<country code="CAN">Pariet </country>
					</tradename>
				</tradenames>
				<class type="func"> Antiulcer, proton pump inhibitor</class>
				<class type="chem"> Benzimidazole</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x33">
				<para>
					<confusion>
						<tradename id="tnidelem4x330">Aciphex</tradename>
						<drug type="generic" refid="idelem4x330">Aricept/Accupril</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x40">
				<sec_title>Action:</sec_title>
				<para>Suppresses gastric secretion by inhibiting hydrogen/potassium ATPase enzyme system in the gastric parietal cells; characterized as a gastric acid pump inhibitor because it blocks the final step of acid production</para>
			</section>
			<section type="uses" id="sidelem4x45">
				<sec_title>Uses:</sec_title>
				<para>Gastroesophageal reflux disease (GERD), severe erosive esophagitis, poorly responsive systemic GERD, pathologic hypersecretory conditions (Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas); treatment of active duodenal ulcers with/without antiinfectives for <emphasis style="italic">Helicobacter pylori;</emphasis> daytime, nighttime heartburn</para>
				<section type="none" id="sidelem4x53">
					<section type="none" id="sidelem4x54">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Gastric ulcer, heartburn, <emphasis style="italic">H. pylori</emphasis> eradication in children</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x62">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or proton pump inhibitors (PPIs)</para>
				<section type="none" id="sidelem4x67">
					<section type="none" id="sidelem4x68">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, Asian patients, diarrhea, geriatric patients, gastric cancer, hepatic/GI disease, IBS, osteoporosis, pseudomembranous colitis, ulcerative colitis, vit B<emphasis style="inf">12</emphasis> deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x76">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x79">
					<section type="none" id="sidelem4x80">
						<sec_title>Healing of duodenal ulcers</sec_title>
						<section type="none" id="sidelem4x88">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x88">
									<item>
										<label>•</label>
										<para> 20 mg/day × ≤4 wk; to be taken after breakfast</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x92">
						<sec_title>Healing of erosive esophagitis or ulcerative GERD</sec_title>
						<section type="none" id="sidelem4x100">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x100">
									<item>
										<label>•</label>
										<para> 20 mg/day × 4-8 wk; may use an additional course</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x107">
							<label>•</label>
							<sec_title>Adolescent and child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x107">
									<item>
										<label>•</label>
										<para> 20 mg/day up to 8 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x114">
							<label>•</label>
							<sec_title>Child 1-11 yr (≥15 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x114">
									<item>
										<label>•</label>
										<para> (sprinkle) 10 mg daily up to 12 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x121">
							<label>•</label>
							<sec_title>Child 1-11 yr (&lt;15 kg)</sec_title>
							<para>
								<list id="lidelem4x121">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child 1-11 yr (&lt;15 kg):</emphasis> 5 mg daily up to 12 wk; may increase to 10 mg daily if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x125">
						<sec_title>
							<emphasis style="italic">H. pylori</emphasis> eradication</sec_title>
						<section type="none" id="sidelem4x135">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x135">
									<item>
										<label>•</label>
										<para> 20 mg bid × 7 days with amoxicillin 1 g bid × 7 days with clarithromycin 500 mg bid × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x139">
						<sec_title>Pathologic hypersecretory conditions</sec_title>
						<section type="none" id="sidelem4x147">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x147">
									<item>
										<label>•</label>
										<para> 60 mg/day; may increase to 120 mg in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x151">
						<sec_title>Gastric ulcer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x159">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x159">
									<item>
										<label>•</label>
										<para> 20 mg/day after <emphasis style="smallcaps">am</emphasis> meal × 3-6 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x166">
						<sec_title>Dyspepsia/heartburn (unlabeled)</sec_title>
						<section type="none" id="sidelem4x174">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x174">
									<item>
										<label>•</label>
										<para> 20 mg/day × ≤14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x178">
						<sec_title>Available forms:</sec_title>
						<para> Del rel tabs 20 mg; del rel caps 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x183">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x191">
							<label>•</label>
							<sec_title>PO</sec_title>
							<para>
								<list id="lidelem4x191">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">PO:</emphasis> Do not break, crush, chew del rel tab; after breakfast daily with full glass of water, without regard to food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x195">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x198">
					<section type="none" id="sidelem4x199">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, asthenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x206">
						<sec_title>CV:</sec_title>
						<para> Chest pain, angina, tachycardia, bradycardia, palpitations, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x211">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, taste perversion</para>
					</section>
					<section type="none" id="sidelem4x216">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, abdominal pain, vomiting, nausea, constipation, flatulence, acid regurgitation,</emphasis> abdominal swelling, anorexia, irritable colon, esophageal candidiasis, dry mouth; <emphasis style="bold">pseudomembranous colitis (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x226">
						<sec_title>GU:</sec_title>
						<para> UTI, urinary frequency, increased creatinine, <emphasis style="bold">proteinuria, hematuria,</emphasis> testicular pain, glycosuria</para>
					</section>
					<section type="none" id="sidelem4x234">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Pancytopenia, thrombocytopenia, neutropenia, leukocytosis,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x242">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> dry skin, urticaria, pruritus, alopecia</para>
					</section>
					<section type="none" id="sidelem4x250">
						<sec_title>META:</sec_title>
						<para> Hypoglycemia, increased hepatic enzymes, weight gain</para>
					</section>
					<section type="none" id="sidelem4x255">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Back pain,</emphasis> fever, fatigue, malaise, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x265">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Upper respiratory tract infections, cough,</emphasis> epistaxis, <emphasis style="bold">pneumonia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x275">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Eliminated in urine as metabolites and in feces, terminal half-life 1-2 hr, metabolized by CYP2C19 enzyme system, protein binding 96.3%</para>
			</section>
			<section type="interactions" id="sidelem4x280">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—warfarin, clopidogrel</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum levels of RABEprazole—benzodiazepines, phenytoin, clarithromycin, antacids, other proton pump inhibitors, H<emphasis style="inf">2</emphasis> blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of—digoxin, nelfinavir/omeprazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of RABEprazole—sucralfate, calcium carbonate, vit B<emphasis style="inf">12</emphasis></para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of ketoconazole, itraconazole, iron salts, atazanavir/ritonavir, ampicillin</para>
				<section type="none" id="sidelem4x308">
					<section type="none" id="sidelem4x309">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> RABEprazole—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x316">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x323">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x326">
					<section type="none" id="sidelem4x327">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x332">
								<item>
									<label>•</label>
									<para>GI system: bowel sounds, abdomen for pain, swelling, anorexia, emesis/stool for occult blood</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x340">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> may occur with most antibiotic therapy; watery diarrhea, abdominal pain, fever</route></sec_title>
						</section>
						<section type="none" id="sidelem4x346">
							<label>•</label>
							<sec_title>
								<route>Vit B</route>
							</sec_title>
							<para>
								<list id="lidelem4x346">
									<item>
										<label>•</label>
										<para>
											<emphasis style="inf">12</emphasis>
											<emphasis style="bold">deficiency/cyanocobalamin/hypomagnesemia:</emphasis> may occur after 3-12 mo of treatment; use magnesium, vit B<emphasis style="inf">12</emphasis>, cyanocobalamin supplement; if severe, discontinuing of product may be needed</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x357">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, alk phos during treatment; CBC with differential periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x363">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin reactions: Stevens-Johnson syndrome</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x368">
								<item>
									<label>•</label>
									<para>CBC with differential before, periodically during treatment; blood dyscrasias may occur (rare)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x373">
								<item>
									<label>•</label>
									<para>Obtain susceptibility testing if <emphasis style="italic">H. pylori</emphasis> treatment is ineffective, another anti-infective may be needed</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x381">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x385">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of epigastric pain, swelling, fullness; decreased symptoms of GERD after 4-8 wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x391">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x399">
							<label>•</label>
							<sec_title>
								<route>To report severe diarrhea or black, tarry stools; product may have to be discontinued</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x402">
								<item>
									<label>•</label>
									<para>That hypoglycemia may occur if patient is diabetic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x407">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities because dizziness, drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x412">
								<item>
									<label>•</label>
									<para>To avoid alcohol, salicylates, NSAIDs because they may cause GI irritation; to avoid other OTC, herbal products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x417">
								<item>
									<label>•</label>
									<para>To use as directed for length of time prescribed; to take missed dose when remembered; not to double dose, take del rel tab whole, do not cut, break; cap should be opened and sprinkled on food (applesauce)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x422">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy planned, suspected</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active" ru="yes">
			<mono_name> radioactive iodine (sodium iodide) 131I (Rx)</mono_name>
			<info>
				<class type="func"> Antithyroid</class>
				<class type="chem"> Radiopharmaceutical</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="uses" id="sidelem4x443">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="italic">High dose:</emphasis> Thyroid cancer, hyperthyroidism</para>
				<para>
					<emphasis style="italic">Low dose:</emphasis> Visualization to determine thyroid cancer, diagnostic aid for thyroid function studies</para>
			</section>
			<section type="contra" id="sidelem4x454">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, age &lt;30 yr, recent MI, large nodular goiter, vomiting/diarrhea, acute hyperthyroidism, use of thyroid products</para>
			</section>
			<section type="doses" id="sidelem4x459">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x462">
					<section type="none" id="sidelem4x463">
						<sec_title>Thyroid cancer</sec_title>
						<section type="none" id="sidelem4x471">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x471">
									<item>
										<label>•</label>
										<para> 50-150 mCi; may repeat, depending on clinical status</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x476">
						<sec_title>Hyperthyroidism</sec_title>
						<section type="none" id="sidelem4x484">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x484">
									<item>
										<label>•</label>
										<para> 4-10 mCi, depending on serum thyroxine level</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x488">
						<sec_title>Available forms:</sec_title>
						<para> Caps 1-50, 0.8-100 mCi; oral sol 7.05 mCi/ml, 3.5-150 mCi/vial; concentrated oral solution 1000 mCi/ml</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>raloxifene (Rx)</mono_name>
			<info>
				<pronunciation>(ral-ox′ih-feen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x4980">Evista</tradename>
				</tradenames>
				<class type="func"> Bone resorption inhibitor</class>
				<class type="chem"> Hormone modifier, selective estrogen receptor modulator (SERM)</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x508">
				<sec_title>Action:</sec_title>
				<para>Tissue-selective estrogen agonist/antagonist; agonist activity in bone and on lipid metabolism; antagonist activity on breast and uterus; reduces resorption of bone and decreases bone turnover</para>
			</section>
			<section type="uses" id="sidelem4x513">
				<sec_title>Uses:</sec_title>
				<para>Prevention, treatment of osteoporosis in postmenopausal women; breast cancer prophylaxis in postmenopausal women with osteoporosis or in postmenopausal women at high risk for developing the disease</para>
				<section type="none" id="sidelem4x518">
					<section type="none" id="sidelem4x519">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Uterine leiomyomata in postmenopausal women with osteoporosis or in postmenopausal women who are at high risk for developing the disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x524">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity</para>
				<para>
					<bbw>Women with active or history of venous thromboembolic events</bbw>
				</para>
				<section type="none" id="sidelem4x539">
					<section type="none" id="sidelem4x540">
						<sec_title>Precautions:</sec_title>
						<para> CV/hepatic disease, cervical/uterine cancer, elevated triglycerides, pulmonary embolism</para>
						<para>
							<bbw>Stroke</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x555">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x563">
					<label>•</label>
					<sec_title>Adult postmenopausal women<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x563">
							<item>
								<label>•</label>
								<para> 60 mg/day, max 60 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x567">
					<section type="none" id="sidelem4x568">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 60 mg</para>
					</section>
					<section type="none" id="sidelem4x573">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x577">
								<item>
									<label>•</label>
									<para>PO: without regard to meals, vit D</para>
								</item>
								<item>
									<label>•</label>
									<para>Add calcium supplement if inadequate</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use during immobilization or prolonged bedrest</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x593">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x596">
					<section type="none" id="sidelem4x597">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, depression, migraines</para>
					</section>
					<section type="none" id="sidelem4x602">
						<sec_title>CV:</sec_title>
						<para> Hot flashes, peripheral edema, <emphasis style="bold">thromboembolism, stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x609">
						<sec_title>EENT:</sec_title>
						<para> Retinal vein occlusion (rare)</para>
					</section>
					<section type="none" id="sidelem4x614">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, dyspepsia, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x622">
						<sec_title>GU:</sec_title>
						<para> Vaginitis, leukorrhea, cystitis, <emphasis style="italic">hot flashes,</emphasis> vaginal bleeding</para>
					</section>
					<section type="none" id="sidelem4x630">
						<sec_title>INTEG:</sec_title>
						<para> Rash, sweating</para>
					</section>
					<section type="none" id="sidelem4x635">
						<sec_title>META:</sec_title>
						<para> Weight gain, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x640">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia, <emphasis style="italic">leg cramps,</emphasis> arthritis</para>
					</section>
					<section type="none" id="sidelem4x648">
						<sec_title>RESP:</sec_title>
						<para> Sinusitis, pharyngitis, increased cough, pneumonia, laryngitis, bronchitis, <emphasis style="bold">pulmonary embolism,</emphasis> flulike symptoms</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x656">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Duration 24 hr, elimination half-life 28-32 hr; excreted in feces, breast milk; highly bound to plasma proteins</para>
			</section>
			<section type="interactions" id="sidelem4x661">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x665">
						<item>
							<label>•</label>
							<para>Administer cautiously with other highly protein-bound products, ibuprofen, diazepam, naproxen, systemic estrogens</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of anticoagulants, dessicated thyroid, levothyroxine, liotrix</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of raloxifene—ampicillin, cholestyramine</para>
				<section type="none" id="sidelem4x679">
					<section type="none" id="sidelem4x680">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> raloxifene—soy</para>
					</section>
					<section type="none" id="sidelem4x687">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> apolipoprotein A-1, hormone-binding globulin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> total cholesterol, LDL, lipoprotein, apolipoprotein B, serum calcium, albumin, total protein</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x699">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x702">
					<section type="none" id="sidelem4x703">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>History of stroke, TIA, thrombosis, atrial fibrillation, hypertension, smoking; venous thrombosis may occur; avoid prolonged sitting; discontinue 3 days before surgery, other immobilization</bbw>
						</para>
						<para>
							<list id="lidelem4x716">
								<item>
									<label>•</label>
									<para>Bone density test at baseline, throughout treatment, bone-specific alk phos, osteocalcin</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x722">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x726">
								<item>
									<label>•</label>
									<para>Therapeutic response: prevention, treatment of osteoporosis in postmenopausal women; prevention of breast cancer in postmenopausal women with osteoporosis or in those who are at high risk for developing the disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x732">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>To discontinue product 72 hr before prolonged bedrest; to avoid staying in one position for long periods, to report possible blood clots immediately usually during first few months of therapy</bbw>
						</para>
						<para>
							<list id="lidelem4x746">
								<item>
									<label>•</label>
									<para>To take calcium supplements, vit D if intake is inadequate</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x751">
								<item>
									<label>•</label>
									<para>To increase exercise using weights</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x756">
								<item>
									<label>•</label>
									<para>To stop smoking; to decrease alcohol consumption</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x761">
								<item>
									<label>•</label>
									<para>That product does not help to control hot flashes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x767">
								<item>
									<para>
										<emphasis alert="nurse">To report fever, acute migraine, insomnia, emotional distress; urinary tract infection, vaginal burning/itching; swelling, warmth, pain in calves</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x773">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber if pregnancy planned, suspected, pregnancy (X); to avoid breastfeeding</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x778">
								<item>
									<label>•</label>
									<para>Provide product package insert and discuss with patient</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>raltegravir (Rx)</mono_name>
			<info>
				<pronunciation>(ral-teg′ra-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7880">Isentress</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> HIV integrase strand transfer inhibitor (ISTIs)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x798">
				<sec_title>Action:</sec_title>
				<para>Inhibits catalytic activity of HIV integrase, which is an HIV-encoded enzyme needed for replication</para>
			</section>
			<section type="uses" id="sidelem4x803">
				<sec_title>Uses:</sec_title>
				<para>HIV in combination with other antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x808">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x813">
					<section type="none" id="sidelem4x814">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, geriatric patients, hepatic disease, immune reconstitution syndrome, hepatitis, antimicrobial resistance, lactase deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x819">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x827">
					<label>•</label>
					<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x827">
							<item>
								<label>•</label>
								<para> 400 mg bid; if using with rifampin, give 800 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x831">
					<section type="none" id="sidelem4x832">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 400 mg; chew tabs 25, 100 mg, granules for oral suspension 100mg</para>
					</section>
					<section type="none" id="sidelem4x837">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x840">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x844">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew tabs</para>
									</item>
									<item>
										<label>•</label>
										<para>May give without regard to meals, with 8 oz of water</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x860">
						<sec_title>Oral suspension:</sec_title>
						<para>
							<list id="lidelem4x864">
								<item>
									<label>•</label>
									<para>Open foil, use 5 ml of water in provided measuring cup, close swirl, do not turn upside down, use oral syringe to administer, use within 30 min, discard any remaining suspension</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x870">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x873">
					<section type="none" id="sidelem4x874">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fatigue,</emphasis> fever, <emphasis style="italic">dizziness, headache,</emphasis> asthenia, <emphasis style="bold">suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x888">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x895">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, abdominal pain, asthenia, gastritis, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x905">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Oliguria, proteinuria, hematuria, glomerulonephritis, acute renal failure, renal tubular necrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x912">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x919">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus, pain or phlebitis at IV site, unusual sweating, alopecia</para>
					</section>
					<section type="none" id="sidelem4x924">
						<sec_title>META:</sec_title>
						<para> Hyperamylasia, hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x929">
						<sec_title>MS:</sec_title>
						<para> Myopathy, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x936">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Immune reconstitution syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x943">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Max absorption 3 hr if taken on an empty stomach; terminal half-life 9 hr; metabolized in the liver by uridine diphosphate glucuronosyltransferase (UGT A1A enzyme system); excreted in feces 51%, urine 32%</para>
			</section>
			<section type="interactions" id="sidelem4x948">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> raltegravir effect—proton pump inhibitors, H<emphasis style="inf">2</emphasis> blockers; UGT1A1 inhibitors (atazanavir)</para>
				<para>
					<emphasis alert="nurse">Increase: rhabdomyolysis, myopathy, elevated CPK—fibric acid derivatives, HMG-CoA reductase inhibitors</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> raltegravir levels—rifampin, efavirenz, tenofovir, tipranavir/ritonavir</para>
				<section type="none" id="sidelem4x967">
					<section type="none" id="sidelem4x968">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, GGT, total bilirubin, alk phos, amylase/lipase, CK, serum glucose, total/HDL/LDL cholesterol</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, platelets, ANC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x979">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x982">
					<section type="none" id="sidelem4x983">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x991">
							<label>•</label>
							<sec_title>HIV infection</sec_title>
							<para>
								<list id="lidelem4x991">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV infection:</emphasis> CD4, T-cell count, plasma HIV RNA, viral load; resistance testing before therapy, at treatment failure</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x996">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: Assess for calf pain, increased CPK, product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1001">
								<item>
									<label>•</label>
									<para>Skin eruptions: rash, urticaria, itching</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1009">
							<label>•</label>
							<sec_title>Suicidal thoughts/behaviors<route> monitor for depression; more common in those with mental illness</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1015">
							<label>•</label>
							<sec_title>
								<route>Immune reconstitution syndrome, usually during initial phase of treatment, may give antiinfective before starting</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1018">
								<item>
									<label>•</label>
									<para>Monitor total/HDL/LDL cholesterol baseline and periodically; all may be elevated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1023">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1027">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in CD4 counts, T-cell counts</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1033">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1038">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose missed, to take as soon as remembered up to 1 hr before next dose; not to double dose; not to share with others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1043">
								<item>
									<label>•</label>
									<para>That sexual partners need to be told that patient has HIV; that product does not cure infection, just controls symptoms; does not prevent infecting others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1049">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue (may indicate superinfection)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1054">
								<item>
									<label>•</label>
									<para>That product must be taken in equal intervals 2×/day to maintain blood levels for duration of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1059">
								<item>
									<para> To notify prescriber immediately of suicidal thoughts/behaviors</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1064">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy planned, suspected; to avoid breastfeeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1069">
								<item>
									<label>•</label>
									<para>To continue with follow-up exams, blood work</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active" ha="yes">
			<mono_name> ramelteon (Rx)</mono_name>
			<info>
				<pronunciation>(rah-mel′tee-on)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x10810">Rozerem</tradename>
				</tradenames>
				<class type="func"> Sedative/hypnotic, antianxiety</class>
				<class type="chem"> Melatonin receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1091">
				<sec_title>Action:</sec_title>
				<para>Binds selectively to melatonin receptors (MT<emphasis style="inf">1</emphasis>, MT<emphasis style="inf">2</emphasis>); thought to be involved in circadian rhythms and in the normal sleep/wake cycle</para>
			</section>
			<section type="uses" id="sidelem4x1102">
				<sec_title>Uses:</sec_title>
				<para>Insomnia (difficulty with sleep onset)</para>
			</section>
			<section type="contra" id="sidelem4x1107">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, infants, hypersensitivity</para>
				<section type="none" id="sidelem4x1112">
					<section type="none" id="sidelem4x1113">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), hepatic disease, alcoholism, COPD, seizure disorder, sleep apnea, suicidal ideation, angioedema, depression, sleep-related behaviors (sleepwalking), schizophrenia, bipolar disorder; alcohol intoxication, hepatic encephalopathy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1120">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1128">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1128">
							<item>
								<label>•</label>
								<para> 8 mg within 30 min of bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1132">
					<section type="none" id="sidelem4x1133">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x1141">
							<label>•</label>
							<sec_title>
								<route>Do not use with severe hepatic disease; use with caution for mild to moderate hepatic disease</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1144">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 8 mg</para>
					</section>
					<section type="none" id="sidelem4x1149">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1153">
								<item>
									<label>•</label>
									<para>Within 30 min of bedtime for sleeplessness; on empty stomach for fast onset</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not break tabs, swallow whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container in cool environment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1169">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1172">
					<section type="none" id="sidelem4x1173">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, somnolence, fatigue, headache, insomnia, depression, complex sleep-related reactions (sleep driving, sleep eating), <emphasis style="bold">suicidal thoughts/behaviors</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1180">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, dysgeusia, vomiting</para>
					</section>
					<section type="none" id="sidelem4x1185">
						<sec_title>MISC:</sec_title>
						<para> Myalgia, arthralgia, decreased blood cortisol, influenza, upper RI</para>
					</section>
					<section type="none" id="sidelem4x1190">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Severe allergic reactions, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1197">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorbed rapidly; peak ½-1½ hr; protein binding 82%; rapid first-pass metabolism via liver; 84% excreted in urine, 4% in feces; half-life 2-5 hr metabolite</para>
			</section>
			<section type="interactions" id="sidelem4x1202">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Possible toxicity: antiretroviral protease inhibitors</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: ramelteon effect, toxicity—alcohol; CYP1A2 inhibitors, azole antifungals (ketoconazole, fluconazole), fluvoxaMINE, anxiolytics, sedatives, hypnotics, barbiturates, ciprofloxacin, strong CYP2C9 inhibitors, strong CYP3A4 inhibitors</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of ramelteon—strong CYP inducer (rifampin)</para>
				<section type="none" id="sidelem4x1219">
					<section type="none" id="sidelem4x1220">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x1224">
								<item>
									<label>•</label>
									<para>Prolonged absorption, sleep onset reduced: high-fat/heavy meal</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1230">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> protein level</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> testosterone level</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1241">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1244">
					<section type="none" id="sidelem4x1245">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1251">
								<item>
									<para>
										<emphasis alert="nurse">Severe hypersensitive reactions: Assess for angioedema (facial swelling), product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1259">
							<label>•</label>
							<sec_title>Sleep characteristics</sec_title>
							<para>
								<list id="lidelem4x1259">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Sleep characteristics:</emphasis> type of sleep problem: falling asleep, staying asleep; complex sleep disorders (sleep walking/driving/eating) after taking product</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1266">
							<label>•</label>
							<sec_title>
								<route>suicidal ideation</route>
							</sec_title>
							<para>
								<list id="lidelem4x1266">
									<item>
										<label>•</label>
										<para>Mental status: mood, sensorium, affect, memory (long, short term), </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1270">
								<item>
									<label>•</label>
									<para>LFTs: before treatment, periodically</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1275">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1279">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to sleep at night, decreased amount of early morning awakening</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1285">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1290">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities requiring alertness until product stabilized; drowsiness may continue the next day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1295">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion, CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1300">
								<item>
									<label>•</label>
									<para>About alternative measures to improve sleep: reading, exercise several hr before bedtime, warm bath, warm milk, TV, self-hypnosis, deep breathing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1305">
								<item>
									<label>•</label>
									<para>To report if pregnancy is planned or suspected (C); to avoid breastfeeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1310">
								<item>
									<label>•</label>
									<para>To take product immediately before going to bed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1315">
								<item>
									<label>•</label>
									<para>Not to ingest a high-fat/heavy meal before taking product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1321">
								<item>
									<para>
										<emphasis alert="nurse">To report cessation of menses, galactorrhea (women), decreased libido, infertility, worsening of insomnia, behavioral changes, severe allergic reactions, suicidal thoughts/behaviors, if insomnia gets worse</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1326">
								<item>
									<label>•</label>
									<para>Med guide should be given to patient and reviewed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>ramipril (Rx)</mono_name>
			<info>
				<pronunciation>(ra-mi′pril)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x13360">Altace</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin-converting enzyme inhibitor (ACE)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1346">
				<para>
					<confusion>
						<tradename id="tnidelem4x13460">ramipril</tradename>
						<drug type="generic" refid="idelem4x13460">enalapril</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1353">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE, prevents conversion of angiotensin I to angiotensin II; results in dilation of arterial, venous vessels</para>
			</section>
			<section type="uses" id="sidelem4x1358">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with thiazide diuretics; CHF (post-MI), reduction in risk for MI, stroke, death from CV disorders</para>
				<section type="none" id="sidelem4x1363">
					<section type="none" id="sidelem4x1364">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Proteinuria due to diabetic nephropathy</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1369">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, hypersensitivity to ACE inhibitors, history of ACE-inhibitor–induced angioedema</para>
				<para>
					<bbw>Pregnancy (D) 2nd/3rd trimesters</bbw>
				</para>
				<section type="none" id="sidelem4x1384">
					<section type="none" id="sidelem4x1385">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, impaired renal/hepatic function, dialysis patients, hypovolemia, blood dyscrasias, CHF, renal artery stenosis, cough, African descent, aortic stenosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1390">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1393">
					<section type="none" id="sidelem4x1394">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x1402">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1402">
									<item>
										<label>•</label>
										<para> 2.5 mg/day initially, then 2.5-20 mg/day divided bid or daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1406">
						<sec_title>CHF post-MI</sec_title>
						<section type="none" id="sidelem4x1414">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1414">
									<item>
										<label>•</label>
										<para> 1.25-2.5 mg bid; may increase to 5 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1418">
						<sec_title>Reduction in risk for MI, stroke, death</sec_title>
						<section type="none" id="sidelem4x1426">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1426">
									<item>
										<label>•</label>
										<para> 2.5 mg/day × 7 days, then 5 mg/day × 21 days, then may increase to 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1430">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x1438">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;40 ml/min, reduce by 50%, titrate upward to max 5 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1441">
						<sec_title>Proteinuria due to diabetic nephropathy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1449">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1449">
									<item>
										<label>•</label>
										<para> 2.5 mg/day up to 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1453">
						<sec_title>Available forms:</sec_title>
						<para> Caps 1.25, 2.5, 5, 10 mg; tabs 1.25, 2.5, 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x1458">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1462">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Caps can be opened, added to food; mixture is stable for 24 hr at room temperature, 48 hr refrigerated</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at ≤86° F (30° C)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1478">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1481">
					<section type="none" id="sidelem4x1482">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> anxiety, insomnia, paresthesia, <emphasis style="italic">fatigue,</emphasis> depression, malaise, vertigo, syncope</para>
					</section>
					<section type="none" id="sidelem4x1493">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis> chest pain, palpitations, angina, syncope, dysrhythmia, <emphasis style="bold">heart failure, MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1503">
						<sec_title>EENT:</sec_title>
						<para> Hearing loss</para>
					</section>
					<section type="none" id="sidelem4x1508">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> constipation, vomiting, dyspepsia, dysphagia, anorexia, diarrhea, abdominal pain, <emphasis style="bold">hepatitis, hepatic failure, pancreatitis, hepatic necrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1518">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Proteinuria,</emphasis> increased BUN, creatinine, impotence</para>
					</section>
					<section type="none" id="sidelem4x1526">
						<sec_title>HEMA:</sec_title>
						<para> Decreased Hct, Hgb, <emphasis style="bold">eosinophilia, leukopenia, pancytopenia, thrombocytopenia, agranulocytosis (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1533">
						<sec_title>INTEG:</sec_title>
						<para> Rash, sweating, photosensitivity, pruritus</para>
					</section>
					<section type="none" id="sidelem4x1538">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hyperkalemia</emphasis>, hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x1546">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Angioedema, toxic epidermal necrolysis, anaphylaxis, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1553">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, arthritis, myalgia</para>
					</section>
					<section type="none" id="sidelem4x1558">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough,</emphasis> dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1566">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability &gt;50%-60%, onset 1-2 hr, peak 1-3 hr, duration 24 hr, protein binding 73%, half-life 13-17 hr, metabolized by liver (metabolites excreted in urine, feces)</para>
			</section>
			<section type="interactions" id="sidelem4x1572">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Do not use with AlisKiren in moderate-severe renal disease</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-sparing diuretics, potassium supplement, angiotensin II receptor agonists</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives, ganglionic blockers, adrenergic blockers, nitrates, acute alcohol ingestion</para>
				<para>
					<emphasis alert="nurse">Increase: toxicity—vasodilators, hydrALAZINE, prazosin, potassium-sparing diuretics, sympathomimetics, potassium supplements</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum levels of lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—indomethacin, NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x1603">
					<section type="none" id="sidelem4x1604">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x1615">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium salt substitutes, avoid use</para>
					</section>
					<section type="none" id="sidelem4x1622">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, BUN, creatinine, glucose, potassium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> RBC, Hgb, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1633">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1636">
					<section type="none" id="sidelem4x1637">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1643">
								<item>
									<para>
										<emphasis alert="nurse">Collagen-vascular disease (SLE, scleroderma): neutrophils, decreased platelets; WBC with differential at baseline, periodically; if neutrophils &lt;1000/mm</emphasis>
										<emphasis style="sup">
											<emphasis style="bold">3</emphasis>
										</emphasis>
										<emphasis alert="nurse">, discontinue treatment</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1656">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x1656">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> monitor B/P baseline and regularly, orthostatic hypotension, syncope</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1663">
							<label>•</label>
							<sec_title>Renal disease<route> protein, BUN, creatinine, potassium, sodium at baseline, periodically; increased levels may indicate nephrotic syndrome; renal symptoms</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1669">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x1669">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema in feet, legs daily; weight daily</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1674">
								<item>
									<para>
										<emphasis alert="nurse">Serious allergic reactions: angioedema, Stevens-Johnson syndrome, rash, fever, pruritus, urticaria; product should be discontinued if antihistamines fail to help</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1679">
								<item>
									<label>•</label>
									<para>Monitor electrolytes baseline and periodically; potassium may be increased</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1684">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1688">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P; CHF</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1694">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1699">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly; to comply with dosage schedule, even if feeling better</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1704">
								<item>
									<label>•</label>
									<para>Not to use OTC products (cough, cold, allergy) unless directed by prescriber; not to use salt substitutes containing potassium without consulting prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1709">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1715">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pain</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1720">
								<item>
									<label>•</label>
									<para>To report excessive perspiration, dehydration, vomiting, diarrhea; may lead to fall in B/P; to maintain hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1725">
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, lightheadedness; that these may occur during first few days of therapy; to avoid hazardous activities until response is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1730">
								<item>
									<label>•</label>
									<para>That product may cause skin rash, impaired perspiration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1735">
								<item>
									<label>•</label>
									<para>How to take B/P, normal readings for age group</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To inform prescriber if pregnancy planned, suspected, pregnancy (D); not to breastfeed</bbw>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>ranibizumab (Rx)</mono_name>
			<info>
				<pronunciation>(ran-ih-biz′oo-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x17600">Lucentis</tradename>
				</tradenames>
				<class type="func"> Ophthalmic</class>
				<class type="chem"> Selective vascular endothelial growth factor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1770">
				<sec_title>Action:</sec_title>
				<para>Binds to receptor-binding site of active forms of vascular endothelial growth factor A (VEGF-A) that causes angiogenesis and cell proliferation</para>
			</section>
			<section type="uses" id="sidelem4x1777">
				<sec_title>Uses:</sec_title>
				<para>Macular degeneration (neovascular) (wet), macular edema after retinal vein occlusion (RVO), diabetic macular edema</para>
			</section>
			<section type="contra" id="sidelem4x1782">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, ocular infections</para>
				<section type="none" id="sidelem4x1787">
					<section type="none" id="sidelem4x1788">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, retinal detachment, increased intraocular pressure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1793">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1796">
					<section type="none" id="sidelem4x1797">
						<sec_title>Macular degeneration/macular edema after retinal vein occlusion (RVO)</sec_title>
						<section type="none" id="sidelem4x1805">
							<label>•</label>
							<sec_title>Adult<route> INTRAVITREAL</route></sec_title>
							<para>
								<list id="lidelem4x1805">
									<item>
										<label>•</label>
										<para> 0.5 mg (0.05 ml) of 10 mg/ml product monthly or 0.5 mg monthly ×4 mo, then 0.5 mg q3mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1809">
						<sec_title>Diabetic macular edema</sec_title>
						<section type="none" id="sidelem4x1817">
							<label>•</label>
							<sec_title>Adults<route> INTRAVITREAL</route></sec_title>
							<para>
								<list id="lidelem4x1817">
									<item>
										<label>•</label>
										<para> 0.3 mg of 6 mg/ml product q28day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1821">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 6 mg/ml, 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x1826">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1830">
								<item>
									<label>•</label>
									<para>By ophthalmologist via intravitreal injection using adequate anesthesia; use 19-gauge filter</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in refrigerator; do not freeze</para>
								</item>
								<item>
									<label>•</label>
									<para>Protect from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1846">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1849">
					<section type="none" id="sidelem4x1850">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x1855">
						<sec_title>EENT:</sec_title>
						<para> Blepharitis, cataract, conjunctival hemorrhage/hyperemia, detachment of retinal pigment epithelium, dry/irritation/pain in eye, visual impairment, vitreous floaters, ocular infection</para>
					</section>
					<section type="none" id="sidelem4x1860">
						<sec_title>GI:</sec_title>
						<para> Constipation, nausea</para>
					</section>
					<section type="none" id="sidelem4x1865">
						<sec_title>MISC:</sec_title>
						<para> Hypertension, UTI, <emphasis style="bold">thromboembolism, nonocular bleeding,</emphasis> anemia, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x1873">
						<sec_title>RESP:</sec_title>
						<para> Bronchitis, cough, sinusitis, URI</para>
					</section>
					<section type="none" id="sidelem4x1878">
						<sec_title>INTEG: </sec_title>
						<para>Impaired wound healing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1883">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Elimination half-life 9 days, peak 1 day</para>
			</section>
			<section type="interactions" id="sidelem4x1888">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe inflammation—verteporfin photodynamic therapy (PDT)</para>
			</section>
			<section type="considerations" id="sidelem4x1895">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1898">
					<section type="none" id="sidelem4x1899">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1907">
							<label>•</label>
							<sec_title>Eye changes</sec_title>
							<para>
								<list id="lidelem4x1907">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Eye changes:</emphasis> redness; sensitivity to light, vision change; increased intraocular pressure change; report infection to ophthalmologist immediately, complete procedure with anesthesia and antibiotic before use, check perfusion of optic nerve after use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1914">
							<label>•</label>
							<sec_title>Hypersensitivity</sec_title>
							<para>
								<list id="lidelem4x1914">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypersensitivity:</emphasis> monitor for inflammation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1918">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1922">
								<item>
									<label>•</label>
									<para>Therapeutic response: prevention of increasing macular degeneration</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1928">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x1936">
							<label>•</label>
							<sec_title>
								<route>That, if eye becomes red, sensitive to light, painful, or if there is a change in vision, to seek immediate care from ophthalmologist</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1939">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>ranitidine (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(ra-nit′i-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x19523">
						<country code="CAN">Acid Reducer</country>
					</tradename>
					<tradename id="tnidelem4x19522">
						<country code="CAN">Nu-Ranit </country>
					</tradename>
					<tradename id="tnidelem4x19521">Zantac</tradename>
					<tradename id="tnidelem4x19520">
						<country code="CAN">Zantac C </country>
					</tradename>
				</tradenames>
				<class type="func"> H-Histamine receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1969">
				<para>
					<confusion>
						<tradename id="tnidelem4x19690">ranitidine</tradename>
						<drug type="generic" refid="idelem4x19690">amantadine/rimantadine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1976">
				<sec_title>Action:</sec_title>
				<para>Inhibits histamine at H<emphasis style="inf">2</emphasis>-receptor site in parietal cells, which inhibits gastric acid secretion</para>
			</section>
			<section type="uses" id="sidelem4x1984">
				<sec_title>Uses:</sec_title>
				<para>Duodenal ulcer, Zollinger-Ellison syndrome, gastric ulcers, hypersecretory conditions, gastroesophageal reflux disease, stress ulcers, erosive esophagitis (maintenance), active duodenal ulcers with <emphasis style="italic">Helicobacter pylori</emphasis> in combination with clarithromycin, systemic mastocytosis, multiple endocrine adenoma syndrome, heartburn</para>
				<section type="none" id="sidelem4x1994">
					<section type="none" id="sidelem4x1995">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Prevention of aspiration pneumonitis, upper GI bleeding, angioedema, gastritis, urticaria, NSAID-induced ulcer prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2000">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x2005">
					<section type="none" id="sidelem4x2006">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, child &lt;12 yr, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2011">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2014">
					<section type="none" id="sidelem4x2015">
						<sec_title>Duodenal ulcer</sec_title>
						<section type="none" id="sidelem4x2023">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2023">
									<item>
										<label>•</label>
										<para> 150 mg bid or 300 mg/day after <emphasis style="smallcaps">pm</emphasis> meal or at bedtime; maintenance 150 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2033">
							<label>•</label>
							<sec_title>Infant and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2033">
									<item>
										<label>•</label>
										<para> 2-4 mg/kg bid, max 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2037">
						<sec_title>Zollinger-Ellison syndrome</sec_title>
						<section type="none" id="sidelem4x2045">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2045">
									<item>
										<label>•</label>
										<para> 150 mg bid, may increase if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2049">
						<sec_title>Gastric ulcer</sec_title>
						<section type="none" id="sidelem4x2057">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2057">
									<item>
										<label>•</label>
										<para> 150 mg bid × 6 wk, then 150 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2064">
							<label>•</label>
							<sec_title>Infant and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2064">
									<item>
										<label>•</label>
										<para> 2-4 mg/kg bid, max 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2068">
						<sec_title>GERD</sec_title>
						<section type="none" id="sidelem4x2076">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2076">
									<item>
										<label>•</label>
										<para> 150 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2080">
						<sec_title>Erosive esophagitis</sec_title>
						<section type="none" id="sidelem4x2088">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2088">
									<item>
										<label>•</label>
										<para> 150 mg qid for up to 12 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2095">
							<label>•</label>
							<sec_title>Child ≥1 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2095">
									<item>
										<label>•</label>
										<para> 5-10 mg/kg/day in 2-3 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2099">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x2108">
							<label>•</label>
							<sec_title>Adult<route> CCr &lt;50 ml/min, give 50% of dose or extend dosing interval</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2111">
						<sec_title>NSAID-induced ulcer prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2119">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2119">
									<item>
										<label>•</label>
										<para> 150 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2123">
						<sec_title>Stress gastritis prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2131">
							<label>•</label>
							<sec_title>Adult<route> IM/INT IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2131">
									<item>
										<label>•</label>
										<para> 50 mg q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2135">
						<sec_title>Severe, acute urticaria/angioedema (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2143">
							<label>•</label>
							<sec_title>Adult<route> INT IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2143">
									<item>
										<label>•</label>
										<para> 50 mg with H<emphasis style="inf">1</emphasis>-blocker</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2150">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 75, 150, 300 mg; sol for inj 25 mg/ml; caps 150, 300 mg; syr 15 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x2155">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2158">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x2162">
									<item>
										<label>•</label>
										<para>Antacids 1 hr before or 1 hr after ranitidine</para>
									</item>
									<item>
										<label>•</label>
										<para>Without regard to meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2178">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x2182">
									<item>
										<label>•</label>
										<para>No dilution needed; inject in large muscle mass, aspirate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2188">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x2192">
									<item>
										<label>•</label>
										<para>Dilute to max 2.5 mg/ml (50 mg/20 ml) using 0.9% NaCl (nonpreserved) or D<emphasis style="inf">5</emphasis>W, give dose over ≥5 min (max 4 mg/ml)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2201">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x2205">
									<item>
										<label>•</label>
										<para>Dilute to max 0.5 mg/ml with D<emphasis style="inf">5</emphasis>W, NS, give over 15-20 min (5-7 ml/min); premixed ready-to-use bags as 1 mg/ml (50 mg/50 ml), infusion over 15-20 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2214">
							<sec_title>Continuous 24 hr IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x2222">
								<label>•</label>
								<sec_title>Adult</sec_title>
								<para>
									<list id="lidelem4x2222">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult:</emphasis> dilute 150 mg/250 ml of D<emphasis style="inf">5</emphasis>W or NS; run over 24 hr (6.25 mg/hr or as directed); use infusion device; use within 48 hr; <emphasis style="italic">Zollinger-Ellison syndrome:</emphasis> dilute in D<emphasis style="inf">5</emphasis>W, NS; max concentration 2.5 mg/ml, use infusion device</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, aldesleukin, alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminophylline, amphotericin B liposome, amsacrine, anikinra, anidulafungin, ascorbic acid, atracurium, atropine, aztreonam, bivalirudin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, ceFAZolin, cefepime, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, doxapram, DOXOrubicin, DOXOrubicin liposome, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, folic acid, foscarnet, furosemide, ganciclovir, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem/cilastatin, inamrinone, indomethacin, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoXANtrone, morphine, multivitamin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pancuronium, papaverine, PEMEtrexed, penicillin G, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyrdoxime, remifentanil, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiopental, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trastuzumab, trimethaphan, urokinase, vancomycin, vecuronium, vinCRIStine, vinorelbine, warfarin, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2241">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2244">
					<section type="none" id="sidelem4x2245">
						<sec_title>CNS:</sec_title>
						<para> Headache, sleeplessness, dizziness, confusion, agitation, depression, hallucination (geriatric patients)</para>
					</section>
					<section type="none" id="sidelem4x2250">
						<sec_title>CV:</sec_title>
						<para> Tachycardia, bradycardia, PVCs</para>
					</section>
					<section type="none" id="sidelem4x2255">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, increased ocular pressure</para>
					</section>
					<section type="none" id="sidelem4x2260">
						<sec_title>GI:</sec_title>
						<para> Constipation, abdominal pain, diarrhea, nausea, vomiting, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2267">
						<sec_title>GU:</sec_title>
						<para> Impotence, <emphasis style="bold">acute interstitial nephritis (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2274">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria, rash, fever</para>
					</section>
					<section type="none" id="sidelem4x2279">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pneumonia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2286">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis (rare)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2293">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2296">
					<section type="none" id="sidelem4x2297">
						<sec_title>PO:</sec_title>
						<para> Peak 2-3 hr; duration 8-12 hr; metabolized by liver; excreted in urine (30% unchanged, PO), breast milk; half-life 2-3 hr; protein binding 15%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2302">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of pramipexole, procainamide, trospium, triazolam, calcium channel blockers, memantine, saquinavir, adefovir</para>
				<para>
					<emphasis alert="nurse">Increase:</emphasis> GI obstruction risk—NIFEdipine ext rel products</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—sulfonylureas, procainamide, benzodiazepines, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of ranitidine—antacids, anticholinergics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of cephalosporins, iron salts, ketoconazole, itraconazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI obstruction risk—NIFEdipine ext rel products</para>
				<section type="none" id="sidelem4x2331">
					<section type="none" id="sidelem4x2332">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, creatinine</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine protein (Multistix)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2343">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2346">
					<section type="none" id="sidelem4x2347">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2355">
							<label>•</label>
							<sec_title>GI complaints</sec_title>
							<para>
								<list id="lidelem4x2355">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI complaints:</emphasis> nausea, vomiting, diarrhea, cramps, abdominal discomfort, jaundice; report immediately</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2359">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, BUN, creatinine, LFTs, serum, stool guaiac before, periodically during therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2364">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2368">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased abdominal pain, heartburn</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2374">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2378">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities until stabilized on product</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be continued for prescribed time to be effective</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy planned, suspected; to avoid breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to take maximum OTC daily dose for &gt;2 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>To take once-daily dose before bedtime</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>ranolazine (Rx)</mono_name>
			<info>
				<pronunciation>(ruh-no′luh-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24090">Ranexa</tradename>
				</tradenames>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2415">
				<sec_title>Action:</sec_title>
				<para>Antianginal, antiischemic; unknown, may work by inhibiting portal fatty-acid oxidation</para>
			</section>
			<section type="uses" id="sidelem4x2420">
				<sec_title>Uses:</sec_title>
				<para>Chronic stable angina pectoris; use in patients who have not responded to other treatment options; should be used in combination with other antianginals such as amlodipine, β-blockers, nitrates</para>
				<section type="none" id="sidelem4x2425">
					<section type="none" id="sidelem4x2426">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Unstable angina</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2431">
				<sec_title>Contraindications:</sec_title>
				<para>Preexisting QT prolongation, hepatic disease (Child-Pugh class A, B, C), hypersensitivity, hypokalemia, renal failure, torsades de pointes, ventricular dysrhythmia, ventricular tachycardia, hepatic cirrhosis</para>
				<section type="none" id="sidelem4x2436">
					<section type="none" id="sidelem4x2437">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, hypotension, renal disease, females at risk for torsades de pointes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2442">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2450">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2450">
							<item>
								<label>•</label>
								<para> 500 mg bid, increased to 1000 mg bid based on response; max 1000 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2454">
					<section type="none" id="sidelem4x2455">
						<sec_title>Available forms:</sec_title>
						<para> Ext rel tabs 500, 1000 mg</para>
					</section>
					<section type="none" id="sidelem4x2460">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2468">
							<label>•</label>
							<sec_title>Ext rel tabs</sec_title>
							<para>
								<list id="lidelem4x2468">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ext rel tabs:</emphasis> do not break, crush, chew tabs; take product as prescribed; do not double or skip dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2472">
								<item>
									<label>•</label>
									<para>Without regard to meals, bid; do not use with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2477">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2480">
					<section type="none" id="sidelem4x2481">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> hallucinations</para>
					</section>
					<section type="none" id="sidelem4x2489">
						<sec_title>CV:</sec_title>
						<para> Palpitations, <emphasis style="bold">QT prolongation,</emphasis> orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x2497">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus</para>
					</section>
					<section type="none" id="sidelem4x2502">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, constipation, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x2507">
						<sec_title>MISC:</sec_title>
						<para> Peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x2512">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2517">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption varied; peak 2-5 hr; half-life 7 hr; extensively metabolized by the liver (CYP3A and less by CYP2D6); excreted in urine (75%), feces (25%); protein binding 62%</para>
			</section>
			<section type="interactions" id="sidelem4x2522">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> ranolazine action—diltiazem, ketoconazole, macrolide antibiotics, dofetilide, PARoxetine, protease inhibitors, quiNIDine, sotalol, thioridazine, verapamil, ziprasidone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of digoxin, simvastatin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ranolazine absorption, toxicity—antiretroviral protease inhibitors</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation and torsades de pointes—class IA/III antidysrythmics, arsenic trioxide, chloroquine, droperidol, haloperidol, levomethadyl, methadone, pentamidine, chlorproMAZINE, mesoridazine, thioridazine, pimozide; CYP3A4 inhibitors (ketoconazole, fluconazole, itraconazole, IV miconazole, voriconazole, diltiazem, verapamil)</emphasis>
				</para>
				<section type="none" id="sidelem4x2542">
					<section type="none" id="sidelem4x2543">
						<sec_title>Drug/Food</sec_title>
						<section type="none" id="sidelem4x2551">
							<label>•</label>
							<sec_title>
								<route>Do not use with grapefruit, grapefruit juice</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2554">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2557">
					<section type="none" id="sidelem4x2558">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2566">
							<label>•</label>
							<sec_title>Angina</sec_title>
							<para>
								<list id="lidelem4x2566">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Angina:</emphasis> characteristics of pain (intensity, location, duration, alleviating/precipitating factors)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2571">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG for QT prolongation, ejection fraction; assess for chest pain, palpitations, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2576">
								<item>
									<label>•</label>
									<para>Cardiac status: B/P, pulse, respirations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2581">
								<item>
									<label>•</label>
									<para>LFTs, serum creatinine/BUN, magnesium, potassium before treatment, periodically</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2586">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2590">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anginal pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2596">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2601">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product, dizziness no longer a problem</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2608">
								<item>
									<para>
										<emphasis alert="nurse">To avoid OTC drugs, grapefruit juice, products prolonging QTc (quiNIDine, dofetilide, sotalol, erythromycin, thioridazine, ziprasidone or protease inhibitors, diltiazem, ketoconazole, macrolide antibiotics, verapamil) unless directed by prescriber; to notify prescriber of palpitations, fainting</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2613">
								<item>
									<label>•</label>
									<para>To comply with all areas of medical regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2618">
								<item>
									<label>•</label>
									<para>To take as directed; not to skip dose, double doses</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2623">
								<item>
									<label>•</label>
									<para>Not to chew or crush; not to use with grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2628">
								<item>
									<label>•</label>
									<para>To notify all health care providers of product use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2636">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of palpitations, dizziness, edema, dyspnea</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2639">
								<item>
									<label>•</label>
									<para>For acute angina, take other products prescribed; this product does not decrease acute attack</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>rasagiline (Rx)</mono_name>
			<info>
				<pronunciation>(ra-sa′ji-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x26490">Azilect</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> MAOI, type B</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2659">
				<sec_title>Action:</sec_title>
				<para>Inhibits MAOI type B at recommended doses; may increase DOPamine levels</para>
			</section>
			<section type="uses" id="sidelem4x2664">
				<sec_title>Uses:</sec_title>
				<para>Idiopathic Parkinson’s disease monotherapy or with levodopa</para>
			</section>
			<section type="contra" id="sidelem4x2669">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding; hypersensitivity to this product, MAOIs; pheochromocytoma</para>
				<section type="none" id="sidelem4x2674">
					<section type="none" id="sidelem4x2675">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, psychiatric disorders, moderate to severe hepatic disorders</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2680">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2683">
					<section type="none" id="sidelem4x2684">
						<sec_title>Monotherapy</sec_title>
						<section type="none" id="sidelem4x2692">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2692">
									<item>
										<label>•</label>
										<para> 1 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2696">
						<sec_title>Adjunctive therapy</sec_title>
						<section type="none" id="sidelem4x2704">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2704">
									<item>
										<label>•</label>
										<para> 0.5 mg/day, may increase 1 mg/day; change of levodopa dose for adjunct therapy; reduced levodopa dose may be needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2708">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x2716">
							<label>•</label>
							<sec_title>Adult<route> PO 0.5 mg for mild hepatic disease</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2719">
						<sec_title>Concomitant ciprofloxacin, other CYP1A2 inhibitors</sec_title>
						<section type="none" id="sidelem4x2727">
							<label>•</label>
							<sec_title>Adult<route> PO 0.5 mg; plasma concentrations of rasagiline may double</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2730">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 1 mg</para>
					</section>
					<section type="none" id="sidelem4x2735">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2741">
								<item>
									<para>
										<emphasis alert="nurse">With meals to prevent nausea; continuing therapy usually reduces or eliminates nausea; do not give with foods/liquids containing large amounts of tyramine</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2746">
								<item>
									<label>•</label>
									<para>Reduce dose of carbidopa/levodopa cautiously</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2751">
								<item>
									<label>•</label>
									<para>Renal failure: in dialysis, increase dose slowly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2756">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2759">
					<section type="none" id="sidelem4x2760">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, hallucinations, depression, headache, malaise, paresthesia, vertigo, syncope</para>
					</section>
					<section type="none" id="sidelem4x2765">
						<sec_title>CV:</sec_title>
						<para> Angina, <emphasis style="bold">hypertensive crisis</emphasis> (ingestion of tyramine products), orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x2773">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea</emphasis>, diarrhea, dry mouth, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x2781">
						<sec_title>GU:</sec_title>
						<para> Impotence, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x2786">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2793">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Alopecia, skin cancers</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2800">
						<sec_title>MISC:</sec_title>
						<para> Conjunctivitis, fever, flu syndrome, neck pain, allergic reaction, alopecia</para>
					</section>
					<section type="none" id="sidelem4x2805">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, arthritis, dyskinesia</para>
					</section>
					<section type="none" id="sidelem4x2810">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2815">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset, peak, duration unknown; well absorbed; protein binding &gt;88%-94%; metabolized by CYP1A2 in liver; excreted by kidneys, half-life 3 hr</para>
			</section>
			<section type="interactions" id="sidelem4x2821">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not give with meperidine, other analgesics because serious reactions (including coma and death) may occur; do not give with sympathomimetics</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: levels of rasagiline up to 2-fold—ciprofloxacin, CYP1A2 inhibitors (atazanavir, mexiletine, taurine)</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: severe CNS toxicity with antidepressants (tricyclics, SSRIs, SNRIs, mirtazapine, cyclobenzaprine)</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: hypertensive crisis—MAOIs</emphasis>
				</para>
				<section type="none" id="sidelem4x2840">
					<section type="none" id="sidelem4x2841">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x2849">
							<label>•</label>
							<sec_title>
								<route>Do not give with St. John’s wort, yohimbe</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2852">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x2856">
								<item>
									<label>•</label>
									<para>Do not give with foods/liquids that have large amounts of tyramine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2862">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBCs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2873">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2876">
					<section type="none" id="sidelem4x2877">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2885">
							<label>•</label>
							<sec_title>Parkinson’s symptoms</sec_title>
							<para>
								<list id="lidelem4x2885">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Parkinson’s symptoms:</emphasis> tremors, ataxia, muscle weakness and rigidity at baseline, periodically; increased dyskinesia, postural hypotension if used in combination with levodopa</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2889">
								<item>
									<label>•</label>
									<para>Mental status: hallucinations, confusion, notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2895">
								<item>
									<para>
										<emphasis alert="nurse">Hypertensive crisis: severe headache, blurred vision, seizures, chest pain, difficulty thinking, nausea, vomiting, signs of stroke; any unexplained severe headache should be considered to be hypertensive crisis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2901">
								<item>
									<para>
										<emphasis alert="nurse">Melanoma: periodic skin exams by a dermatologist</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2906">
								<item>
									<label>•</label>
									<para>Cardiac status: B/P, ECG periodically, orthostatic hypotension during 2 months of treatment during beginning treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2912">
								<item>
									<para>
										<emphasis alert="nurse">Tyramine products: foods, other medications may lead to hypertensive crisis (tachycardia, bradycardia, chest pain, nausea, vomiting, sweating, dilated pupils)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2917">
								<item>
									<label>•</label>
									<para>Drowsiness, daytime sleepiness or falling asleep, may need to be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2922">
								<item>
									<label>•</label>
									<para>Skin should be checked periodically for possible skin cancer</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2927">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2931">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved symptoms in patients with Parkinson’s disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2937">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2942">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2947">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product; that dizziness can occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2952">
								<item>
									<label>•</label>
									<para>To rinse mouth frequently; to use sugarless gum to alleviate dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2957">
								<item>
									<label>•</label>
									<para>To take as prescribed; not to miss dose or double doses; to take missed dose as soon as remembered if several hours before next dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2963">
								<item>
									<para>
										<emphasis alert="nurse">To prevent hypertensive crisis by avoiding high-tyramine foods (&gt;150 mg)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2971">
							<label>•</label>
							<sec_title>
								<route>To report signs of hypertensive crisis</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2974">
								<item>
									<label>•</label>
									<para>To avoid CNS depressants, alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2979">
								<item>
									<label>•</label>
									<para>To notify all providers of product use; to avoid elective surgery, other procedures involving CNS depressants</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>rasburicase (Rx)</mono_name>
			<info>
				<pronunciation>(rass-burr′i-case)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x29891">Elitek</tradename>
					<tradename id="tnidelem4x29890">
						<country code="CAN">Fasturtec </country>
					</tradename>
				</tradenames>
				<class type="func"> Enzyme</class>
				<class type="chem"> Recombinant urate-oxidase enzyme</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3001">
				<sec_title>Action:</sec_title>
				<para>Catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin)</para>
			</section>
			<section type="uses" id="sidelem4x3006">
				<sec_title>Uses:</sec_title>
				<para>To reduce uric acid levels in children with leukemia, lymphoma, solid tumor malignancies who are receiving chemotherapy</para>
			</section>
			<section type="contra" id="sidelem4x3011">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>G6PD deficiency (Mediterranean, African descent), hemolytic reactions, methemoglobinemia reactions to product</bbw>
				</para>
				<section type="none" id="sidelem4x3026">
					<section type="none" id="sidelem4x3027">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;2 yr, anemia</para>
						<para>
							<bbw>Acute bronchospasm, angina, angioedema, atony, African American and Mediterranean patients, hypotension, urticaria</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3043">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3051">
					<label>•</label>
					<sec_title>Adult/adolescent/infant<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x3051">
							<item>
								<label>•</label>
								<para> 0.2 mg/kg as single daily dose × 5 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3055">
					<section type="none" id="sidelem4x3056">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 1.5, 7.5 mg/vial</para>
					</section>
					<section type="none" id="sidelem4x3061">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3064">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3068">
									<item>
										<label>•</label>
										<para>Reconstitute with diluent provided, add 1 ml of diluent/each vial, swirl, withdraw amount needed, mix with NS to final volume of 50 ml, use within 24 hr, give over 30 min, do not use filter, use different line; if not possible, flush with ≥15 ml of saline before, after use</para>
									</item>
									<item>
										<label>•</label>
										<para>Chemotherapy started 4-24 hr after 1st dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3079">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3082">
					<section type="none" id="sidelem4x3083">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> fever</para>
					</section>
					<section type="none" id="sidelem4x3091">
						<sec_title>CV:</sec_title>
						<para> Chest pain, hypotension</para>
					</section>
					<section type="none" id="sidelem4x3096">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea, abdominal pain, constipation, dyspepsia, mucositis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3103">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia with fever, hemolysis, methemoglobinemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3110">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3117">
						<sec_title>MISC:</sec_title>
						<para> Edema</para>
					</section>
					<section type="none" id="sidelem4x3122">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> wheezing, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x3130">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, hemolysis, methemoglobinemia, sepsis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3137">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Elimination half-life 16-21 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3142">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: toxicity—allopurinol</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x3150">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3153">
					<section type="none" id="sidelem4x3154">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3159">
								<item>
									<label>•</label>
									<para>Blood studies: BUN, serum uric acid, urine creatinine clearance, electrolytes, CBC with differential before, during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3164">
								<item>
									<label>•</label>
									<para>Monitor temperature; fever may indicate beginning infection; no rectal temperatures</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3170">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: dyspnea, urticaria, flushing, wheezing, swelling of lips, tongue, throat; have emergency equipment nearby</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3176">
								<item>
									<para>
										<emphasis alert="nurse">G6PD deficiency, hemolytic reactions, methemoglobinemia; these patients should not be given this product; screen patients who are at higher risk for these disorders</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3181">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping; if severe diarrhea occurs, fluid, electrolytes may need to be given</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3186">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3190">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased uric acid levels in children when antineoplastics causing high uric acid levels used</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3196">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3201">
								<item>
									<label>•</label>
									<para>About the reason for therapy, expected results</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3207">
								<item>
									<para>
										<emphasis alert="nurse">To report trouble breathing, jaundice, chest pain</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active" ha="yes">
			<mono_name> regorafenib</mono_name>
			<info>
				<pronunciation>(re′goe-raf′e-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x32190">Stivarga</tradename>
				</tradenames>
				<class type="func"> Antineoplastic biologic-response modifier; multikinase inhibitor</class>
				<class type="chem"> Signal transduction inhibitor (STI)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x3229">
				<sec_title>Action:</sec_title>
				<para>Inhibits tyrosine kinase in patients with colorectal cancer</para>
			</section>
			<section type="uses" id="sidelem4x3234">
				<sec_title>Uses:</sec_title>
				<para>Metastatic colorectal cancer in those who have received fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, an anti-VEGF therapy; and an anti-EGFR therapy if <emphasis style="italic">KRAS</emphasis> wild type</para>
			</section>
			<section type="contra" id="sidelem4x3242">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>)</para>
				<section type="none" id="sidelem4x3247">
					<section type="none" id="sidelem4x3248">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, cardiac/renal/hepatic/dental disease, fistula, GI bleeding or perforation, bone marrow suppression, infection, wound dehiscence, thrombocytopenia, neutropenia, immunosuppression</para>
						<para>
							<bbw>Hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3264">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3272">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3272">
							<item>
								<label>•</label>
								<para> 160 mg/day with a low-fat breakfast × 21 days of a 28-day cycle, cycles may be repeated</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3276">
					<section type="none" id="sidelem4x3277">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 40 mg</para>
					</section>
					<section type="none" id="sidelem4x3282">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3286">
								<item>
									<label>•</label>
									<para>Store at 77°F (25°C)</para>
								</item>
								<item>
									<label>•</label>
									<para>Give at the same time each day with a low-fat breakfast that contains less than 30% fat such as 2 slices of white toast with 1 tbsp of low-fat margarine and 1 tbsp of jelly, and 8 oz of skim milk; or 1 cup of cereal, 8 oz of skim milk, 1 slice of toast with jam, apple juice, and 1 cup of coffee or tea</para>
								</item>
								<item>
									<label>•</label>
									<para>Swallow tablets whole</para>
								</item>
								<item>
									<label>•</label>
									<para>If a dose is missed, take as soon as possible that day; do not take 2 doses on the same day</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis alert="nurse">Hand–foot skin reaction:</emphasis>
							<emphasis alert="nurse">Reduce to 120 mg (grade 2 palmar–plantar erythrodysesthesia); hold if grade 2 toxicity does not improve in ≤7 days or recurs; hold for ≥7 days in grade 3 toxicity; reduce to 80 mg for recurrent grade 2 toxicity; discontinue if 80 mg is not tolerated</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Hypertension:</emphasis>
							<emphasis alert="nurse">Hold in grade 2 hypertension</emphasis>
						</para>
						<section type="none" id="sidelem4x3321">
							<sec_title>Other severe toxicity (except hepatotoxicity)</sec_title>
							<para>
								<emphasis alert="nurse">Hold until toxicity resolves in grade 3 or 4 toxicity; consider the risk/benefits of continuing therapy in grade 4 toxicity, reduce dosage to 120 mg; if grade 3 or 4 toxicity recurs, hold until toxicity resolves, then reduce to 80 mg; discontinue in those who do not tolerate 80-mg dose</emphasis>
							</para>
							<para>
								<emphasis alert="nurse">Hepatic dose: Baseline mild (Child-Pugh class A) or moderate (Child-Pugh class B): no change; baseline severe hepatic impairment (Child-Pugh class C): use not recommended; AST/ALT elevations during therapy: For grade 3 AST/AST level elevations, hold dose; if therapy is continued, reduce to 120 mg after levels recover; discontinue in those with AST/ALT &gt;203 ULN; AST/ ALT &gt;33 ULN and bilirubin &gt;23 ULN; recurrence of AST/ALT &gt;53 ULN despite a reduction to 120 mg</emphasis>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3334">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3337">
					<section type="none" id="sidelem4x3338">
						<sec_title>CNS:</sec_title>
						<para> Headache, tremor</para>
					</section>
					<section type="none" id="sidelem4x3343">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Hypertensive crisis, MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3350">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x3355">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Hepatotoxicity, GI hemorrhage,</emphasis> diarrhea, <emphasis style="bold">GI perforation, xerostomia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3365">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3372">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia</para>
					</section>
					<section type="none" id="sidelem4x3377">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x3382">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, decreased weight, hand–foot syndrome, hypothyroidism</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3387">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 99%, metabolized by CYP3A4, UGT1A0, half-life 14-58 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3392">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> regorafenib concentrations—CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of simvastatin, calcium channel blockers, ergots</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentration of warfarin; avoid use with warfarin; use low-molecular-weight anticoagulants instead</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> regorafenib concentrations—CYP3A4 inducers (dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital)</para>
				<section type="none" id="sidelem4x3411">
					<section type="none" id="sidelem4x3412">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> regorafenib effect—grapefruit juice; avoid use while taking product</para>
					</section>
					<section type="none" id="sidelem4x3419">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> imatinib concentration—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3426">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3429">
					<section type="none" id="sidelem4x3430">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Hepatic disease: fatal hepatotoxicity can occur; obtain LFTs baseline and at least every 2 wk × 2 mo, then monthly</bbw>
						</para>
						<para>
							<emphasis alert="nurse">Fatal bleeding: From GI, respiratory, GU tracts; permanently discontinue in those with severe bleeding</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Palmar–plantar erythrodysesthesia (hand–foot syndrome): More common in those previously treated; reddening swelling, numbness, desquamation on palms, soles</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">GI perforation/fistula: Discontinue if this occurs; assess for pain in epigastric area, dyspepsia, flatulence, fever, chills</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Hypertension/hypertensive crisis: Hypertension usually occurs in the first cycle in those with preexisting hypertension; do not start treatment until B/P is controlled; monitor B/P every wk × 6 wk, then at start of each cycle or more often if needed; temporarily or permanently discontinue for severe uncontrolled hypertension</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x3463">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3467">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in spread or size of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3473">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3477">
								<item>
									<label>•</label>
									<para>To report adverse reactions immediately: bleeding, rash</para>
								</item>
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>That effect on male fertility is unknown</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active" ha="yes">
			<mono_name> remifentanil (Rx)</mono_name>
			<info>
				<pronunciation>(rem-ih-fin′ta-nill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x35000">Ultiva</tradename>
				</tradenames>
				<class type="func"> Opiate agonist analgesic</class>
				<class type="chem"> μ-Opioid agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="actions" id="sidelem4x3513">
				<sec_title>Action:</sec_title>
				<para>Inhibits ascending pain pathways in limbic system, thalamus, midbrain, hypothalamus</para>
			</section>
			<section type="uses" id="sidelem4x3518">
				<sec_title>Uses:</sec_title>
				<para>In combination with other products for general anesthesia to provide analgesia</para>
			</section>
			<section type="contra" id="sidelem4x3523">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x3528">
					<section type="none" id="sidelem4x3529">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;12 yr, geriatric patients, increased intracranial pressure, acute MI, severe heart disease, GI/renal/hepatic disease, asthma, respiratory conditions, seizure disorders, bradyarrhythmias</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3534">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3542">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x3542">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis> induction  0.5-1 mcg/kg/min with hypnotic or volative agent; maintenance with isoflurane (0.4-1.5 MAC) or propofol (100-200 mcg/kg/min);  0.025-0.2 mcg/kg/min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3555">
					<label>•</label>
					<sec_title>Child 1-12 yr<route> CONT IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x3555">
							<item>
								<label>•</label>
								<para> 0.25 mcg/kg/min with isoflurane</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3562">
					<label>•</label>
					<sec_title>Full-term neonate and infant up to 2 mo<route> CONT IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x3562">
							<item>
								<label>•</label>
								<para> 0.4 mcg/kg/min with nitrous oxide</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3566">
					<section type="none" id="sidelem4x3567">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj lyophilized 1, 2, 5 mg</para>
					</section>
					<section type="none" id="sidelem4x3572">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3576">
								<item>
									<label>•</label>
									<para>Add 1 ml diluent per mg remifentanil</para>
								</item>
								<item>
									<label>•</label>
									<para>Shake well; further dilute to a final concentration of 20, 25, 50, or 250 mcg/mg</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in light-resistant area at room temperature</para>
								</item>
								<item>
									<label>•</label>
									<para>Interruption of infusion results in rapid reversal (no residual opioid effect within 5-10 min)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3597">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x3601">
									<item>
										<label>•</label>
										<para>To be used only during maintenance of general anesthesia; inject into tubing close to venous cannula; give to nonintubated patients over 30-60 sec</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3607">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3611">
									<item>
										<label>•</label>
										<para>Use infusion device, max 16 hr; do not use same tubing as blood, do not admix</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, ceFAZolin, cefepine, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOPamine, doxacurium, doxycycline, droperidol, enalaprilat, EPINEPHrine, esmolol, famotidine, fentaNYL, fluconazole, furosemide, ganciclovir, gatifloxacin, gentamicin, haloperidol, heparin, hydrocortisone sodium succinate, HYDROmorphone, hydrOXYzine, imipenem-cilastatin, inamrinone, isoproterenol, ketorolac, lidocaine, LORazepam, magnesium sulfate, mannitol, meperidine, methylPREDNISolone sodium succinate, metoclopramide, metroNIDAZOLE, midazolam, morphine, nalbuphine, nitroglycerin, norepinephrine, ondansetron, phenylephrine, piperacillin, potassium chloride, procainamide, prochlorperazine, promethazine, ranitidine, SUFentanil, theophylline, thiopental, ticarcillin/clavulanale, tobramycin, vancomycin, zidovudine</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>, 0.45% NaCl, LR, D<emphasis style="inf">5</emphasis> LR, 0.9% NaCl</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3633">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3636">
					<section type="none" id="sidelem4x3637">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, <emphasis style="italic">dizziness,</emphasis> confusion, <emphasis style="italic">headache,</emphasis> sedation, euphoria, delirium, agitation, anxiety</para>
					</section>
					<section type="none" id="sidelem4x3648">
						<sec_title>CV:</sec_title>
						<para> Palpitations, <emphasis style="italic">bradycardia,</emphasis> change in B/P, facial flushing, syncope, <emphasis style="bold">asystole</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3658">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision, miosis, diplopia</para>
					</section>
					<section type="none" id="sidelem4x3663">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, constipation, cramps, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x3671">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, dysuria</para>
					</section>
					<section type="none" id="sidelem4x3676">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, bruising, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x3681">
						<sec_title>MS:</sec_title>
						<para> Rigidity</para>
					</section>
					<section type="none" id="sidelem4x3686">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression, apnea</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3693">
				<sec_title>Pharmacokinetics</sec_title>
				<para>70% protein binding, terminal half-life 3-10 min, excreted in urine; onset: 1-3 min</para>
			</section>
			<section type="interactions" id="sidelem4x3698">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: respiratory depression, hypotension, profound sedation: alcohol, sedatives, hypnotics, other CNS depressants; antihistamines, phenothiazines, MAOIs</emphasis>
				</para>
				<section type="none" id="sidelem4x3704">
					<section type="none" id="sidelem4x3705">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3712">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3715">
					<section type="none" id="sidelem4x3716">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3721">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention, especially in geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3726">
								<item>
									<label>•</label>
									<para>CNS changes; dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3731">
								<item>
									<label>•</label>
									<para>GI status: nausea, vomiting, anorexia, constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3736">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3744">
							<label>•</label>
							<sec_title>Respiratory dysfunction</sec_title>
							<para>
								<list id="lidelem4x3744">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory dysfunction:</emphasis> respiratory depression, character, rate, rhythm; notify prescriber if respirations &lt;12/min; CV status; bradycardia, syncope</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3748">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3752">
								<item>
									<label>•</label>
									<para>Therapeutic response: maintenance of anesthesia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3758">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3762">
								<item>
									<label>•</label>
									<para>To call for assistance when ambulating or smoking; that drowsiness, dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To make position changes slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active" ha="yes">
			<mono_name> repaglinide (Rx)</mono_name>
			<info>
				<pronunciation>(re-pag′lih′nide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x37801">
						<country code="CAN">Gluconorm </country>
					</tradename>
					<tradename id="tnidelem4x37800">Prandin</tradename>
				</tradenames>
				<class type="func"> Antidiabetic</class>
				<class type="chem"> Meglitinide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3793">
				<para>
					<confusion>
						<tradename id="tnidelem4x37930">Prandin</tradename>
						<drug type="generic" refid="idelem4x37930">Avandia</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3797">
				<sec_title>Action:</sec_title>
				<para>Causes functioning β-cells in pancreas to release insulin, thereby leading to a drop in blood glucose levels; closes ATP-dependent potassium channels in the β-cell membrane; this leads to the opening of calcium channels; increased calcium influx induces insulin secretion</para>
			</section>
			<section type="uses" id="sidelem4x3802">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus</para>
			</section>
			<section type="contra" id="sidelem4x3807">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to meglitinides; diabetic ketoacidosis, type 1 diabetes</para>
				<section type="none" id="sidelem4x3812">
					<section type="none" id="sidelem4x3813">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, thyroid/cardiac disease, severe renal/hepatic disease, severe hypoglycemic reactions</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3819">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3827">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3827">
							<item>
								<label>•</label>
								<para> 0.5-4 mg with each meal, max 16 mg/day; adjust at weekly intervals; oral-hypoglycemic–naive patients or patients with A1c &lt;8% should start with 0.5 mg with each meal</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3831">
					<section type="none" id="sidelem4x3832">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x3840">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 20-39 ml/min, 0.5 mg/day; titrate upward cautiously</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3843">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 1, 2 mg</para>
					</section>
					<section type="none" id="sidelem4x3848">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3852">
								<item>
									<label>•</label>
									<para>Up to 15-30 min before meals; 2, 3, or 4×/day preprandially</para>
								</item>
								<item>
									<label>•</label>
									<para>Skip dose if meal skipped; add dose if meal added</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3868">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3871">
					<section type="none" id="sidelem4x3872">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, weakness,</emphasis> paresthesia</para>
					</section>
					<section type="none" id="sidelem4x3880">
						<sec_title>CV:</sec_title>
						<para> Angina</para>
					</section>
					<section type="none" id="sidelem4x3885">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x3890">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="bold">Hypoglycemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3897">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, constipation, dyspepsia, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3904">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3911">
						<sec_title>INTEG:</sec_title>
						<para> Rash, allergic reactions</para>
					</section>
					<section type="none" id="sidelem4x3916">
						<sec_title>MISC:</sec_title>
						<para> Chest pain, UTI, allergy</para>
					</section>
					<section type="none" id="sidelem4x3921">
						<sec_title>MS:</sec_title>
						<para> Back pains, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x3926">
						<sec_title>RESP:</sec_title>
						<para> URI, sinusitis, rhinitis, bronchitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3931">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Completely absorbed by GI route; onset 30 min; peak 1 hr; duration &lt;4 hr; half-life 1 hr; metabolized in liver by CYP3A4; excreted in urine, feces (metabolites); crosses placenta; 98% protein bound</para>
			</section>
			<section type="interactions" id="sidelem4x3936">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with gemfibrozil, isophane insulin (NPH)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> repaglinide effect—CYP3A4, OATP101, CYP2C9 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> in both—levonorgestrel/ethinyl estradiol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> repaglinide metabolism—CYP3A4 inducers: rifampin, barbiturates, carBAMazepine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> repaglinide effect—NSAIDs, salicylates, sulfonamides, chloramphenicol, MAOIs, coumarins, β-blockers, probenecid, gemfibrozil, simvastatin, fenofibrate, deferasirox</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> repaglinide metabolism—CYP3A4 inhibitors: antifungals (ketoconazole, miconazole), erythromycin, macrolides</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> repaglinide action—calcium channel blockers, corticosteroids, oral contraceptives, thiazide diuretics, thyroid preparations, estrogens, phenothiazines, phenytoin, rifampin, isoniazid, PHENobarbital, sympathomimetics</para>
				<section type="none" id="sidelem4x3968">
					<section type="none" id="sidelem4x3969">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antidiabetic effect—garlic, chromium, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x3976">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> repaglinide level; give before meals</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> repaglinide metabolism—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x3987">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase/decrease:</emphasis> glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3994">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3997">
					<section type="none" id="sidelem4x3998">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis alert="nurse">Hypo/hyperglycemic reaction, which can occur soon after meals: dizziness, weakness, headache, tremors, anxiety, tachycardia, hunger, sweating, abdominal pain, A1c, fasting, postprandial glucose during treatment</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4006">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4010">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait; blood glucose, A1c improvement</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4016">
						<sec_title>Teach family/patient:</sec_title>
						<para>
							<list id="lidelem4x4020">
								<item>
									<label>•</label>
									<para>About technique for blood glucose monitoring; how to use blood glucose meter</para>
								</item>
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia, what to do about each</para>
								</item>
								<item>
									<label>•</label>
									<para>That product must be continued on daily basis; about the consequences of discontinuing product abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications unless ordered by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that product will not cure disease</para>
								</item>
								<item>
									<label>•</label>
									<para>That all food included in diet plan must be eaten to prevent hypoglycemia; that if a meal is omitted, dose should be omitted; to have glucagon emergency kit available; to take repaglinide 15-30 min before meals 2, 3, or 4×/day; to carry emergency ID</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>retapamulin (topical)</mono_name>
			<info>
				<pronunciation>(re-te-pam′you-lin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x40630">Altabax</tradename>
				</tradenames>
				<class type="func"> Topical antiinfective</class>
				<class type="chem"> Pleuromutilin</class>
			</info>
			<section type="actions" id="sidelem4x4073">
				<sec_title>Action:</sec_title>
				<para>Antibacterial activity results from inhibition of protein synthesis</para>
			</section>
			<section type="uses" id="sidelem4x4078">
				<sec_title>Uses:</sec_title>
				<para>For the treatment of impetigo</para>
			</section>
			<section type="contra" id="sidelem4x4083">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product</para>
				<section type="none" id="sidelem4x4088">
					<section type="none" id="sidelem4x4089">
						<sec_title>Precautions:</sec_title>
						<para> Children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4094">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4102">
					<label>•</label>
					<sec_title>Adult/child ≥9 mo<route> TOP</route></sec_title>
					<para>
						<list id="lidelem4x4102">
							<item>
								<label>•</label>
								<para> apply to affected area bid × 5 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4106">
					<section type="none" id="sidelem4x4107">
						<sec_title>Available forms:</sec_title>
						<para> Topical ointment 1%</para>
					</section>
					<section type="none" id="sidelem4x4112">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4115">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x4120">
									<item>
										<label>•</label>
										<para>Do not use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4125">
									<item>
										<label>•</label>
										<para>Wash hands before and after use</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4133">
								<label>•</label>
								<sec_title>Ointment</sec_title>
								<para>
									<list id="lidelem4x4133">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Ointment:</emphasis> Apply a thin film to the cleansed, affected area and massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4137">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4140">
					<section type="none" id="sidelem4x4141">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, irritation, headache, diarrhea, nausea</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4146">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4149">
					<section type="none" id="sidelem4x4150">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4153">
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x4157">
									<item>
										<label>•</label>
										<para>Hypersensitivity, product may need to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4163">
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x4167">
									<item>
										<label>•</label>
										<para>Number of lesions, severity of impetigo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4173">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4177">
								<item>
									<label>•</label>
									<para>Decreased lesions, infusion in impetigo</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4183">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x4186">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x4191">
									<item>
										<label>•</label>
										<para>Not to use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4196">
									<item>
										<label>•</label>
										<para>To wash hands before and after use</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4204">
								<label>•</label>
								<sec_title>Ointment</sec_title>
								<para>
									<list id="lidelem4x4204">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Ointment:</emphasis> to apply a thin film to the cleansed, affected area</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>Rho(D) immune globulin standard dose IM (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x42141">HyperRHO SD</tradename>
					<tradename id="tnidelem4x42140">RhoGAM Ultra-Filtered Plus</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="17" status="active">
			<mono_name>Rho(D) immune globulin microdose IM (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x42224">HyperRHO S/D mini-Dose</tradename>
					<tradename id="tnidelem4x42223">MICRhoGAM Ultra-Filtered Plus</tradename>
					<tradename id="tnidelem4x42222">mini-Gamulin R</tradename>
					<tradename id="tnidelem4x42221">Rho(D) immune globulin microdose (IM</tradename>
					<tradename id="tnidelem4x42220">IV) Rhophylac</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="18" status="active">
			<mono_name>Rho(D) immune globulin IV (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x42301">Rhophylac</tradename>
					<tradename id="tnidelem4x42300">WinRho SDF</tradename>
				</tradenames>
				<class type="func"> Immune globulins</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4236">
				<sec_title>Action:</sec_title>
				<para>Suppresses immune response of nonsensitized Rh<emphasis style="inf">o</emphasis>(D or D<emphasis style="sup">u</emphasis>)-negative patients who are exposed to Rh<emphasis style="inf">o</emphasis>(D or D<emphasis style="sup">u</emphasis>)-positive blood</para>
			</section>
			<section type="uses" id="sidelem4x4253">
				<sec_title>Uses:</sec_title>
				<para>Prevention of isoimmunization in Rh-negative women given Rh-positive blood after abortions, miscarriages, amniocentesis; chronic idiopathic thrombocytopenia purpura (Rhophylac)</para>
			</section>
			<section type="contra" id="sidelem4x4258">
				<sec_title>Contraindications:</sec_title>
				<para>Previous immunization with this product, Rh<emphasis style="inf">o</emphasis>(O)-positive/D<emphasis style="sup">u</emphasis>-positive patient</para>
				<para>
					<bbw>Hemolysis</bbw>
				</para>
				<section type="none" id="sidelem4x4280">
					<section type="none" id="sidelem4x4281">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>)</para>
						<para>
							<bbw>Requires a specialized setting</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4296">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4299">
					<section type="none" id="sidelem4x4300">
						<sec_title>To reduce risk of Rh isoimmunization antepartum/suppression of Rh isoimmunization postpartum following delivery of full-term infant</sec_title>
						<section type="none" id="sidelem4x4308">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4308">
									<item>
										<label>•</label>
										<para> ([HyperRHO S/D] full dose only) 300 mcg (1500 international units) at 28 wk gestation, repeat within 72 hr of delivery of confirmed Rho(D)-positive infant; dose not needed after delivery if delivery within 3 wk of last dose and no fetal maternal hemorrhage of &gt;15 ml of RBC;  (RhoGam only) 300 mcg (1500 international units) at 26-28 wk gestation, repeat within 72 hr even if status of Rho unknown or if 72 hr have passed;  (WinRho SDF only) 300 mcg (1500 international units) at 28 wk gestation; if given earlier during pregnancy, give at 12-wk intervals during pregnancy, 120-mcg (600 international units) dose; IM/IV should be given as soon as possible and preferably within 72 hr of delivery of confirmed Rho(D)-positive infant and even if status unknown; give ≤28 days after delivery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4318">
						<sec_title>Known or suspected massive fetomaternal hemorrhage (<emphasis style="bold">&gt;</emphasis>15 ml of fetal RBC or <emphasis style="bold">&gt;</emphasis>30 ml of fetal whole blood)</sec_title>
						<section type="none" id="sidelem4x4332">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4332">
									<item>
										<label>•</label>
										<para> ([HyperRHO S/D] full dose only) 300 mcg (1500 international units) per every 15 ml of fetal blood cells or 30 ml of whole blood; multiple syringes may be injected IM at same time in different sites, give within 72 hr of exposure, repeat dose within 72 hr of delivery;  (RhoGAM only) 300 mcg (1500 international units) for every 15 ml of fetal blood cells or 30 ml of whole blood, give total dose within 72 hr of exposure;  (WinRho SDF only) if large fetomaternal hemorrhage suspected, give  9 mcg (45 international units) or  12 mcg (60 international units) for every ml of fetal whole blood, give  600 mcg (3000 international units) q8hr or  1200 mcg (6000 international units) q12hr until total dose given, total dose should be given within 72 hr of exposure</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4354">
						<sec_title>Threatened abortion at any stage of pregnancy</sec_title>
						<section type="none" id="sidelem4x4362">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4362">
									<item>
										<label>•</label>
										<para> ([HyperRHO S/D] full dose only) 300 mcg (1500 international units) as soon as possible; if given at 13-18 wk gestation, give another 300 mcg (1500 international units) at 26-28 wk gestation; repeat dose within 72 hr of delivery;  (RhoGam only) 300 mcg (1500 international units) as soon as possible and within 72 hr of exposure;  (Rhophylac only) 300 mcg (1500 international units) as soon as possible and within 72 hr;  (WinRho SDF only) 300 mcg (1500 international units) as soon as possible and within 72 hr, repeat dose at 12-wk intervals during pregnancy and give 120 mcg (600 international units) as soon as possible after delivery and within 72 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4375">
						<sec_title>After spontaneous abortion, induced termination of pregnancy, or ectopic pregnancy that occurs at <emphasis style="bold">≤</emphasis>12 wk gestation</sec_title>
						<section type="none" id="sidelem4x4386">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4386">
									<item>
										<label>•</label>
										<para> (HyperRHO Minidose, MICRhoGAM only) 50 mcg (250 international units) as soon as possible, give within 3 hr of spontaneous or surgical removal, if possible within 72 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4390">
						<sec_title>After spontaneous abortion, induced termination of pregnancy, or ruptured tubal pregnancy that occurs at <emphasis style="bold">≥</emphasis>13 wk</sec_title>
						<section type="none" id="sidelem4x4401">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x4401">
									<item>
										<label>•</label>
										<para> ([HyperRHO SD] full dose, RhoGAM only) 300 mcg (1500 international units) as soon as possible and within 72 hr of event</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4405">
						<sec_title>After spontaneous abortion, induced termination of pregnancy, amniocentesis, chorionic villus sampling, abdominal trauma, ruptured tubal pregnancy, or percutaneous umbilical cord sampling at ≤34 wk gestation</sec_title>
						<section type="none" id="sidelem4x4413">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x4413">
									<item>
										<label>•</label>
										<para> (WinRho SDF only) 300 mcg (1500 international units) within 72 hr, repeat at 12-wk intervals during pregnancy, give 120 mcg (600 international units) as soon as possible and preferably within 72 hr of delivery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4417">
						<sec_title>Available forms:</sec_title>
						<para> BayRho-D sol for inj 300 mcg/ml (HyperRHO S/D sol for inj), MICRhoGAM Ultra Filtered Plus Solution for inj 50 mcg/ml; RhoGam Ultra Filtered Plus Solution for inj 50 mcg; Rhophylac Pre-Filled Syringes Solution for inj 300 mcg/2 ml; WinRho SDF liquid for inj</para>
					</section>
					<section type="none" id="sidelem4x4422">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4427">
								<item>
									<label>•</label>
									<para>Store in refrigerator</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4435">
							<label>•</label>
							<sec_title>
								<route>HyperRHO SD, MICRhoGAM, RhoGAM given by IM only; do not give IV</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4438">
								<item>
									<label>•</label>
									<para>Rhophylac can be given IM or IV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4443">
								<item>
									<label>•</label>
									<para>Inspect for particulate matter; do not use if particulate matter present</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4448">
								<item>
									<label>•</label>
									<para>Reconstitute/dilution: no reconstitution or dilution needed for HyperRHO SD; Rhophylac, MICRhoGAM, RhoGAM, or liquid formulation of WinRho SDF</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4453">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x4457">
									<item>
										<label>•</label>
										<para>Use aseptic technique, observe for 20 min after administration</para>
									</item>
									<item>
										<label>•</label>
										<para>Bring Rhophylac to room temperature before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject into deltoid muscle of upper arm or anterolateral portion of upper thigh; do not inject into gluteal muscle</para>
									</item>
									<item>
										<label>•</label>
										<para>If dose calculated requires multiple vials or syringes, use different sites at same time</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4478">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x4482">
									<item>
										<label>•</label>
										<para>Use aseptic technique</para>
									</item>
									<item>
										<label>•</label>
										<para>WinRho SDF: remove entire contents of vial to obtain calculated dose; if partial vial required for dosage calculation, withdraw entire vial contents to ensure correct calculation; infuse correct calculated dose over 3-5 min; do not infuse with other fluids, products</para>
									</item>
									<item>
										<label>•</label>
										<para>Rhophylac: bring to room temperature; infuse by slow IV; observe for 20 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4498">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4501">
					<section type="none" id="sidelem4x4502">
						<sec_title>CNS:</sec_title>
						<para> Lethargy</para>
					</section>
					<section type="none" id="sidelem4x4507">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x4512">
						<sec_title>INTEG:</sec_title>
						<para> Irritation at inj site, fever</para>
					</section>
					<section type="none" id="sidelem4x4517">
						<sec_title>MISC:</sec_title>
						<para> Infection, <emphasis style="bold">ARDs, anaphylaxis, pulmonary edema, DIC</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4524">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4529">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines (measles, mumps, rubella)</para>
			</section>
			<section type="considerations" id="sidelem4x4536">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4539">
					<section type="none" id="sidelem4x4540">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4546">
								<item>
									<para>
										<emphasis alert="nurse">Allergies, reactions to immunizations; previous immunization with product</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4552">
								<item>
									<para>
										<emphasis alert="nurse">Intravascular hemolysis: back pain, chills, hemoglobinuria, renal insufficiency; usually when WinRho SDF is given in those with immune thrombocytopenia purpura</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4560">
							<label>•</label>
							<sec_title>
								<route>Type, crossmatch mother and newborn’s cord blood; if mother Rh</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4578">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4582">
								<item>
									<label>•</label>
									<para>Rh<emphasis style="inf">o</emphasis>(D) sensitivity in transfusion error, prevention of erythroblastosis fetalis for normal vision</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4591">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4596">
								<item>
									<label>•</label>
									<para>How product works; that product must be given after subsequent deliveries if subsequent babies are Rh-positive</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4603">
								<item>
									<para>
										<emphasis alert="nurse">To report immediately: shaking, fever, chills, dark urine, swelling of hands or feet, back pain, SOB (intravascular hemolysis)</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>riboflavin (vit B2) (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(rye′boh-flay-vin)</pronunciation>
				<class type="func"> Vit B, water soluble</class>
			</info>
			<section type="actions" id="sidelem4x4626">
				<sec_title>Action:</sec_title>
				<para>Needed for respiratory reactions by catalyzing proteins</para>
			</section>
			<section type="uses" id="sidelem4x4631">
				<sec_title>Uses:</sec_title>
				<para>Vit B<emphasis style="inf">2</emphasis> deficiency or polyneuritis; cheilosis adjunct with thiamine</para>
				<section type="none" id="sidelem4x4639">
					<section type="none" id="sidelem4x4640">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Migraine prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4645">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4648">
					<section type="none" id="sidelem4x4649">
						<sec_title>Deficiency</sec_title>
						<section type="none" id="sidelem4x4657">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4657">
									<item>
										<label>•</label>
										<para> 5-30 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4664">
							<label>•</label>
							<sec_title>Child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4664">
									<item>
										<label>•</label>
										<para> 3-10 mg/day, then 0.6 mg/1000 calories ingested</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4668">
						<sec_title>RDA</sec_title>
						<section type="none" id="sidelem4x4676">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4676">
									<item>
										<label>•</label>
										<para> (males) 1.3 mg, (females) 1.1 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4680">
						<sec_title>Migraine prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4688">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4688">
									<item>
										<label>•</label>
										<para> 400 mg/day × 3 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4692">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 25, 50, 100, 250 mg</para>
					</section>
					<section type="none" id="sidelem4x4697">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4701">
								<item>
									<label>•</label>
									<para>With food for better absorption</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in airtight, light-resistant container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4712">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4715">
					<section type="none" id="sidelem4x4716">
						<sec_title>GU:</sec_title>
						<para> Yellow discoloration of urine</para>
					</section>
					<section type="none" id="sidelem4x4721">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="A">A</preg>)</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4726">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 65-85 min, 60% protein bound, unused amounts excreted in urine (unchanged)</para>
			</section>
			<section type="interactions" id="sidelem4x4731">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> riboflavin need—alcohol, probenecid, tricyclics, phenothiazines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of tetracyclines</para>
				<section type="none" id="sidelem4x4742">
					<section type="none" id="sidelem4x4743">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<list id="lidelem4x4747">
								<item>
									<label>•</label>
									<para>May cause false elevations of urinary catecholamines</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4753">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4756">
					<section type="none" id="sidelem4x4757">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4761">
								<item>
									<label>•</label>
									<para>Nutritional status: liver, eggs, dairy products, yeast, whole grains, green vegetables</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4767">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4771">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of headache, GI problems, cheilosis, skin lesions, depression; burning, itchy eyes; anemia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4777">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4781">
								<item>
									<label>•</label>
									<para>That urine may turn bright yellow</para>
								</item>
								<item>
									<label>•</label>
									<para>About the addition of needed foods rich in riboflavin</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>rifabutin (Rx)</mono_name>
			<info>
				<pronunciation>(riff′a-byoo-ten)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x48020">Mycobutin</tradename>
				</tradenames>
				<class type="func"> Antimycobacterial agent</class>
				<class type="chem"> Rifamycin S derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4812">
				<para>
					<confusion>
						<tradename id="tnidelem4x48120">rifabutin</tradename>
						<drug type="generic" refid="idelem4x48120">rifampin/rifapentine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4816">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA-dependent RNA polymerase in susceptible strains of <emphasis style="italic">Escherichia coli</emphasis> and <emphasis style="italic">Bacillus subtilis;</emphasis> mechanism of action against <emphasis style="italic">Mycobacterium avium</emphasis> unknown</para>
			</section>
			<section type="uses" id="sidelem4x4830">
				<sec_title>Uses:</sec_title>
				<para>Prevention of <emphasis style="italic">M. avium</emphasis> complex (MAC) in patients with advanced HIV infection</para>
				<section type="none" id="sidelem4x4838">
					<section type="none" id="sidelem4x4839">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Helicobacter pylori</emphasis> that has not responded to other treatment</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4847">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, active TB, WBC &lt;1000/mm<emphasis style="sup">3</emphasis> or platelet count &lt;50,000/mm<emphasis style="sup">3</emphasis></para>
				<section type="none" id="sidelem4x4857">
					<section type="none" id="sidelem4x4858">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, hepatic disease, blood dyscrasias</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4863">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4871">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4871">
							<item>
								<label>•</label>
								<para> 300 mg/day (may take as 150 mg bid); max 600 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4876">
					<section type="none" id="sidelem4x4877">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4885">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, reduce by 50%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4888">
						<sec_title>Available forms:</sec_title>
						<para> Caps 150 mg</para>
					</section>
					<section type="none" id="sidelem4x4893">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4897">
								<item>
									<label>•</label>
									<para>With food if GI upset occurs; better to take on empty stomach 1 hr before or 2 hr after meals; high-fat foods slow absorption; may take in 2 divided doses, may open capsule, mix with applesauce if unable to swallow whole cap</para>
								</item>
								<item>
									<label>•</label>
									<para>Antiemetic if vomiting occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>After C&amp;S completed; monthly to detect resistance</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4913">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4916">
					<section type="none" id="sidelem4x4917">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> fatigue, anxiety, confusion, insomnia</para>
					</section>
					<section type="none" id="sidelem4x4925">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea,</emphasis> heartburn, <emphasis style="bold">hepatitis,</emphasis> discolored saliva, pseudomembranous colitis</para>
					</section>
					<section type="none" id="sidelem4x4936">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Discolored urine</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4943">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, eosinophilia, thrombocytopenia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4950">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4957">
						<sec_title>MISC:</sec_title>
						<para> Flulike symptoms, shortness of breath, chest pressure</para>
					</section>
					<section type="none" id="sidelem4x4962">
						<sec_title>MS:</sec_title>
						<para> Asthenia, arthralgia, myalgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4967">
				<sec_title>Pharmacokinetics</sec_title>
				<para>53% absorbed, peak 2-3 hr, duration &gt;24 hr, half-life 45 hr, metabolized in liver (active/inactive metabolites), excreted in urine primarily as metabolites</para>
			</section>
			<section type="interactions" id="sidelem4x4972">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of rifabutin: ritonavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of amprenavir, anticoagulants, β-blockers, barbiturates, busPIRone, clofibrate, corticosteroids, cycloSPORINE, dapsone, delavirdine, disopyramide, doxycycline, efavirenz, estrogens, fluconazole, indinavir, ketoconazole, losartan, nelfinavir, nevirapine, oral contraceptives, phenytoin, quiNIDine, saquinavir, sulfonylureas, theophylline, tricyclic antidepressants, zidovudine, zolpidem</para>
				<section type="none" id="sidelem4x4983">
					<section type="none" id="sidelem4x4984">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x4988">
								<item>
									<label>•</label>
									<para>High-fat diet decreases absorption</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4994">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> folate level, vit B<emphasis style="inf">12</emphasis>, BSP, gallbladder studies</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5004">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5007">
					<section type="none" id="sidelem4x5008">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5014">
								<item>
									<para>
										<emphasis alert="nurse">Acute TB: chest x-ray, sputum culture, blood culture, biopsy of lymph nodes, PPD; product should not be given for active TB</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5019">
								<item>
									<label>•</label>
									<para>CBC for neutropenia, thrombocytopenia, eosinophilia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5025">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, abdominal pain/cramping, fever, bloody stools</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5030">
								<item>
									<label>•</label>
									<para>Signs of anemia: Hct, Hgb, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5035">
								<item>
									<label>•</label>
									<para>Hepatic studies weekly: ALT, AST, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5040">
								<item>
									<label>•</label>
									<para>Renal status before, each mo: BUN, creatinine, output, specific gravity, urinalysis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5045">
								<item>
									<label>•</label>
									<para>Hepatic status: decreased appetite, jaundice, dark urine, fatigue</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5050">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5054">
								<item>
									<label>•</label>
									<para>Therapeutic response: not used for active TB because of risk for development of resistance to rifampin; culture negative</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5060">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5066">
								<item>
									<para>
										<emphasis alert="nurse">That patients using oral contraceptives should consider using nonhormonal methods of birth control, may decrease effect; to notify prescriber if pregnancy planned, suspected</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5071">
								<item>
									<label>•</label>
									<para>That compliance with dosage schedule, duration necessary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5076">
								<item>
									<label>•</label>
									<para>That scheduled appointments must be kept because relapse may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5081">
								<item>
									<label>•</label>
									<para>That urine, feces, saliva, sputum, sweat, tears may be colored red-orange; that soft contact lenses may be permanently stained</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5088">
								<item>
									<para>
										<emphasis alert="nurse">To report flulike symptoms: excessive fatigue, anorexia, vomiting, sore throat; unusual bleeding, yellowish discoloration of skin, eyes; myositis: muscle or bone pain; diarrhea, fever, abdominal cramping, bloody stools</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>rifampin (Rx)</mono_name>
			<info>
				<pronunciation>(rif′am-pin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x50981">Rifadin</tradename>
					<tradename id="tnidelem4x50980">
						<country code="CAN">Rofact </country>
					</tradename>
				</tradenames>
				<class type="func"> Antitubercular</class>
				<class type="chem"> Rifamycin B derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5110">
				<para>
					<confusion>
						<tradename id="tnidelem4x51100">rifampin</tradename>
						<drug type="generic" refid="idelem4x51100">rifabutin/rifaximin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5114">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA-dependent polymerase, decreases tubercle bacilli replication</para>
			</section>
			<section type="uses" id="sidelem4x5119">
				<sec_title>Uses:</sec_title>
				<para>Pulmonary TB, meningococcal carriers (prevention)</para>
				<section type="none" id="sidelem4x5124">
					<section type="none" id="sidelem4x5125">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Endocarditis, <emphasis style="italic">Haemophilus influenzae type B prophylaxis,</emphasis> Hansen’s disease, <emphasis style="italic">Mycobacterium avium</emphasis> complex (MAC), orthopedic-device–related infection, pruritus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5136">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, rifamycins; active <emphasis style="italic">Neisseria meningitidis</emphasis> infection</para>
				<section type="none" id="sidelem4x5144">
					<section type="none" id="sidelem4x5145">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;5 yr, hepatic disease, blood dyscrasias</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5150">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5153">
					<section type="none" id="sidelem4x5154">
						<sec_title>Tuberculosis</sec_title>
						<section type="none" id="sidelem4x5162">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5162">
									<item>
										<label>•</label>
										<para> Max 600 mg/day as single dose 1 hr before meals or 2 hr after meals or 10 mg/kg/day 5 days/wk or 2-3×/wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5169">
							<label>•</label>
							<sec_title>Child &gt;5 yr<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5169">
									<item>
										<label>•</label>
										<para> 10-20 mg/kg/day as single dose 1 hr before meals or 2 hr after meals, max 600 mg/day with other antituberculars</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5176">
							<label>•</label>
							<sec_title>6-mo regimen</sec_title>
							<para>
								<list id="lidelem4x5176">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">6-mo regimen:</emphasis> 2 mo treatment of isoniazid, rifampin, pyrazinamide, and possibly streptomycin or ethambutol, then rifampin and isoniazid 3-4 mo</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5183">
							<label>•</label>
							<sec_title>9-mo regimen</sec_title>
							<para>
								<list id="lidelem4x5183">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">9-mo regimen:</emphasis> rifampin and isoniazid supplemented with pyrazinamide, streptomycin, or ethambutol</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5187">
						<sec_title>Meningococcal carriers</sec_title>
						<section type="none" id="sidelem4x5195">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5195">
									<item>
										<label>•</label>
										<para> 600 mg bid × 2 days, max 600 mg/dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5202">
							<label>•</label>
							<sec_title>Child &gt;5 yr<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5202">
									<item>
										<label>•</label>
										<para> 10-20 mg/kg × 2 days, max 600 mg/dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5209">
							<label>•</label>
							<sec_title>Infant 3 mo-1 yr</sec_title>
							<para>
								<list id="lidelem4x5209">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infant 3 mo-1 yr:</emphasis> 5 mg/kg  bid × 2 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5216">
						<sec_title>Prevention of <emphasis style="bold">
								<emphasis style="italic">H. influenzae</emphasis>
							</emphasis> type B infection (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5228">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5228">
									<item>
										<label>•</label>
										<para> 600 mg/day × 4 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5235">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5235">
									<item>
										<label>•</label>
										<para> 20 mg/kg/day × 4 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5239">
						<sec_title>MAC (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5247">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5247">
									<item>
										<label>•</label>
										<para> 600 mg/day used with ≥3 other active microbials</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5254">
							<label>•</label>
							<sec_title>Child<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5254">
									<item>
										<label>•</label>
										<para> 10-20 mg/kg/day used with ≥3 other active microbials</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5258">
						<sec_title>Endocarditis with prosthetic valves (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5266">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5266">
									<item>
										<label>•</label>
										<para> 300 mg q8hr with gentamicin and vancomycin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5273">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5273">
									<item>
										<label>•</label>
										<para> 20 mg/kg/day in 2 divided doses with gentamicin and vancomycin, max 900 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5277">
						<sec_title>Available forms:</sec_title>
						<para> Caps 150, 300 mg; powder for inj 600 mg/vial</para>
					</section>
					<section type="none" id="sidelem4x5282">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5286">
								<item>
									<label>•</label>
									<para>After C&amp;S completed; monthly to detect resistance</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not give IM, SUBCUT</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5297">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x5301">
									<item>
										<label>•</label>
										<para>On empty stomach, 1 hr before or 2 hr after meals with full glass of water; give with other products for TB</para>
									</item>
									<item>
										<label>•</label>
										<para>Antiemetic if vomiting occurs</para>
									</item>
									<item>
										<label>•</label>
										<para>Capsules may be opened, mixed with applesauce or jelly</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5317">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x5321">
									<item>
										<label>•</label>
										<para>After diluting each 600 mg/10 ml of sterile water for inj (60 mg/ml), swirl, withdraw dose, and dilute in 100 ml or 500 ml of D<emphasis style="inf">5</emphasis>W given as infusion over 3 hr; if diluted in 100 ml, give over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; do not admix with other sol or products</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> amiodarone, bumetanide, midazolam, pantoprazole, vancomycin</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5340">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5343">
					<section type="none" id="sidelem4x5344">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue, anxiety, drowsiness, confusion</para>
					</section>
					<section type="none" id="sidelem4x5349">
						<sec_title>EENT:</sec_title>
						<para> Visual disturbances</para>
					</section>
					<section type="none" id="sidelem4x5355">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea,</emphasis><emphasis style="bold">pseudomembranous colitis,</emphasis><emphasis style="italic">heartburn,</emphasis> sore mouth and tongue, <emphasis style="bold">pancreatitis,</emphasis> increased LFTs</para>
					</section>
					<section type="none" id="sidelem4x5370">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hematuria, acute renal failure, hemoglobinuria</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5377">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, eosinophilia, thrombocytopenia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5384">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria</para>
					</section>
					<section type="none" id="sidelem4x5389">
						<sec_title>MISC:</sec_title>
						<para> Flulike symptoms, menstrual disturbances, edema, SOB, <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5396">
						<sec_title>MS:</sec_title>
						<para> Ataxia, weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5401">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5404">
					<section type="none" id="sidelem4x5405">
						<sec_title>PO:</sec_title>
						<para> Peak 1-4 hr, half-life 1-5 hr, metabolized in liver (active/inactive metabolites), excreted in urine as free product (30% crosses placenta) and in breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5410">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with protease inhibitors</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: hepatotoxicity—isoniazid</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of acetaminophen, alcohol, anticoagulants, antidiabetics, β-blockers, barbiturates, benzodiazepines, chloramphenicol, clofibrate, corticosteroids, cycloSPORINE, dapsone, digoxin, doxycycline, haloperidol, hormones, imidazole antifungals, NIFEdipine, oral contraceptives, phenytoin, protease inhibitors, theophylline, verapamil, zidovudine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> LFTs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> Hgb</para>
				<section type="none" id="sidelem4x5433">
					<section type="none" id="sidelem4x5434">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phosphatase, ALT, AST, uric acid, bilirubin, eosinophils</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> folate level, vit B<emphasis style="inf">12</emphasis></para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5447">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5450">
					<section type="none" id="sidelem4x5451">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5459">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x5459">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> sputum culture, lung sounds, characteristics of sputum</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5463">
								<item>
									<label>•</label>
									<para>Signs of anemia: Hct, Hgb, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5468">
								<item>
									<label>•</label>
									<para>Hepatic function monthly: ALT, AST, bilirubin, decreased appetite, jaundice, dark urine, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5473">
								<item>
									<label>•</label>
									<para>Renal status before, each mo: BUN, creatinine, output, specific gravity, urinalysis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5479">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin reactions: fever, sore throat, fatigue, ulcers; lesions in mouth, lips, rash; can be fatal</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5485">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, fever, abdominal pain/cramping, bloody stools; product should be discontinued, prescriber notified</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5490">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5494">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of TB, culture negative</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5500">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5505">
								<item>
									<label>•</label>
									<para>That compliance with dosage schedule, duration necessary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5510">
								<item>
									<label>•</label>
									<para>That scheduled appointments must be kept because relapse may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5518">
							<label>•</label>
							<sec_title>
								<route>To avoid alcohol because hepatotoxicity may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5521">
								<item>
									<label>•</label>
									<para>That urine, feces, saliva, sputum, sweat, tears may be colored red-orange; that soft contact lenses may be permanently stained</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5527">
								<item>
									<para>
										<emphasis alert="nurse">To report flulike symptoms: excessive fatigue, anorexia, vomiting, sore throat; unusual bleeding; yellowish discoloration of skin, eyes; diarrhea with pus, mucous, blood</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5535">
							<label>•</label>
							<sec_title>
								<route>not to breastfeed</route>
							</sec_title>
							<para>
								<list id="lidelem4x5535">
									<item>
										<label>•</label>
										<para>To use nonhormonal form of birth control; to notify prescriber if pregnancy planned, suspected; </para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>rifapentine (Rx)</mono_name>
			<info>
				<pronunciation>(riff′ah-pen-teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x55440">Priftin</tradename>
				</tradenames>
				<class type="func"> Antitubercular</class>
				<class type="chem"> Rifamycin derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5554">
				<para>
					<confusion>
						<tradename id="tnidelem4x55540">rifapentine</tradename>
						<drug type="generic" refid="idelem4x55540">rifampin/rifabutin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5558">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA-dependent polymerase, decreases tubercle bacilli replication</para>
			</section>
			<section type="uses" id="sidelem4x5563">
				<sec_title>Uses:</sec_title>
				<para>Pulmonary TB; must be used with at least one other antitubercular agent</para>
			</section>
			<section type="contra" id="sidelem4x5568">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to rifamycins, porphyria</para>
				<section type="none" id="sidelem4x5573">
					<section type="none" id="sidelem4x5574">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;12 yr, geriatric patients, hepatic disease, blood dyscrasias, HIV</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5579">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5582">
					<section type="none" id="sidelem4x5583">
						<sec_title>Intensive phase</sec_title>
						<section type="none" id="sidelem4x5591">
							<label>•</label>
							<sec_title>Adult/Adolescent &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5591">
									<item>
										<label>•</label>
										<para> 600 mg (four 150-mg tabs) 2×/wk with an interval of 72 hr between doses × 2 mo; must be given with at least 1 other antitubercular agent</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5595">
						<sec_title>Continuation phase</sec_title>
						<section type="none" id="sidelem4x5603">
							<label>•</label>
							<sec_title>Adult/Adolescent &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5603">
									<item>
										<label>•</label>
										<para> 600 mg weekly × 4 mo in combination with isoniazid or other appropriate antitubercular product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5607">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 150 mg</para>
					</section>
					<section type="none" id="sidelem4x5612">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5616">
								<item>
									<label>•</label>
									<para>May give with food for GI upset; use other products for TB</para>
								</item>
								<item>
									<label>•</label>
									<para>Antiemetic if vomiting occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>After C&amp;S completed; monthly to detect resistance</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5632">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5635">
					<section type="none" id="sidelem4x5636">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue, anxiety, dizziness</para>
					</section>
					<section type="none" id="sidelem4x5641">
						<sec_title>EENT:</sec_title>
						<para> Visual disturbances</para>
					</section>
					<section type="none" id="sidelem4x5646">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea,</emphasis> bilirubinemia, hepatitis, increased ALT, AST, <emphasis style="italic">heartburn,</emphasis><emphasis style="bold">pancreatitis, pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5658">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hematuria,</emphasis> pyuria, proteinuria, urinary casts, urine discoloration</para>
					</section>
					<section type="none" id="sidelem4x5666">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, neutropenia, lymphopenia,</emphasis> anemia, <emphasis style="bold">leukocytosis,</emphasis> purpura, hematoma</para>
					</section>
					<section type="none" id="sidelem4x5677">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria, acne</para>
					</section>
					<section type="none" id="sidelem4x5682">
						<sec_title>MISC:</sec_title>
						<para> Increased B/P</para>
					</section>
					<section type="none" id="sidelem4x5687">
						<sec_title>MS:</sec_title>
						<para> Gout, arthrosis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5692">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 5-6 hr; half-life 13 hr; metabolized in liver (active/inactive metabolites); excreted in urine, feces, breast milk; protein binding 97%; steady-state 10 days; CYP450 3A4, 2C8/9 inducer</para>
			</section>
			<section type="interactions" id="sidelem4x5697">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with protease inhibitors</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of amitriptyline, anticoagulants, antidiabetics, barbiturates, β-blockers, chloramphenicol, clarithromycin, clofibrate, corticosteroids, cycloSPORINE, dapsone, delavirdine, diazepam, digoxin, diltiazem, disopyramide, doxycycline, fentaNYL, fluconazole, haloperidol, indinavir, itraconazole, ketoconazole, methadone, mexiletine, nelfinavir, NIFEdipine, nortriptyline, oral contraceptives, phenothiazines, phenytoin, progestins, quiNIDine, quiNINE, ritonavir, saquinavir, sildenafil, tacrolimus, theophylline, thyroid preparations, tocainide, verapamil, warfarin, zidovudine</para>
				<section type="none" id="sidelem4x5709">
					<section type="none" id="sidelem4x5710">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> absorption with food</para>
					</section>
					<section type="none" id="sidelem4x5717">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, platelets</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, WBC</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> folate level, vit B<emphasis style="inf">12</emphasis></para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5734">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5737">
					<section type="none" id="sidelem4x5738">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5743">
								<item>
									<label>•</label>
									<para>Baselines of CBC, AST, ALT, bilirubin, platelets</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5751">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x5751">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> sputum culture, lung sounds</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5755">
								<item>
									<label>•</label>
									<para>Signs of anemia: Hct, Hgb, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5760">
								<item>
									<label>•</label>
									<para>Hepatic studies monthly: ALT, AST, bilirubin; decreased appetite, jaundice, dark urine, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5765">
								<item>
									<label>•</label>
									<para>Renal status monthly: BUN, creatinine, output, specific gravity, urinalysis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5771">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, fever, abdominal pain/cramping, bloody diarrhea; discontinue if present, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5776">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5780">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of TB, culture negative</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5786">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5791">
								<item>
									<label>•</label>
									<para>That compliance with dosage schedule, duration necessary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5796">
								<item>
									<label>•</label>
									<para>That scheduled appointments must be kept because relapse may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5801">
								<item>
									<label>•</label>
									<para>That urine, feces, saliva, sputum, sweat, tears may be colored red-orange; that soft contact lenses, dentures may be permanently stained</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5808">
								<item>
									<para>
										<emphasis alert="nurse">To use alternative method of contraception; that oral contraceptive action may be decreased; to notify prescriber if pregnancy planned, suspected; to avoid breastfeeding</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5814">
								<item>
									<para>
										<emphasis alert="nurse">To report flulike symptoms: excessive fatigue, anorexia, vomiting, sore throat; unusual bleeding, yellowish discoloration of skin, eyes; diarrhea with pus, mucus, blood</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>rifaximin (Rx)</mono_name>
			<info>
				<pronunciation>(rif-ax′i-min)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x58240">Xifaxan</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Analog of rifampin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5834">
				<para>
					<confusion>
						<tradename id="tnidelem4x58340">rifaximin</tradename>
						<drug type="generic" refid="idelem4x58340">rifampin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5838">
				<sec_title>Action:</sec_title>
				<para>Binds to bacterial-DNA–dependent RNA polymerase, thereby inhibiting bacterial RNA synthesis</para>
			</section>
			<section type="uses" id="sidelem4x5843">
				<sec_title>Uses:</sec_title>
				<para>Traveler’s diarrhea in those ≥12 yr caused by <emphasis style="italic">E. coli,</emphasis> hepatic encephalopathy</para>
				<section type="none" id="sidelem4x5851">
					<section type="none" id="sidelem4x5852">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Crohn’s disease, diverticulitis, irritable bowel syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5857">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to product, rifamycins; diarrhea with fever, blood in stool</para>
				<section type="none" id="sidelem4x5862">
					<section type="none" id="sidelem4x5863">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5868">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5871">
					<section type="none" id="sidelem4x5872">
						<sec_title>Traveler’s diarrhea</sec_title>
						<section type="none" id="sidelem4x5880">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5880">
									<item>
										<label>•</label>
										<para> 200 mg tid × 3 days without regard to meals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5884">
						<sec_title>Hepatic encephalopathy</sec_title>
						<section type="none" id="sidelem4x5892">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5892">
									<item>
										<label>•</label>
										<para> 550 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5896">
						<sec_title>Crohn’s disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5904">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5904">
									<item>
										<label>•</label>
										<para> 200 mg tid × 16 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5908">
						<sec_title>Diverticulitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5916">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5916">
									<item>
										<label>•</label>
										<para> 400 mg bid with mesalamine 800 mg tid × 7 days, then 7 days/mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5920">
						<sec_title>Irritable bowel syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5928">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5928">
									<item>
										<label>•</label>
										<para> 550 mg tid × 14 day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5932">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 200, 550 mg</para>
					</section>
					<section type="none" id="sidelem4x5937">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5941">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5947">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5950">
					<section type="none" id="sidelem4x5951">
						<sec_title>CNS:</sec_title>
						<para> Abnormal dreams, dizziness, insomnia, <emphasis style="italic">headache,</emphasis> fatigue, depression</para>
					</section>
					<section type="none" id="sidelem4x5959">
						<sec_title>CV:</sec_title>
						<para> Hypotension, chest pain, peripheral edema, ascites</para>
					</section>
					<section type="none" id="sidelem4x5964">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain, constipation, defecation urgency, flatulence, nausea, rectal tenesmus,</emphasis> vomiting, ascites, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5974">
						<sec_title>GU:</sec_title>
						<para> Proteinuria, polyuria, increased urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x5979">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Pyrexia,</emphasis> motion sickness, tinnitus, rash, photosensitivity, <emphasis style="bold">exfoliative dermatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5989">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, muscle pain, myalgia</para>
					</section>
					<section type="none" id="sidelem4x5994">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, cough, pharyngitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5999">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Low systemic absorption, half-life 1.8-4.5 hr, excreted in feces, peak 1-4 hr</para>
			</section>
			<section type="interactions" id="sidelem4x6004">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—afatinib</para>
				<section type="none" id="sidelem4x6011">
					<section type="none" id="sidelem4x6012">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, potassium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> blood glucose, sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6023">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6026">
					<section type="none" id="sidelem4x6027">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6032">
								<item>
									<label>•</label>
									<para>GI symptoms: amount, character of diarrhea; abdominal pain, nausea, vomiting, blood in stool; do not use in those with blood in stool, increased temperature with diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6038">
								<item>
									<para>
										<emphasis alert="nurse">Overgrowth of infection, pseudomembranous colitis</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6043">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6047">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6053">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6059">
								<item>
									<para>
										<emphasis alert="nurse">To discontinue rifaximin, notify prescriber if diarrhea persists &gt;24-48 hr, if diarrhea worsens, or if blood in stools and fever present</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6064">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6069">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy planned, suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6074">
								<item>
									<label>•</label>
									<para>That headache, rash, insomnia, abnormal dreams, tinnitus may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6080">
								<item>
									<label>•</label>
									<para>To take without regard to food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6085">
								<item>
									<label>•</label>
									<para>To take as directed, consume all of the product prescribed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>rilpivirine</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x60930">Edurant</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nonnucleoside transcriptase inhibitors (NNTIs)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x6103">
				<sec_title>Action:</sec_title>
				<para>Inhibits HIV-1 reverse transcriptase; unlike nucleoside reverse transcriptase inhibitors (NRTIs), it does not compete for binding nor does it require phosphorylation to be active; binds directly to a site on reverse transcriptase causing disruption of the enzyme’s active site thereby blocking RNA-dependent and DNA-dependent DNA polymerase activities</para>
			</section>
			<section type="uses" id="sidelem4x6108">
				<sec_title>Uses:</sec_title>
				<para>HIV in combination with other antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x6113">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x6118">
					<section type="none" id="sidelem4x6119">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, neonates, infants, children, adolescents &lt;18 yr, immune reconstitution syndrome, antimicrobial resistance, pancreatitis, coinfection hepatitis B or C and HIV, hepatic disease, depression, suicidal ideation, QT prolongation, torsades de pointes, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, immune reconstitution syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6124">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6127">
					<section type="none" id="sidelem4x6128">
						<sec_title>Antiretroviral treatment-naive adults (HIV) with other antiretroviral agents</sec_title>
						<section type="none" id="sidelem4x6136">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6136">
									<item>
										<label>•</label>
										<para> 25 mg/day with a meal</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6140">
						<sec_title>Available forms:</sec_title>
						<para> Tab 25 mg</para>
					</section>
					<section type="none" id="sidelem4x6145">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6149">
								<item>
									<label>•</label>
									<para>Give with other antiretroviral agents; in antiretroviral treatment-naive adults, rilpivirine is used as an alternative to efavirenz in NNRTI-based treatment regimens; potential rilpivirine-based treatment regimens combine rilpivirine with either tenofovir plus emtricitabine or lamiVUDine; or abacavir plus emtricitabine or lamiVUDine; or zidovudine plus emtricitabine or lamiVUDine</para>
								</item>
								<item>
									<label>•</label>
									<para>Give with a meal</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature away from heat and moisture</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6165">
				<sec_title>Side effects</sec_title>
				<para>
					<emphasis style="bold">CNS:</emphasis> Depressed mood, dysphoria, major depression, mood alteration, negative thoughts, <emphasis style="bold">suicide attempts,</emphasis> fatigue, headache, dizziness, drowsiness</para>
				<para>
					<emphasis style="bold">GI:</emphasis> Nausea, vomiting, abdominal pain, diarrhea, cholecystitis, cholelithiasis, decreased appetite, elevated hepatic enzymes, hyperbilirubinemia, hypercholesterolemia</para>
				<para>
					<emphasis alert="lifethreat">GU: Glomerulonephritis membranous/glomerulonephritis mesangioproliferative</emphasis>
				</para>
			</section>
			<section type="kinetics" id="sidelem4x6182">
				<sec_title>Pharmacokinetics:</sec_title>
				<para>Protein binding (99.7%) to albumin; metabolism via oxidation CYP3A; terminal elimination half-life 50 hr, excretion feces (85%), 25% excreted unchanged; urine (6.1%); peak 4-5 hr; increased effect 40% (food), decreased effect 50% (high protein drink)</para>
			</section>
			<section type="interactions" id="sidelem4x6187">
				<sec_title>Interactions:</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> rilpivirine effect—CYP3A4 inhibitors (delavirdine, efavirenz, darunavir, tipranavir, atazanavir, fosamprenavir, indinavir, nelfinavir, aldesleukin IL-2, amiodarone aprepitant, basiliximab, boceprevir, bromocriptine, chloramphenicol, clarithromycin, conivaptan danazol, dalfopristin, dasatinib, diltiazem, dronedarone, erythromycin, ethinyl estradiol, fluconazole, FLUoxetine, fluvoxaMINE, fosaprepitant, imatinib, isoniazid, itraconazole, ketoconazole, lanreotide, lapatinib, miconazole, nefazodone, niCARdipine, octreotide, posaconazole, quiNINE, ranolazine, rifaximin, tamoxifen, telaprevir, telithromycin, troleandomycin, verapamil, voriconazole, zafirlukast)</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, chloroquine, droperidol, haloperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin, arsenic trioxide, levomethadyl); CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone, lopinavir, saquinavir, fluconazole, posaconazole, dasatinib, dronedarone, lapatinib, octreotide, ranolazine, citalopram, abarelix, alfuzosin, amoxapine, apomorphine, artemether, lumefantrine, asenapine, ofloxacin, ciprofloxacin, cloZAPine, cyclobenzaprine, dolasetron, eribulin, flecainide, gatifloxacin, gemifloxacin, halogenated anesthetics, iloperidone, levofloxacin, maprotiline, mefloquine, moxifloxacin, nilotinib, norfloxacin, OLANZapine, ondansetron, paliperidone, palonosetron, QUEtiapine)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> rilpivirine adverse reactions, fungal infections—fluconazole, voriconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> rilpivirine effect, treatment failure—CYP3A4 inducers (phenytoin, fosphenytoin, barbiturates, OXcarbazepine, carBAMazepine, rifabutin, rifampin, rifapentine, dexamethasone), efavirenz, nevirapine, ritonavir; aminoglutethimide, bexarotene, bosentan, griseofulvin, metyrapone, modafinil, flutamide, nafcillin, pioglitazone, primidone, topiramate); proton pump inhibitors (PPIs)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> rilpivirine effect, treatment failure—H2 receptor antagonists (cimetidine, famotidine, nizatidine, ranitidine), give 12 hr before or 4 hr after rilpivirine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> rilpivirine effect—antacids, use &gt;2 hr before or 4 hr after rilpivirine</para>
				<section type="none" id="sidelem4x6217">
					<section type="none" id="sidelem4x6218">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> adverse reactions—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6225">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6228">
					<section type="none" id="sidelem4x6229">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6237">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x6237">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> Assess symptoms of HIV including opportunistic infections before and during treatment; some may be life- threatening; monitor plasma HIV RNA, CD4+, CD8+ cell counts, serum β-2 microglobulin, serum ICD+24 antigen levels; treatment failures occur more frequently in those with baseline HIV-1 RNA concentrations &gt;100,000 copies/ml than in patients with concentrations &lt;100,000 copies/ml; monitor serum cholesterol, lipid panel</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6241">
								<item>
									<label>•</label>
									<para>Antiretroviral drug resistance testing before initiation of therapy in antiretroviral treatment-naive patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6246">
								<item>
									<label>•</label>
									<para>For adults and adolescents, initiation of antiretroviral therapy is recommended in any patient with a history of an AIDS-defining infection; with a CD4 ≤500/mm<emphasis style="sup">3</emphasis>; who is pregnant; who has HIV-associated nephropathy; or who is being treated for hepatitis B (HBV) infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6255">
								<item>
									<para>
										<emphasis alert="nurse">Suicidal thoughts/behaviors: Assess frequently for suicidal ideation; report any increase in depressive symptoms</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6263">
							<label>•</label>
							<sec_title>Hepatic disease</sec_title>
							<para>
								<list id="lidelem4x6263">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic disease:</emphasis> Monitor for elevated hepatic enzymes (&gt;2.5 × ULN); grade 3 and 4 may be higher in patients co-infected with hepatitis B or C</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6267">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6272">
								<item>
									<label>•</label>
									<para>That product is not a cure but controls symptoms, that continuing use is required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6277">
								<item>
									<label>•</label>
									<para>That product must be taken in combination with other prescribed products</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6285">
							<label>•</label>
							<sec_title>
								<route>To report if pregnancy is suspected immediately, do not breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6288">
								<item>
									<label>•</label>
									<para>To advise prescriber of all products that are used</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6293">
								<item>
									<label>•</label>
									<para>To report mood changes and depression</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active" ru="yes">
			<mono_name> riluzole (Rx)</mono_name>
			<info>
				<pronunciation>(rill′you-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x63060">Rilutek</tradename>
				</tradenames>
				<class type="func"> ALS agent</class>
				<class type="chem"> Benzathiazole</class>
			</info>
			<section type="uses" id="sidelem4x6316">
				<sec_title>Uses:</sec_title>
				<para>Amyotropic lateral sclerosis (ALS)</para>
			</section>
			<section type="contra" id="sidelem4x6321">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x6326">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6334">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6334">
							<item>
								<label>•</label>
								<para> 50 mg q12hr; take 1 hr before or 2 hr after meals</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>rimexolone ophthalmic</mono_name>
			<section type="none" id="sidelem4x6341">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>riociguat</mono_name>
			<info>
				<pronunciation>(rye′oh-sig′ue-at)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x63500">Adempas</tradename>
				</tradenames>
				<class type="func"> Antihypertensive/vasodilator</class>
				<class type="chem"> Guanylate cyclase stimulator</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x6360">
				<sec_title>Action:</sec_title>
				<para>Guanylate cyclase stimulator, also a vasoconstrictor</para>
			</section>
			<section type="uses" id="sidelem4x6365">
				<sec_title>Uses:</sec_title>
				<para>WHO group I pulmonary arterial hypertension and WHO group IV persistent/recurrent chronic thromboembolic pulmonary hypertension</para>
			</section>
			<section type="contra" id="sidelem4x6370">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding hypersensitivity</para>
				<para>
					<bbw>Pregnancy (X)</bbw>
				</para>
				<section type="none" id="sidelem4x6385">
					<section type="none" id="sidelem4x6386">
						<sec_title>Precautions:</sec_title>
						<para> Hypotension, hypovolemia, pulmonary edema, tobacco smoking</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6391">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6399">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6399">
							<item>
								<label>•</label>
								<para> 1 mg tid; may start at 0.5 mg tid if needed; if systolic B/P remains &gt;95 mmHg increase by 0.5 mg tid; increase no sooner than 2 wk, max 2.5 mg tid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6403">
					<section type="none" id="sidelem4x6404">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x6412">
							<label>•</label>
							<sec_title>Adult<route> Not recommended in CCr &lt;15 ml/min or Child-Pugh C</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6415">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 1, 1.5, 2, 2.5 mg</para>
					</section>
					<section type="none" id="sidelem4x6420">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6424">
								<item>
									<label>•</label>
									<para>tid without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not discontinue abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>If dose is missed, take at next scheduled dose; if stopped for ≥3 days, begin with initial dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6440">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6443">
					<section type="none" id="sidelem4x6444">
						<sec_title>CNS:</sec_title>
						<para> Dizziness</para>
					</section>
					<section type="none" id="sidelem4x6449">
						<sec_title>CV:</sec_title>
						<para> Hypotension, peripheral edema, palpitations</para>
					</section>
					<section type="none" id="sidelem4x6454">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x6459">
						<sec_title>GI:</sec_title>
						<para> Constipation, gastritis, gastroesophageal reflux, nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x6464">
						<sec_title>GU:</sec_title>
						<para> Decreased sperm counts</para>
					</section>
					<section type="none" id="sidelem4x6469">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, bleeding, nosebleeds</para>
					</section>
					<section type="none" id="sidelem4x6474">
						<sec_title>RESP:</sec_title>
						<para> Pulmonary edema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6479">
				<sec_title>Pharmacokinetics</sec_title>
				<para>95% protein binding, peak 1.5 hr, metabolized by P-gb, CYP1A1, CYP3A4, CYP3A, CYP2C8, CYP2J2, terminal half-life 15 hr, half-life 12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x6484">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x6492">
					<label>•</label>
					<sec_title>
						<route>Do not use with nitrates, nitric oxide donors, phosphodiesterase-5 inhibitors</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x6495">
						<item>
							<label>•</label>
							<para>Decreased riociguat effect: tobacco smoking</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> riociguat—CYP3A4 inhibitors (amprenavir, aprepitant, atazanavir, clarithromycin, conivaptan, cycloSPORINE, dalfopristin, danazol, darunavir, erythromycin, estradiol, imatinib, itraconazole, ketoconazole, nefazodone, nelfinavir, propoxyphene, quinupristin, ritonavir, RU-486, saquinavir, tamoxifen, telithromycin, troleandomycin, zafirlukast)</para>
				<section type="none" id="sidelem4x6504">
					<section type="none" id="sidelem4x6505">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x6509">
								<item>
									<label>•</label>
									<para>Need for dosage change: St. John’s wort, ephedra (ma huang)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6515">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6518">
					<section type="none" id="sidelem4x6519">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6523">
								<item>
									<label>•</label>
									<para>Pulmonary status: improvement in breathing, ability to exercise; pulmonary edema may indicate venoocclusive disease
<bbw>Assess pregnancy status before giving this product; pregnancy (X)</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6538">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6542">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P; decreased shortness of breath</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6548">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6552">
								<item>
									<label>•</label>
									<para>The importance of complying with dosage schedule even if feeling better
<bbw>To notify if pregnancy is planned or suspected (if pregnant, product will need to be discontinued, pregnancy test done monthly); to use 2 contraception methods while taking this product</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use OTC products including herbs, supplements unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>risedronate (Rx)</mono_name>
			<info>
				<pronunciation>(rih-sed′roh-nate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x65771">Actonel</tradename>
					<tradename id="tnidelem4x65770">Atelvia</tradename>
				</tradenames>
				<class type="func"> Bone resorption inhibitor</class>
				<class type="chem"> Bisphosphonate</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6587">
				<para>
					<confusion>
						<tradename id="tnidelem4x65870">Actonel</tradename>
						<drug type="generic" refid="idelem4x65870">Actos</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6591">
				<sec_title>Action:</sec_title>
				<para>Inhibits bone resorption, absorbs calcium phosphate crystal in bone, and may directly block dissolution of hydroxyapatite crystals of bone</para>
			</section>
			<section type="uses" id="sidelem4x6596">
				<sec_title>Uses:</sec_title>
				<para>Paget’s disease; prevention, treatment of osteoporosis in postmenopausal women; glucocorticoid-induced osteoporosis; osteoporosis in men</para>
				<section type="none" id="sidelem4x6601">
					<section type="none" id="sidelem4x6602">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Osteolytic metastases</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6607">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to bisphosphonates, inability to stand or sit upright for ≥30 min, esophageal stricture, achalasia, hypocalcemia</para>
				<section type="none" id="sidelem4x6612">
					<section type="none" id="sidelem4x6613">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, renal disease, active upper GI disorders, dental disease, hyperparathyroidism, infection, vit D deficiency, coagulopathy, chemotherapy, asthma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6618">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6621">
					<section type="none" id="sidelem4x6622">
						<sec_title>Paget’s disease</sec_title>
						<section type="none" id="sidelem4x6630">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6630">
									<item>
										<label>•</label>
										<para> 30 mg/day × 2 mo; patients with Paget’s disease should receive calcium and vit D if dietary intake lacking; if relapse occurs, retreatment advised</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6634">
						<sec_title>Treatment/prevention of postmenopausal osteoporosis</sec_title>
						<section type="none" id="sidelem4x6642">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6642">
									<item>
										<label>•</label>
										<para> 5 mg/day or 35 mg/wk or 75 mg/day × 2 consecutive days 2× monthly or 150 mg/mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6646">
						<sec_title>Glucocorticoid osteoporosis</sec_title>
						<section type="none" id="sidelem4x6654">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6654">
									<item>
										<label>•</label>
										<para> 5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6658">
						<sec_title>Osteoporosis in men</sec_title>
						<section type="none" id="sidelem4x6666">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6666">
									<item>
										<label>•</label>
										<para> 35 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6670">
						<sec_title>Osteolytic metastases (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6678">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6678">
									<item>
										<label>•</label>
										<para> 30 mg/day × 6 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6682">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6690">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6693">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 30, 35, 150 mg; tab, weekly 35 mg</para>
					</section>
					<section type="none" id="sidelem4x6698">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6702">
								<item>
									<label>•</label>
									<para>For 2 mo to be effective for Paget’s disease</para>
								</item>
								<item>
									<label>•</label>
									<para>With a full glass of water; patient should be in upright position for <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; swallow whole; do not crush, break, chew, give del rel tablet in <emphasis style="smallcaps">am</emphasis> after breakfast, only use with food (del rel)</para>
								</item>
								<item>
									<label>•</label>
									<para>Supplemental calcium and vit D for Paget’s disease if instructed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Give daily ≥30 min before meals or give weekly</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment, out of direct sunlight</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6737">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6740">
					<section type="none" id="sidelem4x6741">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, depression</para>
					</section>
					<section type="none" id="sidelem4x6746">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Chest pain,</emphasis> hypertension, <emphasis style="bold">atrial fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6757">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain, diarrhea, nausea,</emphasis> constipation, esophagitis</para>
					</section>
					<section type="none" id="sidelem4x6765">
						<sec_title>MISC:</sec_title>
						<para> Rash, UTI, pharyngitis, hypocalcemia, hypophosphatemia, increase PTH</para>
					</section>
					<section type="none" id="sidelem4x6770">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Osteonecrosis of the jaw,</emphasis> severe muscle/joint/bone pain, fractures</para>
					</section>
					<section type="none" id="sidelem4x6778">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6785">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly cleared from circulation, taken up mainly by bones (50%), eliminated primarily through kidneys, absorption decreased by food, terminal half-life 230 hr</para>
			</section>
			<section type="interactions" id="sidelem4x6790">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI irritation—NSAIDs, salicylates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of risedronate—aluminum, calcium, iron, magnesium salts, antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of del rel risedronate-H2 antagonists, proton pump inhibitors, do not use together</para>
				<section type="none" id="sidelem4x6805">
					<section type="none" id="sidelem4x6806">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> bioavailability—take <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr before food or drinks other than water</para>
					</section>
					<section type="none" id="sidelem4x6819">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, phosphorus</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6826">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6829">
					<section type="none" id="sidelem4x6830">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6838">
							<label>•</label>
							<sec_title>Paget’s disease</sec_title>
							<para>
								<list id="lidelem4x6838">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Paget’s disease:</emphasis> headache, bone pain, increased head circumference</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6845">
							<label>•</label>
							<sec_title>Osteoporosis</sec_title>
							<para>
								<list id="lidelem4x6845">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Osteoporosis:</emphasis> in men or postmenopausal women; bone density study before and periodically during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6849">
								<item>
									<label>•</label>
									<para>Phosphate, alk phos, calcium; creatinine, BUN (renal disease)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6857">
							<label>•</label>
							<sec_title>Hypocalcemia</sec_title>
							<para>
								<list id="lidelem4x6857">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypocalcemia:</emphasis> paresthesia, twitching, laryngospasm, Chvostek’s/Trousseau’s signs</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6862">
							<sec_title>Serious skin reactions</sec_title>
							<para>
								<list id="lidelem4x6862">
									<item>
										<para>
											<emphasis alert="nurse">Serious skin reactions:</emphasis> angioedema</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6871">
							<label>•</label>
							<sec_title>Dental health<route> assess dental health, provide antiinfectives for dental extraction; cover with antiinfectives before dental extraction</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x6875">
								<item>
									<para>
										<emphasis alert="nurse">For atrial fibrillation</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6880">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6884">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased bone mass, absence of fractures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6890">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6894">
								<item>
									<label>•</label>
									<para>To sit upright for <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr after dose to prevent irritation</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber immediately if difficulty swallowing, severe heartburn, or pain in chest</para>
								</item>
								<item>
									<label>•</label>
									<para>To comply with diet, vitamin/mineral supplements</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected or if breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>To maintain good oral hygiene</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify all health care providers of use</para>
								</item>
								<item>
									<label>•</label>
									<para>That musculoskeletal pain may occur within a few days/mo after starting but usually resolves; use acetaminophen</para>
								</item>
								<item>
									<label>•</label>
									<para>To exercise regularly; to avoid alcohol, tobacco</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active">
			<mono_name>risperiDONE (Rx)</mono_name>
			<info>
				<pronunciation>(ris-pehr′ih-dohn)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x69462">RisperDAL</tradename>
					<tradename id="tnidelem4x69461">RisperDAL Consta</tradename>
					<tradename id="tnidelem4x69460">RisperDAL M-TAB</tradename>
				</tradenames>
				<class type="func"> Antipsychotic</class>
				<class type="chem"> Benzisoxazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6956">
				<para>
					<confusion>
						<tradename id="tnidelem4x69560">RisperDAL</tradename>
						<drug type="generic" refid="idelem4x69560">reserpine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6960">
				<sec_title>Action:</sec_title>
				<para>Unknown; may be mediated through both dopamine type 2 (D<emphasis style="inf">2</emphasis>) and serotonin type 2 (5-HT<emphasis style="inf">2</emphasis>) antagonism</para>
			</section>
			<section type="uses" id="sidelem4x6971">
				<sec_title>Uses:</sec_title>
				<para>Irritability associated with autism, bipolar disorder, mania, schizophrenia</para>
				<section type="none" id="sidelem4x6976">
					<section type="none" id="sidelem4x6977">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute psychosis, agitation, ADHD, dementia, psychotic depression, Tourette’s syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6982">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding</para>
				<section type="none" id="sidelem4x6987">
					<section type="none" id="sidelem4x6988">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, geriatric patients, cardiac/renal/hepatic disease, breast cancer, Parkinson’s disease, CNS depression, brain tumor, dehydration, diabetes, hematologic disease, seizure disorders, abrupt discontinuation, suicidal ideation, phenylketonuria</para>
						<para>
							<bbw>Increased mortality in elderly patients with dementia-related psychosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7004">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7012">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7012">
							<item>
								<label>•</label>
								<para> 2 mg/day as single dose or in 2 divided doses, adjust dose at intervals of ≥24 hr and 1-2 mg/day as tolerated to 4-8 mg/day;  establish dosing with  before  25 mg q2wk, may increase to max 50 mg q2wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7028">
					<label>•</label>
					<sec_title>Adolescent<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7028">
							<item>
								<label>•</label>
								<para> 0.5 mg/day in <emphasis style="smallcaps">am</emphasis> or <emphasis style="smallcaps">pm</emphasis>, adjust dose at intervals of ≥24 hr and 0.5-1 mg/day as tolerated to 3 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7041">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7041">
							<item>
								<label>•</label>
								<para> 0.5 mg daily-bid, increase by 1 mg/wk;  25 mg q2wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7048">
					<section type="none" id="sidelem4x7049">
						<sec_title>Hepatic/renal dose</sec_title>
						<section type="none" id="sidelem4x7057">
							<label>•</label>
							<sec_title>Adult<route> PO 0.5 mg bid, increase by 0.5 mg bid, increase to 1.5 mg bid at intervals ≥1 wk</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7060">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.25, 0.5, 1, 2, 3, 4 mg; oral sol 1 mg/ml; orally disintegrating tabs 0.25, 0.5, 1, 2, 3, 4 mg; long-acting inj kit (Risperdal Consta) 12.5, 25, 37.5, 50 mg</para>
					</section>
					<section type="none" id="sidelem4x7065">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7070">
								<item>
									<label>•</label>
									<para>Reduced dose in geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7075">
								<item>
									<label>•</label>
									<para>Anticholinergic agent on order from prescriber, to be used for EPS</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7080">
								<item>
									<label>•</label>
									<para>Avoid use with CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7085">
								<item>
									<label>•</label>
									<para>Conventional tabs: give without regard to meals</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7093">
							<label>•</label>
							<sec_title>
								<route>Oral disintegrating tab</route>
							</sec_title>
							<para>
								<list id="lidelem4x7093">
									<item>
										<label>•</label>
										<para> (Risperdal M-TAB): do not open blister pack until ready to use; tear at perforation; bend corner where indicated; peel back foil; do not push tab through foil; remove from pack and place product on patient’s tongue; tab disintegrates in seconds and can be swallowed with/without liquids, do not split or chew</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7100">
							<label>•</label>
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x7100">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral sol:</emphasis> May dilute 3-4 oz of beverage, measure dose using calibrated pipette; not compatible with tea, cola; compatible with water, coffee, orange juice, low-fat milk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7104">
							<sec_title>IM route</sec_title>
							<para>
								<emphasis alert="lifethreat">Preparation</emphasis>
								<list id="lidelem4x7110">
									<item>
										<label>•</label>
										<para>Only suspend in the diluent provided and with the supplied needle</para>
									</item>
									<item>
										<label>•</label>
										<para>Before admixing, allow to come to room temperature for 30 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Remove colored cap from the vial without removing the gray rubber stopper; wipe top of stopper with an alcohol wipe</para>
									</item>
									<item>
										<label>•</label>
										<para>Peel back the blister pouch and remove the Vial Access Device by holding between the white Luer cap and the skirt; do not touch the spike tip at any time</para>
									</item>
									<item>
										<label>•</label>
										<para>Place the vial on a hard surface and hold the base; orient the Vial Access Device vertically over the vial so that the spike tip is at the center of the vial’s rubber stopper</para>
									</item>
									<item>
										<label>•</label>
										<para>With a straight downward push, press the spike tip of the Vial Access Device through the center of the vial’s rubber stopper until the device securely snaps onto the vial top; improper placement of the Vial Access Device on the vial could result in leakage of the diluent upon transfer</para>
									</item>
									<item>
										<label>•</label>
										<para>Hold the base of the vial and swab the syringe connection point (blue circle) of the Vial Access Device with an alcohol wipe and allow to dry before attaching the syringe</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid over-tightening or syringe component parts might loosen from the syringe body</para>
									</item>
									<item>
										<label>•</label>
										<para>While holding the white collar of the syringe, insert and press the syringe tip into the blue circle of the Vial Access Device and twist in a clockwise motion to secure the connection of the syringe to the Vial Access Device; hold the skirt of the Vial Access Device during attachment to prevent it from spinning; keep the syringe and the Vial Access Device aligned</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject the entire contents of the syringe containing the diluent into the vial</para>
									</item>
									<item>
										<label>•</label>
										<para>Holding the plunger down with the thumb, shake the vial vigorously for a minimum of 10 sec; suspension should appear uniform, thick, and milky colored, and all the powder is dispersed in liquid; the microspheres will be visible in liquid, but no dry microspheres remain</para>
									</item>
									<item>
										<label>•</label>
										<para>Invert completely and slowly withdraw the contents of the suspension from the vial into the syringe; tear the section of the vial label at the perforation and apply the detached label to the syringe</para>
									</item>
									<item>
										<label>•</label>
										<para>While holding the white collar of the syringe, unscrew the syringe from the Vial Access Device, then discard both the vial and the Vial Access Device appropriately</para>
									</item>
									<item>
										<label>•</label>
										<para>Select the appropriate color-coded needle provided with the kit; two distinct needles are provided: the needle with the yellow hub and print is for injection into the gluteal muscle (2-inch needle), and the needle with the green hub and print is for deltoid muscles (1-inch needle); they are not interchangeable; do not use the needle intended for gluteal injection for deltoid injection, and vice versa</para>
									</item>
									<item>
										<label>•</label>
										<para>Peel the blister pouch of the Needle-Pro safety device open halfway; grasp the transparent needle sheath using the plastic peel pouch; to prevent contamination, do not touch the orange Needle-Pro safety device’s Luer connector; while holding the white collar of the syringe, attach the Luer connection of the orange Needle-Pro safety device to the syringe with an easy clockwise twisting motion</para>
									</item>
									<item>
										<label>•</label>
										<para>While holding the white collar of the syringe, grasp the transparent needle sheath and seat the needle firmly on the orange Needle-Pro safety device with a push and a clockwise twist; seating the needle will secure the connection between the needle and the orange Needle-Pro safety device</para>
									</item>
									<item>
										<label>•</label>
										<para>While holding the white collar of the syringe, pull the transparent needle sheath straight away from the needle; do not twist the sheath because this can loosen the Luer connection</para>
									</item>
									<item>
										<label>•</label>
										<para>Resuspension is necessary before administration, because settling occurs after reconstitution; resuspend the microspheres in the syringe by shaking vigorously</para>
									</item>
									<item>
										<label>•</label>
										<para>Refer to the Instructions for Use section of the product labeling for detailed visual aids that accompany the written instructions</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis alert="lifethreat">Administration</emphasis>
								<list id="lidelem4x7211">
									<item>
										<label>•</label>
										<para>Only for IM; do not give IV</para>
									</item>
									<item>
										<label>•</label>
										<para>Resuspension is necessary before administration, because settling occurs after reconstitution; resuspend the microspheres in the syringe by shaking vigorously</para>
									</item>
									<item>
										<label>•</label>
										<para>Remove any air bubbles by tapping the syringe and slowly depressing the plunger with the needle in an upright position</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject the entire contents of the syringe into the upper outer quadrant of the gluteal area or the deltoid muscle; inject immediately after reconstitution to avoid settling; gluteal injections should be alternated between the two buttocks</para>
									</item>
									<item>
										<label>•</label>
										<para>After the injection is complete, press the needle into the orange Needle-Pro safety device by gently pressing the orange Needle-Pro safety device against a flat surface with one hand; as the orange Needle-Pro safety device is pressed, the needle firmly engages into the orange Needle-Pro safety device</para>
									</item>
									<item>
										<label>•</label>
										<para>Visually confirm full engagement of the needle into the Needle-Pro safety device, then appropriately discard both the used and unused needle provided in the dose pack</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not store the vial after reconstitution or the suspension will settle</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not combine 2 different dosage strengths of RisperDAL Consta in a single administration</para>
									</item>
									<item>
										<label>•</label>
										<para>The dose pack device is for single use only; do not reprocess for subsequent reuse because the integrity of the device may be compromised, leading to a deterioration in performance</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis alert="lifethreat">Stability after reconstitution</emphasis>
								<list id="lidelem4x7260">
									<item>
										<label>•</label>
										<para>Once in suspension, the product may remain at room temperature, but it must be used within 6 hr; always resuspend before administration if not used immediately</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7267">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7270">
					<section type="none" id="sidelem4x7271">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">EPS, pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia; drowsiness, insomnia, agitation, anxiety, headache,</emphasis><emphasis style="bold">seizures, neuroleptic malignant syndrome,</emphasis> dizziness, <emphasis style="bold">suicidal ideation,</emphasis> head titubation (shaking)</para>
					</section>
					<section type="none" id="sidelem4x7284">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, <emphasis style="bold">tachycardia; heart failure, sudden death (geriatric patients),</emphasis> AV block</para>
					</section>
					<section type="none" id="sidelem4x7292">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x7297">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, <emphasis style="italic">anorexia, constipation,</emphasis> jaundice, weight gain</para>
					</section>
					<section type="none" id="sidelem4x7308">
						<sec_title>GU:</sec_title>
						<para> Hyperprolactinemia, gynecomastia, dysuria</para>
					</section>
					<section type="none" id="sidelem4x7313">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, granulocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7320">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Renal artery occlusion;</emphasis> hyperprolactinemia (child)</para>
					</section>
					<section type="none" id="sidelem4x7328">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7335">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis; sinusitis, upper respiratory infection, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7340">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x7343">
					<section type="none" id="sidelem4x7344">
						<sec_title>PO:</sec_title>
						<para> Extensively metabolized by liver to major active metabolite, plasma protein binding 90%, peak 1-2 hr, excreted 90% in urine, terminal half-life 3-24 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7349">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: seizures—traMADol</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: possible death in dementia-related psychosis: furosemide</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—other CNS depressants, alcohol</para>
				<para>
					<emphasis alert="nurse">Increase: serotonin syndrome, neuroleptic malignant syndrome—CYP2D6 inhibitors (SSRIs, SNRIs)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> EPS—other antipsychotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risperiDONE excretion—carBAMazepine</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA/ III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, methadone, chloroquine, clarithromycin, droperidol, erythromycin, pentamidine, thioridazine, ziprasidone</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: risperiDONE levels: acetylcholinesterase, inhibitors, CYP2D6 inhibitors, SSRIs, valproic acid, verapamil</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> risperiDONE action—CYP2D6 inducers (carBAMazepine, barbiturates, phenytoins, rifampin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levodopa effect—levodopa</para>
				<section type="none" id="sidelem4x7393">
					<section type="none" id="sidelem4x7394">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> risperiDONE effect—echinacea</para>
					</section>
					<section type="none" id="sidelem4x7401">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> prolactin levels, blood, glucose, lipids</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7408">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7411">
					<section type="none" id="sidelem4x7412">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7418">
								<item>
									<para>
										<emphasis alert="nurse">Suicidal thoughts/behaviors: often when depression is lessened; mental status before initial administration</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7423">
								<item>
									<label>•</label>
									<para>Thyroid function test, blood glucose, serum electrolytes/prolactin/lipid profile, bilirubin, creatinine, weight, pregnancy test, CBC, LFTs, AIMS assessment, baseline and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7428">
								<item>
									<label>•</label>
									<para>Affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7434">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: B/P standing, lying; pulse, respirations; take these q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; watch for ECG changes</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7439">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7447">
							<label>•</label>
							<sec_title>EPS</sec_title>
							<para>
								<list id="lidelem4x7447">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">EPS:</emphasis> akathisia, tardive dyskinesia (bizarre movements of the jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7452">
								<item>
									<para>
										<emphasis alert="nurse">Serious reactions in geriatric patient: fatal pneumonia, heart failure, sudden death, dementia</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7458">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignant syndrome: hyperthermia, increased CPK, altered mental status, muscle rigidity, seizures, change in B/P, fatigue, tachycardia</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7463">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; if these occur, increase bulk, water in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7468">
								<item>
									<label>•</label>
									<para>Decreased stimuli by dimming lights, avoiding loud noises</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7473">
								<item>
									<label>•</label>
									<para>Supervised ambulation until patient stabilized on medication; do not involve patient in strenuous exercise program because fainting is possible; patient should not stand still for a long time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7478">
								<item>
									<label>•</label>
									<para>Increased fluids to prevent constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7483">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container (PO); unopened vials in refrigerator, protect from light; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7488">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7492">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7498">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7503">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension may occur; to rise from sitting or lying position gradually</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7508">
								<item>
									<label>•</label>
									<para>To avoid abrupt withdrawal of product because EPS may result; product should be withdrawn slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7513">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber; that serious product interactions may occur; to avoid use of alcohol because increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7518">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsy or dizzy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7523">
								<item>
									<label>•</label>
									<para>To comply with product regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7528">
								<item>
									<label>•</label>
									<para>To report impaired vision, tremors, muscle twitching</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7536">
							<label>•</label>
							<sec_title>
								<route>That heat stroke may occur in hot weather; to take extra precautions to stay cool; to avoid hot tubs, hot showers, tub baths</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7539">
								<item>
									<label>•</label>
									<para>To use contraception; to inform prescriber if pregnancy is planned or suspected; not to breastfeed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7547">
							<label>•</label>
							<sec_title>
								<route>To notify provider of suicidal thoughts/behaviors</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>ritonavir (Rx)</mono_name>
			<info>
				<pronunciation>(ri-toe′na-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x75620">Norvir</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7572">
				<para>
					<confusion>
						<tradename id="tnidelem4x75720">ritonavir</tradename>
						<drug type="generic" refid="idelem4x75720">Retrovir</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7576">
				<sec_title>Action:</sec_title>
				<para>Inhibits human immunodeficiency virus (HIV-1) protease and prevents maturation of the infectious virus</para>
			</section>
			<section type="uses" id="sidelem4x7581">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 in combination with at least 2 other antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x7586">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Coadministration with other drugs</bbw>
				</para>
				<section type="none" id="sidelem4x7601">
					<section type="none" id="sidelem4x7602">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, hepatic disease, pancreatitis, diabetes, hemophilia, AV block, hypercholesterolemia, immune reconstitution syndrome, neonates, cardiomyopathy, immune reconstitution syndrome, infants 1-6 mo (overdose)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7607">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7615">
					<label>•</label>
					<sec_title>Adult and adolescent &gt;16 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7615">
							<item>
								<label>•</label>
								<para> 600 mg bid; if nausea occurs, begin at <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> dose and gradually increase, max 1200 mg/day in divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7628">
					<label>•</label>
					<sec_title>Adolescent ≤16 yr and child, infant<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7628">
							<item>
								<label>•</label>
								<para> 400 mg/m<emphasis style="sup">2</emphasis> bid up to 1200 mg/day in divided doses, may start lower and escalate</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7635">
					<section type="none" id="sidelem4x7636">
						<sec_title>Available forms:</sec_title>
						<para> Caps 100 mg; oral sol 80 mg/ml; tab 100 mg</para>
					</section>
					<section type="none" id="sidelem4x7641">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7644">
							<sec_title>Tablet/capsule</sec_title>
							<para>
								<list id="lidelem4x7649">
									<item>
										<label>•</label>
										<para>Take with food, swallow whole; do not crush, break, chew</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7654">
									<item>
										<label>•</label>
										<para>When switching from cap to tab, more GI symptoms may occur, will lessen over time</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7659">
									<item>
										<label>•</label>
										<para>Use dosage titration to minimize side effects</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7664">
									<item>
										<label>•</label>
										<para>Store caps in refrigerator</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x7672">
								<label>•</label>
								<sec_title>Oral sol</sec_title>
								<para>
									<list id="lidelem4x7672">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral sol:</emphasis> shake well, use calibrated measuring device</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x7676">
									<item>
										<label>•</label>
										<para>Mix liquid formulation with chocolate milk or liquid nutritional supplement to improve taste</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x7684">
								<label>•</label>
								<sec_title>Overdose<route> infants, children, 43.2% alcohol, 26.57% propylene glycol oral sol, calculate total amount of alcohol, propylene glycol from all products given</route></sec_title>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7687">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7690">
					<section type="none" id="sidelem4x7691">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Paresthesia, headache,</emphasis><emphasis style="bold">seizures,</emphasis> fever, dizziness, insomnia, asthenia, <emphasis style="bold">intracranial bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7704">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT, PR interval prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7711">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> buccal mucosa ulceration, <emphasis style="italic">abdominal pain, nausea, taste perversion,</emphasis> dry mouth, <emphasis style="italic">vomiting, anorexia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7724">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x7729">
						<sec_title>MISC:</sec_title>
						<para> Asthenia, <emphasis style="bold">angioedema, anaphylaxis, Stevens-Johnson syndrome,</emphasis> increase lipids, lipodystrophy, <emphasis style="bold">toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7739">
						<sec_title>MS:</sec_title>
						<para> Pain, <emphasis style="bold">rhabdomyolysis,</emphasis> myalgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7747">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, 98% protein binding, hepatic metabolism, peak 2-4 hr, terminal half-life 3-5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7752">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> toxicity—amiodarone, astemizole, azole antifungals, benzodiazepines, buPROPion, CISapride, cloZAPine, desipramine, dihydroergotamine, encainide, ergotamine, flecainide, HMG-CoA reductase inhibitors, interleukins, meperidine, midazolam, pimozide, piroxicam, propafenone, propoxyphene, quiNIDine, ranolazine, saquinavir, terfenadine, triazolam, zolpidem; CYP2D6 inhibitors</bbw>
				</para>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> QT prolongation—class 1A/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine, CYP3A4 inhibitors (amiodarone, clarithromycin, dasatinib, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl, CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ritonavir levels—fluconazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> level of both products—clarithromycin, ddI</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of—bosentan</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> ritonavir levels—rifamycins, nevirapine, barbiturates, phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of anticoagulants, atovaquone, divalproex, ethinyl estradiol, lamotrigine, phenytoin, sulfamethoxazole, theophylline, voriconazole, zidovudine</para>
				<section type="none" id="sidelem4x7799">
					<section type="none" id="sidelem4x7800">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Decrease: ritonavir levels—St. John’s wort; avoid concurrent use</emphasis>
							<list id="lidelem4x7806">
								<item>
									<label>•</label>
									<para>Avoid use with red yeast rice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7812">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, K, CK, cholesterol, GGT, triglycerides, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hct, Hgb, RBC, neutrophils, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7823">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7826">
					<section type="none" id="sidelem4x7827">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7835">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x7835">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> viral load, CD4 at baseline, throughout therapy; blood glucose, plasma HIV RNA, serum cholesterol/lipid profile; resistance testing before starting therapy and after treatment failure</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7842">
							<label>•</label>
							<sec_title>Immune reconstitution syndrome<route> may occur with combination therapy; may develop inflammatory response with opportunistic infection (MAC, Graves’ disease, Guillain-Barré Syndrome, TB, PCP); may occur during initial treatment or months after</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7845">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7850">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, in those with hepatic disease, monitor q3mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7855">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, discontinue product; monitor hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7860">
								<item>
									<label>•</label>
									<para>Skin eruptions; rash</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7866">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: muscle pain, increased CPK, weakness, swelling of affected muscles; if these occur and if confirmed by CPK, product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7872">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG for QT prolongation, ejection fraction; assess for chest pain, palpitations, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7878">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin disorders: Stevens-Johnson syndrome, angioedema, anaphylaxis, toxic epidermal necrolysis</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7883">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7887">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in HIV symptoms; improving viral load, CD4+ T cells</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7894">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7899">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7904">
								<item>
									<label>•</label>
									<para>That product not a cure for HIV; that opportunistic infections may continue to be acquired</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7909">
								<item>
									<label>•</label>
									<para>That redistribution of body fat or accumulation of body fat may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7914">
								<item>
									<label>•</label>
									<para>That others may continue to contract HIV from patient</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7922">
							<label>•</label>
							<sec_title>
								<route>To avoid OTC, prescription medications, herbs, supplements unless approved by prescriber; not to use St. John’s wort because it decreases product’s effect</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7925">
								<item>
									<label>•</label>
									<para>That regular follow-up exams and blood work will be required</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active" ha="yes">
			<mono_name> riTUXimab (Rx)</mono_name>
			<info>
				<pronunciation>(rih-tuks′ih-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x79370">Rituxan</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous; DMARDs</class>
				<class type="chem"> Murine/human monoclonal antibody</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x7947">
				<sec_title>Action:</sec_title>
				<para>Directed against the CD20 antigen that is found on malignant B lymphocytes; CD20 regulates a portion of cell-cycle initiation/differentiation</para>
			</section>
			<section type="uses" id="sidelem4x7952">
				<sec_title>Uses:</sec_title>
				<para>Non-Hodgkin’s lymphoma (CD20+, B-cell), bulky disease (tumors &gt;10 cm), rheumatoid arthritis, Wegener’s granulomatosis, microscopic polyangitis</para>
				<section type="none" id="sidelem4x7957">
					<section type="none" id="sidelem4x7958">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acquired blood factor deficiency, acute lymphocytic leukemia (ALL), Burkitt’s lymphoma, chronic lymphocytic leukemia (CLL), hemolytic anemia, human herpesvirus 8, mantle cell lymphoma (MCL), multicentric Castleman’s disease, peripheral blood stem cell (PBSC) mobilization, refractory pemphigus vulgaris, relapsing/remitting MS, ITP with dexamethasone, steroid refractory chronic graft-versus-host disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7963">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, murine proteins</para>
				<section type="none" id="sidelem4x7968">
					<section type="none" id="sidelem4x7969">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, pulmonary/cardiac/renal conditions</para>
						<para>
							<bbw>Exfoliative dermatitis, infusion-related reactions, progressive multifocal leukoencephalopathy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7984">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7987">
					<section type="none" id="sidelem4x7988">
						<sec_title>Relapsed or refractory low-grade or follicular, CD20+, B-cell non-Hodgkin’s lymphoma (NHL)</sec_title>
						<section type="none" id="sidelem4x7996">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7996">
									<item>
										<label>•</label>
										<para> 375 mg/m<emphasis style="sup">2</emphasis> every wk × 4 doses, may re-treat with 4 more doses of 375 mg/m<emphasis style="sup">2</emphasis>/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8006">
						<sec_title>First-line treatment of follicular, CD20+, B-cell NHL in combination with chemotherapy</sec_title>
						<section type="none" id="sidelem4x8014">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8014">
									<item>
										<label>•</label>
										<para> 375 mg/m<emphasis style="sup">2</emphasis> on day 1 of each cycle for up to 8 cycles; may be given with cyclophosphamide IV 750 mg/m<emphasis style="sup">2</emphasis> on day 1, vinCRIStine IV 1.4 mg/m<emphasis style="sup">2</emphasis> (max 2 mg) on day 1, and predniSONE 40 mg/m<emphasis style="sup">2</emphasis>/day PO on days 1-5</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8030">
						<sec_title>Single-agent maintenance therapy in patients with follicular, CD20+, B-cell NHL (complete or partial response following first-line treatment with riTUXimab in combination with chemotherapy)</sec_title>
						<section type="none" id="sidelem4x8038">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8038">
									<item>
										<label>•</label>
										<para> 375 mg/m<emphasis style="sup">2</emphasis> IV every 8 wk × 12 doses as maintenance therapy starting 8 wk after the completion of induction chemotherapy with 8 doses of riTUXimab with 6-8 cycles of cyclophosphamide, vinCRIStine, and predniSONE 4-6 cycles of cyclophosphamide, DOXOrubicin, vinCRIStine, and predniSONE</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8045">
						<sec_title>Component of the Zevalin (ibritumomab tiuxetan) regimen</sec_title>
						<section type="none" id="sidelem4x8053">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8053">
									<item>
										<label>•</label>
										<para> As a required component of the ibritumomab regimen; riTUXimab 250 mg/m<emphasis style="sup">2</emphasis> given within 4 hr before administration of Yttrium-90 ibritumomab that may occur on day 7, 8, or 9</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8061">
						<sec_title>First-line treatment of diffuse large B-cell, CD20+ NHL in combination with CHOP or other anthracycline-based chemotherapy regimen</sec_title>
						<section type="none" id="sidelem4x8069">
							<label>•</label>
							<sec_title>Adult 18-59 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8069">
									<item>
										<label>•</label>
										<para> 375 mg/m<emphasis style="sup">2</emphasis> on day 1 of each cycle for up to 8 infusions</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8076">
						<sec_title>Single-agent maintenance therapy in patients with low-grade, CD20+, B-cell NHL with nonprogressing disease (stable disease or better) following first-line treatment with cyclophosphamide, vinCRIStine, and predniSONE (CVP)</sec_title>
						<section type="none" id="sidelem4x8084">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8084">
									<item>
										<label>•</label>
										<para> 375 mg/m<emphasis style="sup">2</emphasis> weekly × 4 wk repeated every 6 mo × 2 yr (total of 16 doses) as maintenance therapy starting 4 wk after the completion of first-line chemotherapy with 6-8 cycles of cyclophosphamide, vinCRIStine, and predniSONE (CVP)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8091">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 mg/ml (100 mg/10 ml, 500 mg/50 ml)</para>
					</section>
					<section type="none" id="sidelem4x8096">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x8099">
							<sec_title>Rheumatoid arthritis:</sec_title>
							<para>
								<list id="lidelem4x8103">
									<item>
										<label>•</label>
										<para>Give methylPREDNISolone 100 mg or similar product 30 min before infusion to decrease reactions</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8109">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x8113">
									<item>
										<label>•</label>
										<para>Hold antihypertensives 12 hr before administration</para>
									</item>
									<item>
										<label>•</label>
										<para>After diluting to final concentration of 1-4 mg/ml; use 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, gently invert bag to mix; do not mix with other products; give 50 mg/hr initially; if no reaction, increase rate by 50 mg/hr to max 400 mg/hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Store vials at 36° F-40° F; protect vials from direct sunlight; infusion sol is stable at 36° F-46° F × 24 hr and at room temperature for another 12 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amcyclovir, amifostine, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium gluconate, CARBOplatin, carmustine, ceFAZolin, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, CISplatin, clindamycin, cyclophosphamide, cytarabine, DACTINomycin, DAUNOrubicin hydrochloride, dexamethasone, dexrazoxane, digoxin, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, DOXOrubicin liposome, doxycycline, droperidol, enalaprilat, etoposide phosphate, famotidine, fentaNYL, filgrastim, floxuridine, fluconazole, fludarabine, fluorouracil, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem/cilastatin, irinotecan, leucovorin, levorphanol, LORazepam, magnesium sulfate, mannitol, meperidine, mesna, methotrexate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, mitoMYcin, mitoXANtrone, morphine, nalbuphine, netilmicin, PACLitaxel, pentamidine, piperacillin/tazobactam, plicamycin, potassium chloride, prochlorperazine, promethazine, ranitidine, sargramostim, streptozocin, teniposide, theophylline, thiotepa, ticarcillin/clavulanate, tobramycin, trimethoprim/sulfamethoxazole, trimethobenzamide, vinBLAStine, vincCRIStine, vinorelbine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8136">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8139">
					<section type="none" id="sidelem4x8140">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Life-threatening brain infection (progressive multifocal leukoencephalopathy)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8147">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Cardiac dysrhythmias, heart failure, hypertension, MI, supraventricular tachycardia,</emphasis> angina</para>
					</section>
					<section type="none" id="sidelem4x8155">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis><emphasis style="bold">GI obstruction/perforation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8164">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8171">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, neutropenia, thrombocytopenia,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x8179">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Irritation at site, rash,</emphasis><emphasis style="bold">fatal mucocutaneous infections (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8188">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Fever,</emphasis> chills, asthenia, <emphasis style="italic">headache,</emphasis><emphasis style="bold">angioedema,</emphasis> hypotension, myalgia, <emphasis style="bold">bronchospasm, ARDs</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8203">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Toxic epidermal necrolysis, tumor lysis syndrome, Stevens-Johnson syndrome, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8210">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life varies, binds to CD20 sites or lymphoma cells</para>
			</section>
			<section type="interactions" id="sidelem4x8216">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—antihypertensives, separate by 12 hr</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nephrotoxicity—CISplatin, avoid concurrent use; if used, monitor renal status</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—anticoagulants<list id="lidelem4x8231">
						<item>
							<label>•</label>
							<para>Avoid with vaccines, toxoids</para>
						</item>
					</list></para>
			</section>
			<section type="considerations" id="sidelem4x8237">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8240">
					<section type="none" id="sidelem4x8241">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Fatal infusion reaction:</emphasis> hypoxia, pulmonary infiltrates, ARDS, MI, ventricular fibrillation, cardiogenic shock; most fatal reactions occur with 1st infusion; potentially fatal</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Severe mucocutaneous reactions:</emphasis> Stevens-Johnson syndrome, lichenoid dermatitis, toxic epidermal lysis; occur 1-13 wk after product given, discontinue treatment immediately</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Tumor lysis syndrome:</emphasis> acute renal failure requiring hemodialysis, hyperkalemia, hypocalcemia, hyperuricemia, hyperphosphatemia; allopurinol and adequate hydration may be needed</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Multifocal leukoencephalopathy:</emphasis> confusion, dizziness, lethargy, hemiparesis; monitor periodically</bbw>
						</para>
						<para>
							<list id="lidelem4x8293">
								<item>
									<label>•</label>
									<para>CBC, differential, platelet count weekly; withhold product if WBC is &lt;3500/mm<emphasis style="sup">3</emphasis> or platelet count &lt;100,000/mm<emphasis style="sup">3</emphasis>; notify prescriber of results; product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8304">
								<item>
									<label>•</label>
									<para>ECG, serum creatinine/BUN, electrolytes, uric acid</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8309">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, abdominal pain, perforation/obstruction may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8317">
							<label>•</label>
							<sec_title>Infection<route> fever, increased temperature, flulike symptoms in those with Wegener’s granulomatosis and microscopic polyangiitis in those using DMARDs</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8320">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8324">
								<item>
									<label>•</label>
									<para>Therapeutic response: prevention of increasing cancer progression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8330">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8335">
								<item>
									<label>•</label>
									<para>To avoid use with vaccines, toxoids</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8343">
							<label>•</label>
							<sec_title>
								<route>To use contraception during, for up to 12 mo after therapy</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8347">
								<item>
									<para>
										<emphasis alert="nurse">To report to prescriber possible infection (cough, fever, chills, sore throat), renal issues (painful urination, back/side pain), bleeding (gums, stools, urine, bruising, emesis, fatigue)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8352">
								<item>
									<label>•</label>
									<para>To avoid OTC products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8357">
								<item>
									<label>•</label>
									<para>To avoid crowds, those with known infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8362">
								<item>
									<label>•</label>
									<para>To maintain fluid intake</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active" ha="yes">
			<mono_name> rivaroxaban</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x83720">Xarelto</tradename>
				</tradenames>
				<class type="func"> Anticoagulant</class>
				<class type="chem"> Factor Xa inhibitor</class>
			</info>
			<section type="actions" id="sidelem4x8382">
				<sec_title>Action:</sec_title>
				<para>A novel, oral anticoagulant that selectively and potently inhibits coagulation factor Xa</para>
			</section>
			<section type="uses" id="sidelem4x8387">
				<sec_title>Uses:</sec_title>
				<para>For deep venous thrombosis (DVT) prophylaxis/treatment, pulmonary embolism (PE), in patients undergoing knee or hip replacement surgery; for stroke prophylaxis and systemic embolism prophylaxis in patients with nonvalvular atrial fibrillation</para>
			</section>
			<section type="doses" id="sidelem4x8424">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8427">
					<section type="none" id="sidelem4x8428">
						<sec_title>DVT prophylaxis, which may lead to pulmonary embolism (PE) (knee or hip replacement)</sec_title>
						<section type="none" id="sidelem4x8436">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8436">
									<item>
										<label>•</label>
										<para> 10 mg/day × 12 days after knee replacement surgery or × 35 days after hip replacement; administer the initial dose ≥6-10 hr after surgery once hemostasis has been established</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8440">
						<sec_title>DVT/PE treatment/reduction of risk</sec_title>
						<section type="none" id="sidelem4x8448">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8448">
									<item>
										<label>•</label>
										<para> 15 mg bid with food × 21 days, then 20 mg daily for a total of 6 mo, may continue after 6 mo to reduce risk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8452">
						<sec_title>Stroke prophylaxis and systemic embolism prophylaxis (with nonvalvular atrial fibrillation)</sec_title>
						<para>
							<list id="lidelem4x8457">
								<item>
									<label>•</label>
									<para>Unless pathological bleeding occurs, do not discontinue rivaroxaban in the absence of alternative anticoagulation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8465">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8465">
									<item>
										<label>•</label>
										<para> 20 mg/day with evening meal (CrCl &gt;50 ml/min)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8469">
						<sec_title>Converting from warfarin to rivaroxaban</sec_title>
						<para>
							<list id="lidelem4x8473">
								<item>
									<label>•</label>
									<para>Discontinue warfarin and start rivaroxaban when INR is &lt;3</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8479">
						<sec_title>Converting from another anticoagulant other than warfarin to rivaroxaban</sec_title>
						<para>
							<list id="lidelem4x8483">
								<item>
									<label>•</label>
									<para>Start rivaroxaban 0-2 hr before the next scheduled evening administration of anticoagulant (omit that dose of anticoagulant); for continuous infusion of unfractionated heparin, stop the infusion and initiate rivaroxaban simultaneously</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8489">
						<sec_title>Converting from rivaroxaban to another anticoagulant with rapid onset (not warfarin)</sec_title>
						<para>
							<list id="lidelem4x8493">
								<item>
									<label>•</label>
									<para>Discontinue rivaroxaban and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next dose of rivaroxaban would have been administered</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8499">
						<sec_title>Hepatic Dose</sec_title>
						<section type="none" id="sidelem4x8507">
							<label>•</label>
							<sec_title>Adult<route> PO Child-Pugh class B or C</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8510">
						<sec_title>Renal Dose</sec_title>
						<section type="none" id="sidelem4x8518">
							<label>•</label>
							<sec_title>Adult<route> PO (nonvalvular atrial fibrillation) CCr 15-50 ml/min 15 mg daily; CCr &lt;15 ml/min avoid use; (treatment/prophylaxis of DVT/pulmonary embolism) CCr &lt;30 ml/min avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8521">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 15, 20 mg</para>
					</section>
					<section type="none" id="sidelem4x8526">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8532">
								<item>
									<para>
										<emphasis alert="nurse">For DVT prophylaxis: give daily without regard to food; give initial dose ≥6-10 hr after surgery when hemostasis has been established</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8538">
								<item>
									<para>
										<emphasis alert="nurse">For stroke/systemic embolism prophylaxis: give daily with evening meal</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8543">
								<item>
									<label>•</label>
									<para>If dose is not given at correct time, give as soon as possible on the same day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8548">
								<item>
									<label>•</label>
									<para>15-, 20-mg tabs should be taken with food; for those unable to swallow whole, tabs may be crushed, mixed with applesauce; immediately following administration, instruct to eat; crushed tabs are stable in applesauce for up to 4 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8553">
								<item>
									<label>•</label>
									<para>10-mg tab can be taken without regard to food</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8558">
							<sec_title>Nasogastric (NG) tube or gastric feeding tube:</sec_title>
							<para>
								<list id="lidelem4x8562">
									<item>
										<label>•</label>
										<para>Confirm gastric placement of tube</para>
									</item>
									<item>
										<label>•</label>
										<para>Crush 15- or 20-mg tab, suspend in 50 ml of water, and administer via NG or gastric feeding tube</para>
									</item>
									<item>
										<label>•</label>
										<para>To minimize reduced absorption, avoid administration distal to the stomach</para>
									</item>
									<item>
										<label>•</label>
										<para>Enteral feeding should immediately follow administration of a crushed dose</para>
									</item>
									<item>
										<label>•</label>
										<para>Crushed tabs are stable in water for up to 4 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8588">
							<sec_title>Missed doses</sec_title>
							<para>
								<list id="lidelem4x8592">
									<item>
										<label>•</label>
										<para>Patients receiving 15 mg twice daily should take their missed dose immediately to ensure intake of 30 mg per day; two 15-mg tabs may be taken at once followed by the regular 15 mg twice daily dose the next day</para>
									</item>
									<item>
										<label>•</label>
										<para>For patients receiving once-daily dosing, take the missed dose as soon as it is remembered</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8610">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8613">
					<section type="none" id="sidelem4x8614">
						<sec_title>GI:</sec_title>
						<para> Increased hepatic enzymes, hyperbilirubinemia, jaundice, nausea, cholestasis, <emphasis style="bold">cytolytic hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8621">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bleeding, intracranial bleeding, epidural hematoma, GI bleeding, retinal hemorrhage, adrenal bleeding, retroperitoneal hemorrhage, cerebral hemorrhage, subdural hematoma, epidural hematoma, hemiparesis, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8628">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, blister, hypersensitivity, <emphasis style="bold">anaphylactic reaction, anaphylactic shock</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8635">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8642">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 80%-100%, protein binding (92%-95%) albumin, excreted in urine 66% (36% unchanged, 30% metabolites), 28% in feces (7% unchanged, 21% metabolites), unchanged drug excreted in urine (via active tubular secretion, glomerular filtration); terminal elimination half-life 5-9 hr, peak 2-4 hr; increased effect in hepatic/renal disease, Japanese patients, increased terminal half-life in geriatric patients</para>
			</section>
			<section type="interactions" id="sidelem4x8647">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> rivaroxaban effect, possible bleeding—ketoconazole itraconazole, ritonavir, lopinavir/ritonavir; conivaptan, clarithromycin, erythromycin, salicylates, NSAIDs, other anticoagulants, thrombolytics, platelet inhibitors, niCARdipine, fluconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> rivaroxaban effect—carBAMazepine, phenytoin, rifampin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> rivaroxaban effect in renal impairment—telithromycin, darunavir, mifepristone, nelfinavir, pantoprazole, posaconazole, saquinavir, tamoxifen, lapatinib, azithromycin, diltiazem, verapamil, quiNIDine, ranolazine, dronedarone, amiodarone, felodipine</para>
				<section type="none" id="sidelem4x8662">
					<section type="none" id="sidelem4x8663">
						<sec_title>Drug/Herb:</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> rivaroxaban effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x8670">
						<sec_title>Drug/Food:</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> rivaroxaban effect in renal disease—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8677">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8680">
					<section type="none" id="sidelem4x8681">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bleeding:</emphasis> monitor for bleeding, including bleeding during dental procedures (easy bruising, blood in urine, stools, emesis, sputum, epistaxis); there is no specific antidote</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Abrupt discontinuation:</emphasis> avoid abrupt discontinuation unless an alternative anticoagulant in those with atrial fibrillation; discontinuing puts patients at an increased risk of thrombotic events; if product must be discontinued for reasons other than pathological bleeding, consider administering another anticoagulant</bbw>
						</para>
						<section type="none" id="sidelem4x8712">
							<label>•</label>
							<sec_title>Pregnancy/breastfeeding<route> pregnancy (C); identify if pregnancy is suspected or planned; pregnancy-related hemorrhage may occur and anticoagulation cannot be monitored with standard laboratory testing; breastfeeding should be discontinued before beginning use of this product</route></sec_title>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Epidural/spinal anesthesia:</emphasis> epidural or spinal hematomas that result in long-term or permanent paralysis may occur in patients who have received anticoagulants and are receiving neuraxial anesthesia or undergoing spinal puncture; epidural catheter should not be removed &lt;18 hr after the last dose of rivaroxaban; do not administer the next rivaroxaban dose &lt;6 hr after the catheter removal; delay rivaroxaban administration for 24 hr if traumatic puncture occurs; monitor for neuro changes</bbw>
						</para>
						<section type="none" id="sidelem4x8732">
							<label>•</label>
							<sec_title>Hepatic/renal disease<route> increase in effect of product in hepatic disease (Child-Pugh class B or C), hepatic disease with coagulopathy; renal failure/severe renal impairment (creatinine clearance &lt;30 ml/min in DVT prophylaxis and &lt;15 ml/min for stroke or systemic embolism prophylaxis in nonvalvular atrial fibrillation); product should be discontinued in acute renal failure; reduce dose in those with atrial fibrillation and CrCl 15-50 ml/min; monitor renal function periodically (creatinine clearance, BUN)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8735">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8739">
								<item>
									<label>•</label>
									<para>Prevention of DVT, stroke, and systemic embolism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8745">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x8753">
							<label>•</label>
							<sec_title>
								<route>To report if pregnancy is planned or suspected; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<bbw>To report bleeding (bruising, blood in urine, stools, sputum, emesis, heavy menstrual flow); use soft toothbrush, electric shaver</bbw>
						</para>
						<para>
							<list id="lidelem4x8766">
								<item>
									<label>•</label>
									<para>To inform all health care providers of use, report to prescriber all products used, to take only as directed</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To avoid abrupt discontinuation without another blood thinner</bbw>
						</para>
						<para>
							<list id="lidelem4x8782">
								<item>
									<label>•</label>
									<para>To report numbness of extremities, weakness, tingling, contact prescriber immediately (neuraxial anesthesia, spinal puncture)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active">
			<mono_name>rivastigmine (Rx)</mono_name>
			<info>
				<pronunciation>(riv-as-tig′mine)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x87931">Exelon</tradename>
					<tradename id="tnidelem4x87930">Exelon Patch</tradename>
				</tradenames>
				<class type="func"> Anti-Alzheimer agent</class>
				<class type="chem"> Cholinesterase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x8803">
				<sec_title>Action:</sec_title>
				<para>Potent, selective inhibitor of brain acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)</para>
			</section>
			<section type="uses" id="sidelem4x8808">
				<sec_title>Uses:</sec_title>
				<para>Mild to severe Alzheimer’s dementia, mild to moderate Parkinson’s disease dementia (PDD)</para>
				<section type="none" id="sidelem4x8813">
					<section type="none" id="sidelem4x8814">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Vascular dementia, dementia with Lewy bodies, Pick’s disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8819">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, other carbamates</para>
				<section type="none" id="sidelem4x8824">
					<section type="none" id="sidelem4x8825">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, respiratory/cardiac/renal/hepatic disease, seizure disorder, peptic ulcer, urinary obstruction, asthma, increased intracranial pressure, surgery, GI bleeding, jaundice</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8830">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8838">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8838">
							<item>
								<label>•</label>
								<para> 1.5 mg bid with food; after ≥4 wk, may increase to 3 mg bid; may increase to 4.5 mg bid and thereafter 6 mg bid, max 12 mg/day;  apply 4.6 mg/24 hr/day, after ≥4 wk may increase to 9.5 mg/24 hr/day; max 13.3 mg/24 hr; for those using 6-12 mg/day PO and switching to transdermal use one 9.5 mg/24 hr daily, for those using &lt;6 mg/day PO and switching to transdermal use one 4.6 mg/24 hr daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8845">
					<section type="none" id="sidelem4x8846">
						<sec_title>Available forms:</sec_title>
						<para> Caps 1.5, 3, 4.5, 6 mg; transdermal patch 4.6, 9.5, 13.3 mg/24 hr</para>
					</section>
					<section type="none" id="sidelem4x8851">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8855">
								<item>
									<label>•</label>
									<para>With meals; take with morning and evening meal even though absorption may be decreased</para>
								</item>
								<item>
									<label>•</label>
									<para>Discontinue treatment for several doses; restart at same or next lower dosage level if adverse reactions cause intolerance</para>
								</item>
								<item>
									<label>•</label>
									<para>If treatment is interrupted for more than several days, treatment should be initiated with lowest daily dose and titrated as indicated previously</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8871">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x8875">
									<item>
										<label>•</label>
										<para>Once a day to hairless, clean, dry skin, not in an area that clothing will rub; rotate sites daily; do not apply to same site more than once q14days; remove liner; apply firmly; may be used during bathing, swimming; avoid saunas, excess sunlight; or external heat such as saunas; each 5-cm<emphasis style="sup">2</emphasis> patch contains 9 mg base, rate of 4.6 mg/24 hr, each 10-cm<emphasis style="sup">2</emphasis> patch 18 mg base, rate of 9.5 mg/24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8889">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8892">
					<section type="none" id="sidelem4x8893">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT prolongation, AV block, cardiac arrest,</emphasis> angina, <emphasis style="bold">MI,</emphasis> palpitations</para>
					</section>
					<section type="none" id="sidelem4x8904">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, confusion, insomnia,</emphasis> psychosis, hallucination, depression, dizziness, headache, anxiety, somnolence, fatigue, syncope, EPS, exacerbation of Parkinson’s disease</para>
					</section>
					<section type="none" id="sidelem4x8912">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, abdominal distress, flatulence,</emphasis> diarrhea, constipation, dyspepsia, colitis, eructation, fecal incontinence, <emphasis style="bold">GI bleeding/obstruction,</emphasis> GERD, gastritis, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8925">
						<sec_title>MISC:</sec_title>
						<para> Urinary tract infection, asthenia, increased sweating, hypertension, flulike symptoms, weight change</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8930">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly and completely absorbed; peak 1 hr, metabolized to decarbamylated metabolite; half-life 1.5 hr; excreted via kidneys (metabolites); clearance lowered in geriatric patients, hepatic disease and increased with nicotine use; 40% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x8935">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> synergistic effect—cholinergic agonists, other cholinesterase inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> metabolism—nicotine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI effects—NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> rivastigmine effect—anticholinergics, sedating H<emphasis style="inf">1</emphasis> blockers, tricyclics, phenothiazines</para>
			</section>
			<section type="considerations" id="sidelem4x8957">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8960">
					<section type="none" id="sidelem4x8961">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8966">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, alk phos, LDH, bilirubin, CBC</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8974">
							<label>•</label>
							<sec_title>Severe GI effects</sec_title>
							<para>
								<list id="lidelem4x8974">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Severe GI effects:</emphasis> nausea, vomiting, anorexia, weight loss, diarrhea, GI bleeding</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8978">
								<item>
									<label>•</label>
									<para>B/P, heart rate, respiration during initial treatment; hypo/hypertension should be reported</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8986">
							<label>•</label>
							<sec_title>Cognitive/mental status</sec_title>
							<para>
								<list id="lidelem4x8986">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cognitive/mental status:</emphasis> affect, mood, behavioral changes, depression, insomnia; complete suicide assessment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8990">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy; dizziness may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8995">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8999">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved mood/cognition</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9005">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x9013">
							<label>•</label>
							<sec_title>
								<route>transdermal</route>
							</sec_title>
							<para>
								<list id="lidelem4x9013">
									<item>
										<label>•</label>
										<para>How to apply  product, to fold in half and throw away, not to get in eyes, to wash hands after application; not to use heating pad, sauna, tanning bed</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9018">
								<item>
									<label>•</label>
									<para>To notify prescriber of severe GI effects</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9023">
								<item>
									<label>•</label>
									<para>That product may cause dizziness, anorexia, weight loss</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9028">
								<item>
									<label>•</label>
									<para>That effect may take weeks or months; not to discontinue abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9033">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9038">
								<item>
									<label>•</label>
									<para>To give with food in <emphasis style="smallcaps">am</emphasis>, <emphasis style="smallcaps">pm</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9048">
								<item>
									<label>•</label>
									<para>To report nausea, vomiting, diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9053">
								<item>
									<label>•</label>
									<para>To inform prescriber to all products taken</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active">
			<mono_name>rizatriptan (Rx)</mono_name>
			<info>
				<pronunciation>(rye-zah-trip′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x90631">Maxalt</tradename>
					<tradename id="tnidelem4x90630">Maxalt-MLT</tradename>
				</tradenames>
				<class type="func"> Migraine agent</class>
				<class type="chem"> 5-HT receptor agonist, abortive agent-triptan</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x9076">
				<sec_title>Action:</sec_title>
				<para>Binds selectively to the vascular 5-HT<emphasis style="inf">1B/1D</emphasis> receptor subtype; exerts antimigraine effect; causes vasoconstriction of the cranial arteries</para>
			</section>
			<section type="uses" id="sidelem4x9084">
				<sec_title>Uses:</sec_title>
				<para>Acute treatment of migraine</para>
			</section>
			<section type="contra" id="sidelem4x9089">
				<sec_title>Contraindications:</sec_title>
				<para>Angina pectoris, history of MI, documented silent ischemia, Prinzmetal’s angina, ischemic heart disease, concurrent ergotamine-containing preparations, uncontrolled hypertension, hypersensitivity, basilar or hemiplegic migraine</para>
				<section type="none" id="sidelem4x9096">
					<section type="none" id="sidelem4x9097">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, postmenopausal women, men &gt;40 yr, risk factors for CAD, hypercholesterolemia, obesity, diabetes, impaired renal/hepatic function</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9102">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9110">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9110">
							<item>
								<label>•</label>
								<para> 5-10 mg single dose, redosing separated by ≥2 hr, max 30 mg/24 hr; use 5 mg for patient receiving propranolol, max 15 mg/24 hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9114">
					<section type="none" id="sidelem4x9115">
						<sec_title>Available forms:</sec_title>
						<para> Tabs (Maxalt) 5, 10 mg; orally disintegrating tabs (Maxalt-MLT) 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x9120">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9128">
							<label>•</label>
							<sec_title>Orally disintegrating tab</sec_title>
							<para>
								<list id="lidelem4x9128">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orally disintegrating tab:</emphasis> do not open blister until use; peel blister open with dry hands; place tab on patient’s tongue, where it will dissolve, and have patient swallow with saliva (contains phenylalanine)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9132">
								<item>
									<label>•</label>
									<para>Not to be used for more than 3-4 times per month</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9137">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9140">
					<section type="none" id="sidelem4x9141">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness, headache, fatigue,</emphasis> warm/cold sensations, flushing</para>
					</section>
					<section type="none" id="sidelem4x9149">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI, ventricular fibrillation, ventricular tachycardia, coronary artery vasospasm,</emphasis> palpitations, hypertension, peripheral vascular ischemia, ECG changes</para>
					</section>
					<section type="none" id="sidelem4x9157">
						<sec_title>ENDO:</sec_title>
						<para> Hot flashes, mild increase in growth hormone</para>
					</section>
					<section type="none" id="sidelem4x9162">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> dry mouth, diarrhea, abdominal pain, ischemic colitis</para>
					</section>
					<section type="none" id="sidelem4x9170">
						<sec_title>RESP:</sec_title>
						<para> Chest tightness, pressure, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9175">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset of pain relief 10 min-2 hr; peak 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; duration 14-16 hr; 14% plasma protein binding; metabolized in liver (metabolite); excreted in urine (82%), feces (12%); half-life 2-3 hr</para>
			</section>
			<section type="interactions" id="sidelem4x9186">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Weakness, hyperreflexia, incoordination: SSRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of sibutramine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> rizatriptan action—cimetidine, oral contraceptives, MAOIs, nonselective MAOI (type A and B), isocarboxazide, pargyline, phenelzine, propranolol, tranylcypromine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> vasospastic effects—ergot, ergot derivatives, other 5-HT receptor agonists</para>
				<section type="none" id="sidelem4x9206">
					<section type="none" id="sidelem4x9207">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="nurse">Serotonin syndrome: St. John’s wort</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9215">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9218">
					<section type="none" id="sidelem4x9219">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9227">
							<label>•</label>
							<sec_title>Migraine symptoms</sec_title>
							<para>
								<list id="lidelem4x9227">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Migraine symptoms:</emphasis> visual disturbances, aura, intensity, nausea, vomiting, photophobia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9231">
								<item>
									<label>•</label>
									<para>Stress level, activity, recreation, coping mechanisms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9236">
								<item>
									<label>•</label>
									<para>Neurologic status: LOC, blurring vision, nausea, vomiting, tingling in extremities preceding headache</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9244">
							<label>•</label>
							<sec_title>
								<route>Ingestion of tyramine foods</route>
							</sec_title>
							<para>
								<list id="lidelem4x9244">
									<item>
										<label>•</label>
										<para> (pickled products, beer, wine, aged cheese), food additives, preservatives, colorings, artificial sweeteners, chocolate, caffeine, which may precipitate these types of headaches</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9248">
								<item>
									<label>•</label>
									<para>Renal status: urine output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9253">
								<item>
									<label>•</label>
									<para>Quiet, calm environment with decreased stimulation: noise, bright light, excessive talking</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9258">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9262">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in frequency, severity of headache</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9268">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x9276">
							<label>•</label>
							<sec_title>About use of orally disintegrating tab</sec_title>
							<para>
								<list id="lidelem4x9276">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">About use of orally disintegrating tab:</emphasis> instruct patient not to open blister until use, to peel blister open with dry hands, to place tab on tongue, where it will dissolve, and to swallow with saliva (contains phenylalanine)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9280">
								<item>
									<label>•</label>
									<para>To report any side effects to prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9285">
								<item>
									<label>•</label>
									<para>To use alternative contraception while taking product if oral contraceptives are being used</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9290">
								<item>
									<label>•</label>
									<para>That product does not prevent or reduce number of migraines; if 1st dose does not relieve pain, do not use more; notify prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="35" status="active">
			<mono_name>roflumilast</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x92980">Daliresp</tradename>
				</tradenames>
				<class type="func"> Respiratory anti-inflammatory agent</class>
				<class type="chem"> Phosphodiesterase-4 (PDE4) inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x9308">
				<sec_title>Action:</sec_title>
				<para>Roflumilast (and the active metabolite roflumilast N-oxide) selectively inhibit phosphodiesterase-4 (PDE4); not a bronchodilator; inhibition of the PDE4 enzyme blocks the hydrolyses and inactivation of cyclic adenosine monophosphate (cAMP), resulting in intracellular cAMP accumulation; decreases inflammatory activity, PDE4 inhibition may affect migration and actions of proinflammatory cells (neutrophils, other leukocytes, T-lymphocytes, monocytes, macrophages, fibroblasts)</para>
			</section>
			<section type="uses" id="sidelem4x9313">
				<sec_title>Uses:</sec_title>
				<para>For the prevention of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations</para>
			</section>
			<section type="contra" id="sidelem4x9318">
				<sec_title>Contraindications:</sec_title>
				<para>
					<emphasis style="italic">Moderate to severe hepatic disease</emphasis> (Child-Pugh B or C)</para>
				<section type="none" id="sidelem4x9325">
					<section type="none" id="sidelem4x9326">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, neonates, infants, children, adolescents, acute bronchospasm, anxiety, insomnia, depression, suicidal ideation or behavior</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9331">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9339">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9339">
							<item>
								<label>•</label>
								<para> 500 mcg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9343">
					<section type="none" id="sidelem4x9344">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 500 mcg</para>
					</section>
					<section type="none" id="sidelem4x9349">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9352">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x9356">
									<item>
										<label>•</label>
										<para>Give without regard to meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9367">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9370">
					<section type="none" id="sidelem4x9371">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, anxiety, depression, headache, dizziness, tremors, <emphasis style="bold">suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9378">
						<sec_title>EENT:</sec_title>
						<para> Rhinitis, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x9383">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Weight loss, diarrhea</emphasis>, <emphasis style="italic">nausea</emphasis>, anorexia, abdominal pain, dyspepsia, gastritis, vomiting</para>
					</section>
					<section type="none" id="sidelem4x9394">
						<sec_title>GU:</sec_title>
						<para> Urinary tract infection</para>
					</section>
					<section type="none" id="sidelem4x9399">
						<sec_title>MS:</sec_title>
						<para> Back pain, muscle cramps/spasm</para>
					</section>
					<section type="none" id="sidelem4x9404">
						<sec_title>SYST:</sec_title>
						<para> Infections, influenza</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9409">
				<sec_title>Pharmacokinetics</sec_title>
				<para>80% absolute bioavailability; protein binding 99% (roflumilast); 97% (N-oxide metabolite); low penetration across the blood–brain barrier; extensively metabolized (liver); metabolism by CYP3A4 and CYP1A2 produces (active metabolite N-oxide); half-life parent drug 17 hr, metabolite 30; steady-state 4 days (parent drug), 6 days (metabolite); 70% excreted in urine; parent drug peak 1 hr (range, 0.5-2 hr), metabolite peak 8 hr (range, 4-13 hr); contraindicated in moderate to severe hepatic impairment; use with caution in patients with mild hepatic</para>
			</section>
			<section type="interactions" id="sidelem4x9414">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> roflumilast effect—CYP3A4/CYP1A2 inhibitors (enoxacin, cimetidine, delavirdine, indinavir, isoniazid, itraconazole, dalfopristin, quinupristin, tipranavir)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> roflumilast effect—oral contraceptives (gestodene and ethinyl estradiol)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> roflumilast effect—CYP3A4 inducers (rifampin, barbiturates, carBAMazepine, phenytoin, erythromycin, ketoconazole, fluvoxaMINE, alcohol, etravirine, ritonavir, bexarotene, rifabutin, OXcarbazepine, nevirapine, modafinil, metyrapone, PHENobarbital, bosentan, dexamethasone)</para>
				<para>
					<emphasis style="bold">Altered effect of:</emphasis> fosamprenavir</para>
				<section type="none" id="sidelem4x9433">
					<section type="none" id="sidelem4x9434">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> roflumilast effect—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9441">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9444">
					<section type="none" id="sidelem4x9445">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9450">
								<item>
									<label>•</label>
									<para>Lung sounds and respiratory function baseline and periodically thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9457">
								<item>
									<para>
										<emphasis alert="nurse">Behavioral changes including mood, depression, suicidal thoughts/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9462">
								<item>
									<label>•</label>
									<para>Liver function tests baseline and periodically thereafter; if increases in liver function studies occur, product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9467">
								<item>
									<label>•</label>
									<para>Weight; weight loss is common</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9472">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9476">
								<item>
									<label>•</label>
									<para>Decreasing exacerbations in COPD</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9482">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9487">
								<item>
									<label>•</label>
									<para>To take product as directed; not to skip or double doses; to take missed doses as soon as remembered unless almost time for next dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9492">
								<item>
									<label>•</label>
									<para>Not to use OTC or other products without prescriber approval; not to discontinue other respiratory products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9497">
								<item>
									<label>•</label>
									<para>Not to be used for acute bronchospasm but may be continued during acute asthma attacks</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9503">
								<item>
									<para>
										<emphasis alert="nurse">Suicidal thoughts/behaviors: To notify prescriber of worsening depression or suicidal thoughts/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>romiPLOStim (Rx)</mono_name>
			<info>
				<pronunciation>(roe-mi-ploe′stim)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x95130">Nplate</tradename>
				</tradenames>
				<class type="func"> Hematopoietin</class>
				<class type="chem"> Thrombopoietin receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x9523">
				<sec_title>Action:</sec_title>
				<para>Thrombopoietin-like fusion protein produced by DNA recombinant technology</para>
			</section>
			<section type="uses" id="sidelem4x9528">
				<sec_title>Uses:</sec_title>
				<para>Chronic idiopathic thrombocytopenic purpura in patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy</para>
			</section>
			<section type="contra" id="sidelem4x9533">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or mannitol</para>
				<section type="none" id="sidelem4x9538">
					<section type="none" id="sidelem4x9539">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, malignancies, bleeding, bone marrow suppression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9544">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9547">
					<section type="none" id="sidelem4x9548">
						<sec_title>Thrombocytopenia in chronic idiopathic thrombocytopenic purpura (ITP) with insufficient response to corticosteroids, immunoglobulins, splenectomy</sec_title>
						<section type="none" id="sidelem4x9556">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x9556">
									<item>
										<label>•</label>
										<para> 1 mcg/kg q wk (based on actual body weight); increase the weekly dosage by 1 mcg/kg until platelet count ≥50,000/mm<emphasis style="sup">3</emphasis>; 10 mcg/kg/wk max; use the lowest dosage needed to achieve and maintain a platelet count ≥50,000/mm<emphasis style="sup">3</emphasis>; monitor CBC, including platelet counts, weekly until a stable platelet count is achieved with platelets ≥50,000/mm<emphasis style="sup">3</emphasis> ≥4 wk without dosage adjustment; then monitor the CBC, including platelet counts, monthly; once a stable dosage is achieved, if the platelet count falls to &lt;50,000/mm<emphasis style="sup">3</emphasis>, increase the dosage by 1 mcg/kg/wk; if the platelet count increases to &gt;200,000/mm<emphasis style="sup">3</emphasis> for 2 consecutive weeks, reduce the dosage by 1 mcg/kg; if the platelet count is &gt;400,000/mm<emphasis style="sup">3</emphasis>, temporarily stop romiPLOStim and continue to monitor the platelet count every wk; once the platelets are &lt;200,000/mm<emphasis style="sup">3</emphasis>, restart, but reduce the previous dosage by 1 mcg/kg/wk; romiPLOStim may be administered concomitantly with other medical ITP therapies; if platelet counts exceed 50,000/mm<emphasis style="sup">3</emphasis>, other medical ITP therapies may be reduced or discontinued; discontinue romiPLOStim if the platelet count does not increase to avoid important bleeding after 4 wk of therapy at max dosage of 10 mcg/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9584">
						<sec_title>Available forms:</sec_title>
						<para> Inj vials 250, 500 mcg</para>
					</section>
					<section type="none" id="sidelem4x9589">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9593">
								<item>
									<label>•</label>
									<para>Refrigerated storage of vials; do not freeze; protect from light; diluted sol is stable refrigerated or at room temperature for 24 hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9599">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x9603">
									<item>
										<label>•</label>
										<para>Use syringe with 0.01-ml graduations</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard any unused portion in vial; do not pool unused portions from vials</para>
									</item>
									<item>
										<label>•</label>
										<para>Dilute 250 mcg/0.72 preservative-free sterile water for inj; 500 mcg/1.2 preservative-free sterile water for inj; final concentration 500 mcg/ml</para>
									</item>
									<item>
										<label>•</label>
										<para>Gently swirl until dissolved; do not shake</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use if discolored or if particulate matter is present</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject into outer aspect of upper arm or abdomen except for 2 inches around navel or front aspect of middle thigh; do not use areas that are bruised, scratched, or scarred</para>
									</item>
									<item>
										<label>•</label>
										<para>Rotate inj sites</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9640">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9643">
					<section type="none" id="sidelem4x9644">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, insomnia, headache,</emphasis> fatigue</para>
					</section>
					<section type="none" id="sidelem4x9652">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, dyspepsia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x9657">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thromboembolism, thrombosis,</emphasis> bleeding, myelofibrosis, erythromelalgia</para>
					</section>
					<section type="none" id="sidelem4x9665">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x9670">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Secondary malignancy,</emphasis> antibody formation</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9678">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 7-50 hr, half-life 1-34 days</para>
			</section>
			<section type="interactions" id="sidelem4x9683">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x9687">
						<item>
							<label>•</label>
							<para>Possible bleeding risk: anticoagulants, NSAIDs, platelet inhibitors, thrombolytics, salicylates</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x9693">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9696">
					<section type="none" id="sidelem4x9697">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9702">
								<item>
									<label>•</label>
									<para>Blood studies: CBC during treatment weekly and for 2 wk after discontinuing</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9710">
							<label>•</label>
							<sec_title>Bone marrow suppression<route> if cytopenias occur, product should be discontinued; may use a bone marrow biopsy and staining for fibrosis</route></sec_title>
						</section>
						<section type="none" id="sidelem4x9716">
							<label>•</label>
							<sec_title>Thromboembolic disease<route> do not use to normalize patients; use only in those with thrombocytopenia in idiopathic thrombocytopenic purpura, maintain platelets ≥ 50,000/mm</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9721">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9725">
								<item>
									<label>•</label>
									<para>Therapeutic response: increase in platelet counts, absence of bleeding</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9731">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9736">
								<item>
									<label>•</label>
									<para>To report bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9741">
								<item>
									<label>•</label>
									<para>About the reason for product and expected results; to avoid hazardous activities that may cause bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9746">
								<item>
									<label>•</label>
									<para>To report a missed dose to prescriber due to increased risk of bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9751">
								<item>
									<label>•</label>
									<para>That lab tests will be done weekly and dose may be changed; if dose is not changed, lab will be checked monthly; after drug is discontinued, labs will be checked weekly × 2 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9756">
								<item>
									<label>•</label>
									<para>To advise prescriber if spleen has been removed, bleeding or clotting problems</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9765">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (C); if pregnancy occurs, call registry 1-877-675-2831</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>rOPINIRole (Rx)</mono_name>
			<info>
				<pronunciation>(roh-pin′ih-role)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x97731">Requip</tradename>
					<tradename id="tnidelem4x97730">Requip XL</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> DOPamine-receptor agonist, nonergot</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9783">
				<para>
					<confusion>
						<tradename id="tnidelem4x97830">rOPINIRole</tradename>
						<drug type="generic" refid="idelem4x97830">risperiDONE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9787">
				<sec_title>Action:</sec_title>
				<para>Selective agonist for D<emphasis style="inf">2</emphasis> receptors (presynaptic/postsynaptic sites); binding at D<emphasis style="inf">3</emphasis> receptor contributes to antiparkinson effects</para>
			</section>
			<section type="uses" id="sidelem4x9798">
				<sec_title>Uses:</sec_title>
				<para>Parkinson’s disease, restless leg syndrome (RLS)</para>
			</section>
			<section type="contra" id="sidelem4x9803">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x9808">
					<section type="none" id="sidelem4x9809">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), dysrhythmias, affective disorder, psychosis, cardiac/renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9814">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9817">
					<section type="none" id="sidelem4x9818">
						<sec_title>Parkinson’s disease</sec_title>
						<section type="none" id="sidelem4x9826">
							<label>•</label>
							<sec_title>Adult<route> PO (regular release)</route></sec_title>
							<para>
								<list id="lidelem4x9826">
									<item>
										<label>•</label>
										<para> Initially, 0.25 mg PO tid × 1 wk; gradually titrate at weekly intervals: , 0.5 mg tid;  0.75 mg tid; , 1 mg tid; , may increase by 1.5 mg/day each week, max 9 mg/day total dosage, and then by 3 mg/day each week, max 24 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9847">
							<label>•</label>
							<sec_title>
								<route>PO (ext rel)</route>
							</sec_title>
							<para>
								<list id="lidelem4x9847">
									<item>
										<label>•</label>
										<para> initially, 2 mg/day × 1-2 wk, may increase by mg/day at intervals ≥1 wk based upon response; max 24 mg/day; if significant interruption of therapy occurs, retitration may be necessary</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9851">
						<sec_title>Conversion from immediate-release to extended-release tablets</sec_title>
						<section type="none" id="sidelem4x9859">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9859">
									<item>
										<label>•</label>
										<para> currently taking 0.75-2.25 mg/day imm rel: give 2 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9866">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x9866">
									<item>
										<label>•</label>
										<para> currently taking 3-4.5 mg/day imm rel: give 4 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9873">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x9873">
									<item>
										<label>•</label>
										<para> currently taking 6 mg/day imm rel: give 6 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9880">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x9880">
									<item>
										<label>•</label>
										<para> currently taking 7.5-9 mg/day imm rel: give 8 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9887">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x9887">
									<item>
										<label>•</label>
										<para> currently taking 12 mg/day imm rel: give 12 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9894">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x9894">
									<item>
										<label>•</label>
										<para> currently taking 15-18 mg/day imm rel: give 16 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9901">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x9901">
									<item>
										<label>•</label>
										<para> currently taking 21 mg/day imm rel: give 20 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9908">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x9908">
									<item>
										<label>•</label>
										<para> currently taking 24 mg/day imm rel: give 24 mg/day ext rel</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9912">
						<sec_title>Restless legs syndrome</sec_title>
						<section type="none" id="sidelem4x9920">
							<label>•</label>
							<sec_title>Adult<route> PO (reg rel)</route></sec_title>
							<para>
								<list id="lidelem4x9920">
									<item>
										<label>•</label>
										<para> Initially, 0.25 mg every day 1-3 hr before bedtime; days 3-7, may increase to 0.5 mg every day; at the beginning of wk 2 (day 8); the dosage may be increased to 1 mg every day × 1 wk; weeks 3-6, dosage may be titrated up by 0.5 mg each wk (from 1.5-3 mg over the 5-wk period) as needed to achieve desired effect; wk 7, may increase dosage to 4 mg/day; dosage is titrated based on clinical response; give all doses 1-3 hr before bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9924">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.25, 0.5, 1, 2, 3, 4, 5 mg; ext rel tab 2, 4, 6, 8, 12 mg</para>
					</section>
					<section type="none" id="sidelem4x9929">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9934">
								<item>
									<label>•</label>
									<para>Product until NPO before surgery</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9939">
								<item>
									<label>•</label>
									<para>Adjust dosage to patient response; taper when discontinuing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9944">
								<item>
									<label>•</label>
									<para>With meals to reduce nausea</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9952">
							<label>•</label>
							<sec_title>Extended release</sec_title>
							<para>
								<list id="lidelem4x9952">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Extended release:</emphasis> do not chew, crush, or divide</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9956">
								<item>
									<label>•</label>
									<para>Testing for diabetes mellitus, acromegaly if patient receiving long-term therapy</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9961">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9964">
					<section type="none" id="sidelem4x9965">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Agitation, insomnia,</emphasis> psychosis, hallucination, dystonia, depression, dizziness, somnolence, <emphasis style="bold">sleep attacks,</emphasis> impulse control disorders</para>
					</section>
					<section type="none" id="sidelem4x9976">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> tachycardia, hypo/hypertension, syncope, palpitations</para>
					</section>
					<section type="none" id="sidelem4x9984">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x9989">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, dry mouth,</emphasis> constipation, dyspepsia, flatulence</para>
					</section>
					<section type="none" id="sidelem4x9997">
						<sec_title>GU:</sec_title>
						<para> Impotence, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x10002">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, leukopenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10009">
						<sec_title>INTEG:</sec_title>
						<para> Rash, sweating</para>
					</section>
					<section type="none" id="sidelem4x10014">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, rhinitis, sinusitis, bronchitis, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10019">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr, half-life 6 hr, extensively metabolized by liver by P450 CYP1A2 enzyme system, protein binding 40%</para>
			</section>
			<section type="interactions" id="sidelem4x10024">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> rOPINIRole effect—cimetidine, ciprofloxacin, diltiazem, enoxacin, erythromycin, fluvoxaMINE, mexiletine, norfloxacin, tacrine, digoxin, theophylline, <emphasis style="smallcaps">l</emphasis>-dopa</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> rOPINIRole effects—butyrophenones, metoclopramide, phenothiazines, thioxanthenes</para>
			</section>
			<section type="considerations" id="sidelem4x10038">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10041">
					<section type="none" id="sidelem4x10042">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x10050">
							<label>•</label>
							<sec_title>Parkinsonism</sec_title>
							<para>
								<list id="lidelem4x10050">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Parkinsonism:</emphasis> akinesia, tremors, staggering gait, muscle rigidity, drooling</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10054">
								<item>
									<label>•</label>
									<para>B/P, respirations during initial treatment; hypo/hypertension should be reported</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10060">
								<item>
									<para>
										<emphasis alert="nurse">Sleep attacks: drowsiness, falling asleep without warning even during hazardous activities</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10065">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, depression; complete suicide assessment; worsening of symptoms in restless leg syndrome</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10070">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10074">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in movement disorder</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10081">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10086">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected, pregnancy (C), breastfeeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10091">
								<item>
									<label>•</label>
									<para>To take with food to prevent nausea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10096">
								<item>
									<label>•</label>
									<para>To report hallucinations, confusion (usually in geriatric patients)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10101">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take several weeks to a few months</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10106">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10114">
							<label>•</label>
							<sec_title>
								<route>To use product exactly as prescribed; if product is discontinued abruptly, parkinsonian crisis may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10117">
								<item>
									<label>•</label>
									<para>That drowsiness, sleep attacks may occur; to avoid driving, other hazardous activities until response known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10122">
								<item>
									<label>•</label>
									<para>To avoid alcohol, CNS depressants, cough and cold products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10128">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber if unusual urges occur</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="38" status="active" ha="yes">
			<mono_name> rosiglitazone (Rx)</mono_name>
			<info>
				<pronunciation>(ros-ih-glit′ah-zone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x101400">Avandia</tradename>
				</tradenames>
				<class type="func"> Antidiabetic, oral</class>
				<class type="chem"> Thiazolidinedione</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10150">
				<para>
					<confusion>
						<tradename id="tnidelem4x101500"/>
						<drug type="generic" refid="idelem4x101500">pioglitazone Avandia/Prandin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10156">
				<sec_title>Action:</sec_title>
				<para>Improves insulin resistance by hepatic glucose metabolism, insulin receptor kinase activity, insulin receptor phosphorylation</para>
			</section>
			<section type="uses" id="sidelem4x10161">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus, alone or in combination with sulfonylureas, metformin, insulin</para>
			</section>
			<section type="contra" id="sidelem4x10166">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, hypersensitivity to thiazolidinediones, diabetic ketoacidosis, jaundice</para>
				<para>
					<bbw>NYHA III, IV acute heart failure, heart failure</bbw>
				</para>
				<section type="none" id="sidelem4x10181">
					<section type="none" id="sidelem4x10182">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, thyroid disease, renal/hepatic disease, heart failure, class I, II NYHA</para>
						<para>
							<bbw>MI</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10197">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10205">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10205">
							<item>
								<label>•</label>
								<para> 4 mg/day or in 2 divided doses, may increase to 8 mg/day or in 2 divided doses after 12 wk; may be added to metformin, sulfonylurea for adult dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10209">
					<section type="none" id="sidelem4x10210">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2, 4, 8 mg</para>
					</section>
					<section type="none" id="sidelem4x10215">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10219">
								<item>
									<label>•</label>
									<para>Conversion from other oral hypoglycemic agents if needed; change may be made without gradual dosage change; monitor blood glucose during conversion</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container in cool environment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10230">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x10235">
									<item>
										<label>•</label>
										<para>Once or in 2 divided doses, without regard to food</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10240">
									<item>
										<label>•</label>
										<para>Tabs crushed and mixed with food or fluids for patients with difficulty swallowing</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x10248">
								<label>•</label>
								<sec_title>
									<route>Only through the REMS Program 1-800-Avandia</route>
								</sec_title>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10251">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10254">
					<section type="none" id="sidelem4x10255">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, <emphasis style="italic">headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10262">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI, CHF, death (geriatric patients)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10269">
						<sec_title>ENDO:</sec_title>
						<para> Hypo/hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x10274">
						<sec_title>GI:</sec_title>
						<para> Weight gain, <emphasis style="bold">hepatotoxicity,</emphasis> increase total, LDL, HDL cholesterol; decrease free fatty acids, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x10282">
						<sec_title>MISC:</sec_title>
						<para> Accidental injury, URI, sinusitis, anemia, back pain, diarrhea, edema, bone fractures (female), pulmonary/macular/peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x10287">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10294">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Maximal reductions in FBS after 6-12 wk; protein binding 99.8%; excreted in urine, feces; elimination half-life 3-4 hr; may be excreted in breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x10299">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—gemfibrozil, fluvoxaMINE, ketoconazole, trimethoprim; monitor glucose<list id="lidelem4x10306">
						<item>
							<label>•</label>
							<para>Avoid concurrent use with insulin, nitrates</para>
						</item>
						<item>
							<label>•</label>
							<para>May increase or decrease level: CYP2C5 inducer/inhibitors</para>
						</item>
					</list></para>
				<section type="none" id="sidelem4x10317">
					<section type="none" id="sidelem4x10318">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antidiabetic effect—garlic, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x10325">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, HDL, LDL, total cholesterol, blood glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10336">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10339">
					<section type="none" id="sidelem4x10340">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">CHF/MI:</emphasis> dyspnea, crackles, edema, weight gain ≥5 lb, jugular venous distention; may need to change dose or discontinue product, do not use in acute coronary syndrome, NYHA Class 3/IV heart failure</bbw>
						</para>
						<para>
							<list id="lidelem4x10356">
								<item>
									<label>•</label>
									<para>Hypoglycemic reactions (sweating, weakness, dizziness, anxiety, tremors, hunger), hyperglycemic reactions soon after meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10362">
								<item>
									<para>
										<emphasis alert="nurse">Systemic reactions: anaphylaxis, Stevens-Johnson syndrome</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10368">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: LFTs periodically AST, ALT (if ALT &gt;2.5 × ULN, do not use product)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10373">
								<item>
									<label>•</label>
									<para>Fasting blood sugar, A1c, plasma lipids/lipoproteins, B/P, body weight during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10378">
								<item>
									<label>•</label>
									<para>To use product provider/patient must be enrolled in the Avandia-Rosiglitazone Medicines Access Program</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10383">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10387">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait; blood glucose, A1c improvement</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10393">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10398">
								<item>
									<label>•</label>
									<para>To monitor blood glucose; that periodic liver function tests mandatory; to report edema, weight gain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10403">
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia, what to do about each</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10408">
								<item>
									<label>•</label>
									<para>That product must be continued on daily basis; about the consequences of discontinuing the product abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10413">
								<item>
									<label>•</label>
									<para>To avoid OTC medications, herbal preparations, nitrates, or insulin unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10418">
								<item>
									<label>•</label>
									<para>That diabetes is lifelong; that product is not a cure, only controls symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10423">
								<item>
									<label>•</label>
									<para>That all food included in diet plan must be eaten to prevent hypoglycemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10428">
								<item>
									<label>•</label>
									<para>To carry emergency ID and glucagon emergency kit</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10434">
								<item>
									<para>
										<emphasis alert="nurse">To report symptoms of hepatic dysfunction (nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, jaundice) immediately; to report macular edema (change in vision)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10439">
								<item>
									<label>•</label>
									<para>That 2 wk is needed to see reduction in blood glucose level and 2-3 mo needed to see full effect of product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10444">
								<item>
									<label>•</label>
									<para>To notify prescriber if oral contraceptives are used</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10452">
							<label>•</label>
							<sec_title>
								<route>Not to use if breastfeeding, may be secreted in breast milk</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10455">
								<item>
									<label>•</label>
									<para>That a medication guide should be dispensed with each prescription/refill</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="39" status="active">
			<mono_name>rosuvastatin (Rx)</mono_name>
			<info>
				<pronunciation>(roe-soo′va-sta-tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x104650">Crestor</tradename>
				</tradenames>
				<class type="func"> Antilipemic</class>
				<class type="chem"> HMG-CoA reductase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x10475">
				<sec_title>Action:</sec_title>
				<para>Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis</para>
			</section>
			<section type="uses" id="sidelem4x10480">
				<sec_title>Uses:</sec_title>
				<para>As an adjunct for primary hypercholesterolemia (types IIa, IIb) and mixed dyslipidemia, elevated serum triglycerides, homozygous/heterozygous familial hypercholesterolemia (FH), slowing of atherosclerosis, CV disease prophylaxis, MI, stroke prophylaxis (normal LDL)</para>
			</section>
			<section type="contra" id="sidelem4x10485">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, active hepatic disease</para>
				<section type="none" id="sidelem4x10491">
					<section type="none" id="sidelem4x10492">
						<sec_title>Precautions:</sec_title>
						<para> Children &lt;10 yr, geriatric patients, past hepatic disease, alcoholism, severe acute infections, trauma, hypotension, uncontrolled seizure disorders, severe metabolic disorders, electrolyte imbalances, severe renal impairment, hypothyroidism, Asian patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10497">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10500">
					<section type="none" id="sidelem4x10501">
						<sec_title>Hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x10509">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10509">
									<item>
										<label>•</label>
										<para> 5-40 mg/day; initial dose 10 mg/day, reanalyze lipid levels at 2-4 wk, adjust dosage accordingly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10513">
						<sec_title>Homozygous familial hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x10521">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10521">
									<item>
										<label>•</label>
										<para> 20 mg/day, max 40 mg; Asian patients 5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10525">
						<sec_title>Dose in patients taking cycloSPORINE/gemfibrozil/lopinavir/ritonavir/atazanavir</sec_title>
						<section type="none" id="sidelem4x10533">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10533">
									<item>
										<label>•</label>
										<para> 5 mg/day, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10537">
						<sec_title>Asian patients/patients with predisposition for myopathy</sec_title>
						<section type="none" id="sidelem4x10545">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10545">
									<item>
										<label>•</label>
										<para> 5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10549">
						<sec_title>Atherosclerosis slowing</sec_title>
						<section type="none" id="sidelem4x10557">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10557">
									<item>
										<label>•</label>
										<para> 10 mg/day (for those not taking cycloSPORINE or gemfibrozil)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10561">
						<sec_title>Heterozygous familial hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x10569">
							<label>•</label>
							<sec_title>Females ≥1 yr postmenarche and ≥10 yr)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10569">
									<item>
										<label>•</label>
										<para> 5-20 mg/day individualized</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10573">
						<sec_title>MI/stroke prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10581">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10581">
									<item>
										<label>•</label>
										<para> 20 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10585">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x10593">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, 5 mg/day; max 10 mg/day; avoid use with hepatic disease</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10596">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x10601">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10605">
								<item>
									<label>•</label>
									<para>May be taken at any time of day, with/without food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment in airtight, light-resistant container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10616">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10619">
					<section type="none" id="sidelem4x10620">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> insomnia, paresthesia, confusion</para>
					</section>
					<section type="none" id="sidelem4x10628">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, constipation, abdominal pain, flatus, diarrhea, dyspepsia, heartburn,</emphasis><emphasis style="bold">kidney failure, liver dysfunction,</emphasis> vomiting</para>
					</section>
					<section type="none" id="sidelem4x10638">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, hemolytic anemia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10645">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10652">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Asthenia, muscle cramps, arthritis, arthralgia, myalgia,</emphasis><emphasis style="bold">myositis, rhabdomyolysis;</emphasis> leg, shoulder, or localized pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10662">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3-5 hr, minimal live metabolism (about 10%), 88% protein bound, excreted primarily in feces (90%), crosses placenta, half-life 19 hr, not dialyzable</para>
			</section>
			<section type="interactions" id="sidelem4x10667">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hepatotoxicity—alcohol</para>
				<para>
					<emphasis alert="nurse">Increase: myalgia, myositis, rhabdomyolysis—cycloSPORINE, gemfibrozil, niacin, clofibrate, azole antifungals, antiretroviral protease inhibitors, fibric acid derivatives</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—warfarin</para>
				<section type="none" id="sidelem4x10683">
					<section type="none" id="sidelem4x10684">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10691">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10694">
					<section type="none" id="sidelem4x10695">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10700">
								<item>
									<label>•</label>
									<para>Diet; obtain diet history including fat, cholesterol in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10705">
								<item>
									<label>•</label>
									<para>Fasting cholesterol, LDL, HDL, triglycerides at baseline and q4-6wk, then periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10710">
								<item>
									<label>•</label>
									<para>Liver function: LFTs at baseline, 12 wk, then q6mo; AST, ALT, LFTs may increase</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10715">
								<item>
									<label>•</label>
									<para>Renal function in patients with compromised renal system: BUN, creatinine, I&amp;O ratio</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10721">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: muscle pain, tenderness, obtain CPK; if these occur, product may need to be discontinued; for patients with Asian ancestry: increased blood levels, rhabdomyolysis</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10726">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10730">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased LDL, cholesterol, triglycerides, increased HDL, slowing CAD</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10737">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10743">
								<item>
									<para>
										<emphasis alert="nurse">To report suspected pregnancy; to use contraception while taking product, pregnancy (X); not to breastfeed</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10749">
								<item>
									<para>
										<emphasis alert="nurse">To report weakness, muscle tenderness, pain, fever, liver injury (jaundice, anorexia, abdominal pain)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10754">
								<item>
									<label>•</label>
									<para>That blood work and follow-up exams will be necessary during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10759">
								<item>
									<label>•</label>
									<para>To report severe GI symptoms, dizziness, headache, muscle pain, weakness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10764">
								<item>
									<label>•</label>
									<para>That previously prescribed regimen will continue: low-cholesterol diet, exercise program, smoking cessation</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="40" status="active">
			<mono_name>rufinamide (Rx)</mono_name>
			<info>
				<pronunciation>(roo-fin′a-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x107740">Banzel</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> Triazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x10784">
				<sec_title>Action:</sec_title>
				<para>May act through action at sodium channels; exact action is unknown</para>
			</section>
			<section type="uses" id="sidelem4x10789">
				<sec_title>Uses:</sec_title>
				<para>Lennox-Gastaut syndrome</para>
				<section type="none" id="sidelem4x10794">
					<section type="none" id="sidelem4x10795">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Partial seizures</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10800">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, familial short QT syndrome</para>
				<section type="none" id="sidelem4x10805">
					<section type="none" id="sidelem4x10806">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;16 yr, geriatric patients, renal/hepatic disease, depression, dialysis, hazardous activities, suicidal ideation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10811">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10819">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10819">
							<item>
								<label>•</label>
								<para> 400-800 mg/day divided bid; increase by 400-800 mg/day q2days to 3200 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10826">
					<label>•</label>
					<sec_title>Child ≥4 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10826">
							<item>
								<label>•</label>
								<para> 10 mg/kg/day divided equally bid; increase by 10 mg/kg/day every other day to 45 mg/kg/day or 3200 mg/day, whichever is less</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10830">
					<section type="none" id="sidelem4x10831">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 200, 400 mg; oral susp 40 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x10836">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10844">
							<label>•</label>
							<sec_title>PO tabs</sec_title>
							<para>
								<list id="lidelem4x10844">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">PO tabs:</emphasis> give with food; may give whole, crushed, or halved</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10851">
							<label>•</label>
							<sec_title>Oral susp</sec_title>
							<para>
								<list id="lidelem4x10851">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral susp:</emphasis> shake well before use; use provided adapter and calibrated oral dosing syringe; insert adapter firmly in neck of bottle before use; keep in place for duration of bottle use; insert dosing syringe into adapter; withdraw dose from inverted bottle; replace cap after each use; use within 90 days of opening; give with food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10855">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10858">
					<section type="none" id="sidelem4x10859">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, ataxia, drowsiness, fever, seizures, tremors, fatigue, headache, gait disturbance, <emphasis style="bold">suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10866">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, blurred vision, nystagmus</para>
					</section>
					<section type="none" id="sidelem4x10871">
						<sec_title>GI:</sec_title>
						<para> Nausea, hepatitis, vomiting, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x10876">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukopenia, neutropenia, thrombocytopenia,</emphasis> lymphadenopathy, DRESS</para>
					</section>
					<section type="none" id="sidelem4x10884">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10891">
						<sec_title>MISC:</sec_title>
						<para> Edema, hematuria, influenzae, nephrolithiasis, back pain, urinary frequency</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10896">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 4-6 hr, half-life 6-10 hr, metabolized by liver, excreted by kidneys, 34% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x10901">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> rufinamide effect—valproate</para>
				<para>
					<emphasis alert="lifethreat">Decrease: effect of hormonal contraceptives</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of rufinamide—carBAMazepine, phenytoin, primidone, PHENobarbital</para>
				<section type="none" id="sidelem4x10915">
					<section type="none" id="sidelem4x10916">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10923">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10926">
					<section type="none" id="sidelem4x10927">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x10935">
							<label>•</label>
							<sec_title>Seizures<route> duration, type, intensity precipitating factors</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x10939">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, memory (long, short), increased suicidal thoughts/actions</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10944">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10948">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in severity of seizures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10954">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10959">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly because seizures may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10965">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10970">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating product use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10978">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; to use alternative form of contraception because effect of hormonal contraceptives may be decreased</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10981">
								<item>
									<label>•</label>
									<para>To consume adequate fluids</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10989">
							<label>•</label>
							<sec_title>
								<route>To report suicidal thoughts/behavior immediately</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10992">
								<item>
									<label>•</label>
									<para>To report rash/fever to prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>